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General introduction 
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Alzheimer’s disease 
 
 
1. General features of Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia and was first 
described by Alois Alzheimer in 1907. AD is a neurodegenerative disease characterized by 
impaired memory function and cognitive decline. The most prevalent form of AD is the 
late-onset or sporadic form of AD, which occurs after the age of 65. The average survival 
of AD patients is 5 to 8 years after clinical diagnosis. Since the average life expectancy of 
the Western population is increasing, the number of people affected by AD is also 
mounting. The incidence, at present, doubles every five years, and thus results in 
increasing pressure on the health care systems of all western countries. 
 
1.1 Clinical features of Alzheimer’s disease  
On average, 5 years before patients are clinically diagnosed with AD, mild 
impairment of cognitive functions is revealed. Significant impairment of learning and 
memory are clinical features for the early stages of AD (1). In later stages of AD, the 
declarative memory is affected and patients may suffer from depression and emotional 
disturbances (2), followed by language difficulties and declined reading abilities. 
Symptoms as restlessness, aggression and disorientation increase during development of 
the disease, and approximately one in every five patients will develop hallucinations.    
    
1.2 Diagnosis of Alzheimer’s disease 
The diagnosis of AD is usually made by using clinical, neurological and 
neuropsychological investigations such as routine blood examinations, neuropsychological 
tests, neuroimaging (MRI) and biochemical analysis of the cerebrospinal fluid using so-
called biomarkers. However, these new techniques are still not accurate enough to 
determine a definitive diagnosis of AD during lifetime. Therefore, the postmortem 
histopathological analysis of the brain is still the golden standard that results in a definite 
diagnosis. 
Postmortem neuropathological analysis of the brain reveals cortical atrophy and 
enlargement of the ventricles. Severe atrophy of the neocortex, hippocampus, amygdala 
and the entorhinal cortex are characteristic of AD, whereas cerebellum and striatum 
remain largely unaffected. Microscopical analysis of the affected brain areas reveals three 
pathological lesions typical of AD: senile plaques (SPs) (Fig. 1A), characterized by 
extracellular deposition of amyloid-beta peptide (Aβ) filaments in the brain parenchyma, 
neurofibrillary tangles (NFTs) (Fig. 1B), intracellular deposits of hyperphosphorylated tau 
protein in the cytoplasm of neurons, and cerebral amyloid angiopathy (CAA), 
characterized by the deposition of Aβ in the vessel walls of the brain (3) (Fig. 1C).        
 
2. Senile plaques 
 Senile plaques (SPs) are extracellular lesions characterized by accumulation of the 
Aβ (Fig. 1A). These SPs are predominantly found in the gray matter of the neocortex and 
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hippocampus and are roughly spherical. In general, two types of SPs can be distinguished: 
diffuse senile plaques, predominantly composed of diffuse, non-fibrillar, Aβ1-42 peptide and 
abundantly present in the upper cortical layers, and classic senile plaques, composed of 
fibrillar Aβ, found in the deeper layers of the cortex (4). Classic senile plaques consist of 
both Aβ1-40 and Aβ1-42, and are characterized by a central core of amyloid surrounded by 
dystrophic neurites. Furthermore, classic SPs are also associated with activated microglia 
and reactive astrocytes. In contrast to the classic SPs, the diffuse SPs lack a fibrillar core, 
dystrophic neurites and gliosis. Since diffuse SPs lack the typical features of classic SPs, 
the hypothesis that diffuse SPs are immature SPs eventually developing into classic SPs, 
was postulated (3). This hypothesis was strengthened by the presence of diffuse SPs in 
brain areas that are not clinically implicated in AD, such as the cerebellum, the striatum 
and the thalamus, and the absence of classic SPs in these regions (5). In addition, diffuse 
SPs are also found in healthy aged individuals in the same brain areas as affected in AD. 
Finally, in transgenic mouse models, expressing mutant APP, diffuse SPs develop before 
fibrillar SPs become visible (6). On the other hand, other transgenic mouse models show 
that both cored and diffuse SPs appearing simultaneously, suggesting that diffuse SPs 
might not be simply immature classic SPs, but that classic SPs may develop independently 
(7).   
 
3. Neurofibrillary tangles 
 The second characteristic lesion of AD is the NFT, consisting of intracellular 
aggregates of tau protein in the cytoplasm of neurons (Fig. 1B). These aggregates are 
composed of hyperphosphorylated forms of the microtubule-binding protein tau and form 
two strands of filaments twisted around one another with a periodicity of 80 nm and a 
diameter varying from 8 to 20 nm (also called paired helical filaments PHFs) (8). The tau 
protein is abundantly expressed in the central nervous system, predominantly in axons 
(9), and is involved in the assembly of microtubules, neurite outgrowth, signal 
transduction and in organelle transport (10, 11). Although the underlying mechanism of 
the hyperphosphorylation and accumulation of the tau protein remains unclear, it is 
obvious that intracellular accumulation of hyperphosphorylated tau eventually results in 
neural loss. Hyperphosphorylation is believed to be a very early event in the formation of 
NFTs, which progresses from a soluble to an insoluble form and, eventually, to a 
filamentous protein (12). Unlike the distribution of SPs, the number of NFTs in AD is 
closely correlated with the cognitive decline observed in AD (13). In addition, the 
distribution of NFTs in the various brain areas is used to define six neuropathological 
stages, the Braak stages (14). Next to AD, NFTs are also found in other neurodegenerative 
diseases, collectively named “tauopathies”, including progressive supranuclear palsy, 
corticobasal degeneration, Pick's disease.  
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4. Cerebral amyloid angiopathy 
The third characteristic lesion of AD is CAA, defined as the accumulation of Aβ in 
the vessel wall of meningeal and cerebral arteries, arterioles, and, less frequently, 
capillaries and veins (Fig. 1C). Affected vessels are thickened and Aβ deposition is 
observed in the tunica media and adventitia. Like in classic SPs, both Aβ1-40 and Aβ1-42 
accumulate in the vessel wall in CAA, although the Aβ1-40 form is predominantly 
observed. In 80-90% of AD patients, CAA is present, and might therefore play an 
important role in the pathogenesis of AD. First, the frequency and severity of CAA is 
increased during the progression of AD (15). Second, CAA might lead to ischemia and 
hemorrhages that could contribute to the cognitive decline (16-18). Third, extensive CAA 
alone is sufficient to cause dementia in patients with hereditary cerebral hemorrhages 
with amyloidosis of the ‘Dutch’ type (HCHWA-D) and Iowa pedigree (16, 19). Although 
CAA is mostly found in the parietal, temporal and occipital regions, CAA is occasionally 
found in hippocampus, cerebellum and basal ganglia (20). Aβ accumulation in the vessel 
walls initiates degeneration of endothelial cells, smooth muscle cells (SMC) and pericytes 
(21, 22). Since both endothelial cells and pericytes are involved in the maintenance of the 
blood-brain barrier (BBB), degeneration of these cells may lead to dysfunction of the BBB 
in AD (23). Next to CAA, unrelated secondary vascular pathology, such as hypertension, 
diabetes mellitus, hypercholesterolemia and atherosclerosis, might also contribute to the 
pathogenesis of AD (24). Like SPs, Aβ-affected vessels show macrophage infiltration in the 
vessel wall, indicating that inflammatory reactions may also be associated with CAA. All 
these changes in the vessel wall may contribute to the vascular pathology and the 
development or progression of AD pathogenesis, although the exact implication of CAA 
on the pathogenesis of AD remains to be elucidated.  
  
5. Genetic factors in AD 
The amyloid precursor protein (APP) is a transmembrane protein encoded by a 
gene located on chromosome 21. The Aβ protein that accumulates in AD is a 4 kDa 
proteolytic cleavage product of this APP. Missense mutations within APP, that reside 
within the Aβ sequence, predominantly result in aggregation and accumulation of Aβ and 
are found in familial diseases related to AD. These familial diseases strengthened the 
hypothesis that the Aβ peptide is directly involved in the pathogenesis of AD. Patients 
A CB C
Figure 1. Immunochistochemical staining of the characteristic pathological lesions of AD. Senile plaque
(A, anti-Aβ (6C6)), neurofibrillary tangle (B, anti-hyperphosphorylated tau (AT8)) and cerebral amyloid
angiopathy (C, anti-Aβ (6C6)). Magnifications: A and C, 25 x and B, 40 x. 
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carrying the (693EQ) (25) mutation within the Aβ peptide, for instance, suffer from 
HCHWA-D. These patients are characterized by Aβ deposition in the cerebral vessel wall 
before the age of 65, causing fatal hemorrhages (26). Apart from the 22GluGln 
mutation, several other familial forms of dementia with mutations within APP have been 
found, such as the Arctic (693EG) and the Iowa (694DN) mutation both characterized 
by early-onset of AD and severe CAA (27, 28). The Flemish APP mutation (692AG) is 
characterized by severe CAA and large-core plaques (29, 30).  
Apart from mutations in the middle part of Aβ, mutations next to the N and C 
terminal part of Aβ also result in advanced aggregation and accumulation of Aβ in the 
brain before the age of 65. The Swedish double mutation is found next to the N-terminal 
part of Aβ (670KN, 671ML) (31). Mutations next to the C-terminal part of Aβ also 
cause early onset AD, such as the Florida mutation (716IV), the London mutation 
(717VI, F, G, L), the German mutation (715VA), and the French mutation (715VM) 
(32). Together, these findings indicated that APP mutations are directly involved in Aβ 
deposition and, thus, might play an important role in the pathogenesis in familial AD 
(FAD). However, in only a small number of the FAD cases mutations in the APP were 
found. Therefore, other genes had to be involved.  
One of the first non-APP mutations, linked to FAD, was found on chromosome 14, 
in the presenilin-1 gene (33). Both presenilin-1 (PS1) and presenilin-2 (PS2) are involved 
in the cleavage of Aβ from APP. Nowadays, 150 different PS1 mutations are known, all 
linked to early onset of AD (34, 35). Two PS1 mutations are also linked to the 
development of CAA, the L282V and the Q184D mutation. Both mutations cause 
extensive CAA in these patients (36, 37). Only a small number of AD patients have a 
mutation in the presenilin-2 gene (38, 39). Although PS1 and PS2 mutations are 
responsible for approximately 70-80% of the cases of early onset AD, FAD is rare and 
covers a minority of all AD cases.  
 
6. Risk factors in AD 
The cause of late-onset sporadic AD remains unknown, although this is the largest 
group of AD patients. Risk factor in AD can be divided into two groups, genetic risk 
factors and vascular risk factors. The apolipoprotein E (ApoE) gene is such a genetic risk 
factor for this type of AD (40). Of this gene, located at chromosome 19, three alleles exist, 
ApoE ε2, 3 and 4, differing from each other in only one amino acid, and of which the ε3 
allele is the most frequent one. The ApoE protein is a plasma glycoprotein involved in the 
cholesterol metabolism (41). Inheritance of one or two copies of the ε4 allele is associated 
with a dose-dependent increased risk for AD, and an earlier age of onset of AD (42, 43), 
although even individuals homozygous for ε4 may reach high age without cognitive 
impairment (44). On the contrary, the ε2 allele seems to have a protective effect against 
AD (45). Surprisingly however, both the ε2 and the ε4 allele are associated with an 
increased risk for CAA or CAA-related hemorrhages (46-49). Inheritance of one or two 
copies of the ApoE ε4 allele is associated with a higher load of SPs and CAA (47, 50). In 
vitro studies have shown that ApoE is able to bind to Aβ (51, 52): native ApoE3 binds Aβ 
more efficiently than ApoE4 (53). ApoE may also accelerate the formation of Aβ fibrils 
(51, 54, 55). In mice transgenic for human APP and deficient in ApoE, the amount of 
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amyloid, but not that of Aβ immunoreactivity, was strongly reduced in comparison with 
transgenic APP/ApoE+/+ mice (56), suggesting that ApoE plays a critical role in facilitating 
Aβ deposition. In contrast to these studies, early Aβ deposition is suppressed in mice 
transgenic for both APP and human ApoE on an ApoE knock-out background (57). These 
results show that the role of ApoE and its specific isoforms in Aβ fibrillogenesis, 
deposition, or clearance still remains unclear. Although ApoE appears to be a risk factor, it 
is not sufficient to cause AD. Therefore, a combination of risk factors or environmental 
factors might be necessary to cause AD.  
Recently, other potential genetic risk factors for AD have been suggested including 
loci on chromosome 1, 14, 21 and 10q (58). Apart from mutations within the APP gene or 
the PS genes (discussed in 5), genetic studies indicate that polymorphisms of some plaque-
associated pro-inflammatory cytokines as interleukin-1 and 6, and acute phase proteins as 
α1-antichymotrypsin, might also be risk factors for AD (59-62).  However, future research 
needs to confirm whether these genes are true risk factors for AD.  
Risk factors without clear genetic backgrounds, such as cardiovascular disease also 
seem to be associated with an increased risk of AD. Both atherosclerotic vascular disease 
and cerebral ischemia might play an important role in the development and progression of 
AD (63). In addition, factors such as hypertension, diabetes mellitus, high cholesterol, 
homocysteine levels, artial fibrillation, and cigarette smoking are also risk factors for AD 
(24). Although age seems to be the most important risk factor for AD, other factors such as 
lower educational levels and head injury are also associated with increased risk of AD 
(64).  
 
7. The amyloid precursor protein (APP)  
Both SPs and CAA are formed by extracellular deposition of aggregated Aβ. This 
Aβ protein is a 4kDa proteolytic cleavage product of APP (Fig. 2) (65). APP is a type I 
transmembrane membrane-anchored glycoprotein, and member of the amyloid precursor-
like proteins (APLPs), including APLP1 and APLP2 (66-68). Both APLP1 and APLP2 lack 
the Aβ fragment. APP is encoded by a gene on chromosome 21 and yields several 
isoforms, such as the APP695, APP751 and full length APP770, according to the number 
of amino acids. Although all APP isoforms are expressed in various tissues, in neuronal 
tissue only the APP695 form is expressed. Soluble forms of APP act as autocrine factors 
and are known to have neuroprotecting and neurotrophic properties (69, 70). Both 
APP751 and APP770 contain a KPI motif (Kunitz protease inhibitor domain), and are able 
to inhibit serine proteases such as trypsin and chymotrypsin (71). APP is synthesized in 
the endoplasmatic reticulum and post-translationaly modified by N- and O-glycosylation 
before transportation to the cell surface.   
APP is proteolytically degraded by a number of enzymes (designated as secretases). 
APP cleavage can be divided into two major pathways; the amyloidogenic pathway and 
the non-amyloidogenic pathway. In the non-amyloidogenic pathway, the first secretase 
involved in the cleavage of APP, is α-secretase. Several candidates for this secretase have 
been suggested, such as ADAM 9, ADAM 10 (A membrane-bound Disintegrin And 
Metalloproteinases) and TACE (tumor necrosis factor alpha converting enzyme) (72, 73). 
The result of this cleavage is a C-terminal fragment called C83 that remains in the 
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membrane, and a large APPs-α fragment that is released into the extracellular space. The 
remaining C83 fragment is cleaved by a γ-secretase, resulting in the production of a small 
peptide (p3), of which little is known. γ-Secretase is a protein complex composed of 
presenilin (PS), nicastrin (NCT), anterior pharynx defective-1 (APH-1) and PEN-2 
(presenilin enhancer) (74). 
Cleavage of APP at the N-terminus by β-secretases, is the start of the 
amyloidogenic pathway. Two enzymes capable of this type of cleavage are β-site APP-
cleaving enzyme 1 and 2 (BACE1 and BACE2) (75). Both are membrane-bound aspartyl 
proteases and cleave the APP protein generating a large secreted derivative (APPs-β) and 
a membrane bound APP carboxy-terminal fragment (C99). BACE2 mRNA has a very low 
or even undetectable expression in most brain regions (76). On the other hand, BACE1 is 
expressed by neurons in most brain regions, and knockout studies of BACE1 demonstrated 
that BACE1 is the authentic β-secretase, initiating the formation of Aβ (77).  After 
cleavage of APP by β-secretases, the C99 fragment is cleaved by γ-secretase, releasing an 
Aβ peptide of 40 or 42 amino acids, Aβ1-40 or Aβ1-42, respectively. 
 
  
 8. The amyloid-β peptide 
Amyloid-β (Aβ) is a 4 kDa proteolytic cleavage product of the APP transmembrane 
protein. The soluble form of the 4 kDa Aβ peptide is capable of self-aggregation, forming 
dimers, oligomers, protofibrils and eventually mature Aβ fibrils. The first stages in the 
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Figure 2. Schematic representation of transmembrane protein APP and its cleavage product amyloid-β.
The Aβ peptide is proteolytically cleaved from APP by β-secretases and γ-secretases. This cleavage
results in two Aβ forms, the Aβ1-40 and the Aβ1-42 peptide (40 and 42 amino acids, respectively).
Mutations within and near the Aβ peptide: the ‘Dutch’ mutation (693EQ), Artic mutation (693EG),
Iowa mutation (694DN), Flemish mutation (692AG), Swedish double mutation (670KN,
671ML), French mutation (715VM), German mutation (715VA), Florida mutation (716IV), and
London mutation (717VI, F, G, L). The numbering of the mutations is according to the amino acid
sequence of APP. KPI; Kunitz protease inhibitor domain. 
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aggregation of Aβ is the formation of so-called ‘seeds’, which appear as spherical or 
globular aggregates (Fig. 3), with a molecular mass between 103-107 kDa (78, 79).  
In addition, Aβ oligomers are formed that are rich of β-sheet structures (80). The N-
terminus of the Aβ peptide is believed to play a dominant role in the conformational 
switch to these β-sheets (81). The precursors of mature Aβ fibrils are the protofibrils; these 
aggregates have a curved appearance and are shorter than the fully mature fibrils. 
Protofibrils have a diameter of approximately 30 Å and are 200-700 Å in length (82) (Fig. 
3).  
In addition, bundles of protofibrils form nodular fibrils, and eventually 
unbranched mature fibrils with a helix structure, 70-120 Å in diameter and of varying 
length (Fig. 3). These mature Aβ fibrils are rich in β-sheets and both the core of classic SPs 
and CAA consist of these mature Aβ fibrils, whereas diffuse SPs rather contain more 
soluble forms of Aβ. Although these mature Aβ fibrils are found in the pathological lesions 
of AD, they are suggested to be less toxic than oligomers and protofibrils which are 
directly linked to neurotoxicity (80, 82). 
Aβ is a proteolytical cleavage product of the APP, released by the cleavage of γ- 
and β-secretases (as described in 7). Several forms of the Aβ peptide result from this 
 
Figure 3. Schematic model of the different stages in the amyloid fibril formation process: i) monomeric
Aβ1–42 associates to form protofibrils and globular oligomers; the data presented here do not provide
evidence for the incorporation of oligomers into growing protofibrils (ii); protofibrils that reach  100 nm
can form bundles (iii); through end-to-end stacking (iv), bundles generate the nodular type fibrils (v),
which may be related to a helical structure formed by intertwined protofilaments (vi); finally, nodular
fibrils might evolve further to yield smooth fibrils (vii). To illustrate the model, AFM images of the
different structures are included. Reprint from Arimon et al (162). 
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cleavage process, however, the two major products are Aβ1-40 and Aβ1-42. Although both 
peptides only vary in 2 amino acids from each other, Aβ1-42 is much more hydrophobic 
and has a higher propensity to form Aβ aggregates that play a role in the degeneration of 
the various brain cells (83). Normally, both peptides are secreted at a fixed ratio, 90% of 
all Aβ being secreted as Aβ1-40, whereas Aβ1-42 comprises 10% of the total Aβ pool. The 
importance of this ratio in the development of AD and other familial forms of dementia 
linked to AD was discovered in patients having mutations in the Aβ peptide, which 
resulted in an imbalance in this fixed Aβ1-40:Aβ1-42 ratio. Both the Flemish APP mutation 
and the Swedish double mutation result in an increase in Aβ1-42 production, and shifts the 
Aβ1-40:Aβ1-42 ratio at the expense of Aβ1-40 (29-31). More recently, it was found that 
mutations in the presenilin-1 and presenilin-2 (PS1, PS2) genes also result in an increased 
production of the amyloidogenic Aβ1-42, suggesting involvement of these presenilins in 
APP cleavage (γ-secretase) activity. Thus, both mutations within APP and PS1 and PS2 
reveal the mechanisms that lead to the disturbance of the Aβ balance in the brain and 
provide tools to investigate the processes that eventually lead to AD. However, in the 
development of sporadic AD, the most common form, these mutations are absent. So, 
other mechanisms might be involved that lead to a disturbance in this Aβ1-40:Aβ1-42 ratio in 
the brain, and thus play an important role in the pathogenesis of AD. 
 
 
9. Amyloid-β interacting proteins  
In vivo, Aβ does not only interact with itself, it also interacts with various other 
proteins. This suggests that proteins that bind Aβ might influence the aggregation process 
of Aβ and thus its bioactivity and toxicity. Although many different macromolecules 
interact with Aβ, the best studied proteins are apolipoprotein E (ApoE) (84), 
glycosaminoglycans (GAGs), heparan sulfate proteoglycans (HSPGs) (85, 86), serum 
amyloid P (SAP) (87) and complement factors (C1q, C3d and C4d) (88).  
Since ApoE immunoreactivity was found in extracellular amyloid deposits in 
subjects with AD and Creutzfeldt-Jakob disease, it was suggested that ApoE might play 
role in the aggregation, accumulation and deposition of Aβ (89, 90). This idea is supported 
by the finding of association of ApoE with both fibrillar and soluble Aβ, isolated from AD 
brains (91-93). In vitro studies provided evidence for a direct interaction of ApoE with 
Aβ, and the formation of stable ApoE-Aβ complexes (84, 94), which are formed in an 
ApoE isoform-specific manner (ε2>ε3>>ε4) (95, 96).  In addition, ApoE does not only bind 
Aβ, it also promotes the conformation of soluble Aβ to β-sheet-rich amyloid (97, 98).  
Proteoglycans are biological macromolecules characterized by side chains of linear 
sulfated polysaccharides, consisting of disaccharide units, covalently bound to a core 
protein. Among the members of this protein superfamily is the HSPG family. HSPGs can 
be divided into a family of extracellular matrix proteins, including perlecan, agrin and 
collagen XVIII, and a family of cell surface proteins, including syndecans and glypicans 
(99, 100). Ever since GAGs were demonstrated in amyloid deposition, the proteoglycans 
became a topic of interest in amyloidogenesis. The presence of HSPGs in SPs, CAA and 
NFTs in AD brains was already discovered in the early nineties (86, 101, 102). Nowadays, 
it is shown that in both diffuse and classic SPs several HSPG are found, such as agrin, 
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glypican 1 and syndecan 1-3, whereas collagen XVIII is only demonstrated in classic SPs 
and CAA (103-105, 105, 106). These co-localizations suggest that HSPGs interact with Aβ 
and contribute to the development or persistence of SPs or CAA. Furthermore, HSPGs, 
isolated from the Engelbreth-Holm-Swarm tumor, prevented proteolytic breakdown of 
aggregated Aβ (107). In addition, both agrin and perlecan directly interact with Aβ, 
promote the conversion of non-fibrillar Aβ into fibrillar Aβ (103, 108-110), and thus 
might be directly involved in the formation of SPs or CAA. Recently, it has been 
suggested that the sulfated group of the proteoglycans play a role in the interaction with 
Aβ, since small polysulfated compounds demonstrated a protective activity against Aβ-
induced effects (111). Therefore, highly sulfated compounds, such as sulfated GAG 
mimetics, might offer a novel therapeutic strategy, since these compounds inhibit binding 
of GAGs to Aβ and might block adherence of Aβ to the cell surface (112, 113). 
 In AD brains, the expression of several complement factors is increased (114-116), 
and Hageman Factor, C1q, C3 and C5-9 are commonly found in SPs and NFTs (114, 117-
119). Beside reactive astrocytes as a source of complement, neurons also seem to produce 
complement factors (120) and activation of complement in an antibody-independent 
fashion is achieved by binding of aggregated, but not soluble, Aβ to C1q (121-124). This 
latter finding suggests that in AD the aggregated Aβ might induce a chronic activation of 
complement. Cultured human microglial cells show an increase in cytokine production 
after co-stimulation of Aβ with C1q (119), whereas the inhibiting factor (C1 INH), is 
downregulated in AD (125, 126). Furthermore, complement activation can protect against 
Aβ-induced toxicity and even may reduce the accumulation of Aβ in SPs (127).   
  
10. Amyloid-β clearance from the brain 
Accumulation of Aβ in the brain is the key event in the pathogenesis of AD. 
Increased production of Aβ, however, does not seem to be responsible for late-onset AD 
or the familial forms of CAA, e.g. the Dutch and Iowa kindreds (128, 129). Rather, 
inefficient clearance of Aβ might result in the accumulation of Aβ observed in AD. Recent 
studies demonstrated that Aβ is cleared from the CNS towards the blood via transport 
across the blood-brain barrier (BBB) into the bloodstream (130, 131). The endothelium of 
brain vessels does not allow free exchanges of peptides such as Aβ, therefore, specialized 
transporters regulate passage of Aβ across the BBB. This specialized transport is mediated 
by specific Aβ-receptors, which directly bind Aβ, or bind Aβ in a complex with Aβ-
associated proteins such as ApoE, allowing it to cross the BBB, thereby regulating the 
clearance of Aβ from the brain (132). The low-density lipoprotein receptor (LDLR) gene 
family includes two receptors suggested to mediate Aβ clearance from the brain. First, the 
LDLR is a transmembrane receptor for internalizing cholesterol-containing lipoproteins 
(133). Second, the low-density lipoprotein receptor-related protein-1 (LRP-1) is a 
multifunctional scavenger receptor that plays a role in the homeostasis of proteinases and 
proteinase inhibitors, in cellular signal transduction, vascular wall integrity and protection 
against atherosclerosis (134-139). LRP-1 binds Aβ at the abluminal side of the 
endothelium and regulates its clearance from the brain to the blood by controlling its 
efflux across the BBB (131, 132). Accordingly, LRP-1 depletion in animal models resulted 
in increased cerebral amyloid (140). All members of the LDL receptor family are capable 
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of binding apolipoprotein E, the important risk factor in AD that is able to form a complex 
with Aβ, and transport this ApoE/Aβ complex across the BBB (141).  
 In addition to these two receptors, a number of other potential Aβ receptors exist, 
including megalin, p-glycoprotein, RAGE, CD36, the formylpeptide receptor-like-1, and 
APP. The Aβ-receptor megalin might also be involved in the efflux of Aβ from the brain. 
Although megalin does not directly bind to Aβ, this Apolipoprotein J (ApoJ) receptor is 
assumed to transport ApoJ-Aβ complexes from brain to blood (142, 143). P-glycoprotein or 
MDR1 is a multi-drug transporter that could also take part in the efflux of Aβ across the 
BBB (144). RAGE, a multiligand receptor in the immunoglobulin superfamily, expressed on 
brain endothelium, also binds soluble Aβ (145). However, in contrast to LRP-1, RAGE 
transports Aβ from the circulation into the CNS (146). The scavenger receptor CD36 is 
expressed on microglia and endothelial cells in the brain, and is suggested to act as a 
receptor for fibrillar Aβ, whereas the formylpeptide receptor-like-1 (FPRL1) mediates the 
chemotactic activity of Aβ, and plays a role in the endocytosis and aggregation of Aβ in 
mononuclear phagocytes (147-149). Finally, APP itself also acts as an Aβ-receptor, and 
binds to a variety of fibrillar forms of Aβ (150, 151).  
 Transport of Aβ from the brain into the circulation is crucial in regulating the 
concentration of soluble Aβ in the CNS (132), and thus, for the prevention of formation of 
toxic oligomeric and aggregated Aβ species in the brain (152). Nowadays, several 
therapeutic approaches are being studied to achieve stimulation of Aβ clearance from the 
brain. First, immunization with aggregated Aβ reduced the SPs load in transgenic mice as 
demonstrated by Schenk and colleagues (153). The modulation of the plaque load was 
caused by serum IgG directed against the aggregated Aβ (154, 155). Vaccination with Aβ 
resulted in clearance of SPs and even prevented loss of memory (156). However, 
vaccination only seemed to be effective in rather young mice, whereas in aged mice, 
clearance was less pronounced (156). Accordingly, after passive immunization with 
immunoglobulin G directed against aggregated Aβ similar effects were observed (154, 
155). However, immunization also demonstrated some unfortunate side effects. In 
transgenic mice that develop CAA while they age, an increase in CAA-associated cerebral 
hemorrhages was observed after immunization (157), and immunization of patients in a 
phase II clinical trial resulted in a rather unacceptable outcome, since several patients 
developed fatal meningoecephalitis (158).     
 Presently, there are two hypotheses on the mechanism of clearance of Aβ from 
the brain by either passive or active immunization. First, IgG binds Aβ and triggers the 
microglial cells to clear the plaques via phagocytosis (154, 155). Secondly, the anti-Aβ 
antibodies bind Aβ and by doing so induce a change in the Aβ equilibrium between the 
central nervous system and the plasma, serving as a so-called peripheral “sink” (159, 160). 
Active immunization of transgenic mice demonstrated a 28-fold increase in serum Aβ 
induced by the immunization, supporting the “sink-hypothesis” (160). In addition, 
treatment with other Aβ peripheral-binding agents also increased the levels of Aβ in the 
plasma in transgenic mouse models of AD (130, 146, 161).  
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 In conclusion, accumulation of Aβ in the brain seems to be the key event in AD 
pathogenesis. Mutations found in the APP gene, such as in HCHWA-D patients, and in 
the secretases (PS1 and PS2) demonstrated that not only the increasing amounts of Aβ in 
the brain, but also a shift in the Aβ1-40:Aβ1-42 ratio seems to be an early event in the 
pathogenesis of AD. This accumulation of the more amyloidogenic Aβ1-42 is suggested to 
trigger Aβ self-aggregation, forming neurotoxic Aβ oligomers and protofibrils. Since 
clearance of these intermediates from the brain is far less efficient than soluble Aβ, toxic 
aggregates significantly contribute to the increasing burden of Aβ in the brain. Aβ-
binding proteins, such as ApoE, not only prevent the interaction of Aβ with itself, and 
thus prevent the formation of toxic Aβ intermediates, but also have a positive contribution 
in the clearance of soluble Aβ from the brain, as demonstrated for Aβ/ApoE-complexes. 
Therefore, Aβ-binding proteins might play an important role in the development of AD, 
and thus, may form important targets for therapeutic intervention in AD. 
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Outline of this thesis 
 
Chapter 2 
This chapter summarizes current literature on the involvement of several Aβ-binding 
proteins, such as apoliprotein E, HSPGs, complement factors and heat shock proteins in 
the pathogenesis of AD. These Aβ-binding proteins often colocalize with the pathological 
lesions of AD and directly bind to Aβ. Several of these Aβ-binding proteins affect 
aggregation and accumulation of Aβ in vitro and in vivo. Since these Aβ-binding proteins 
form complexes with Aβ, they might play an important role both in receptor-mediated 
clearance of Aβ from the brain and in inflammation. 
 
Chapter 3 
Since AD is a disease in which misfolded proteins play an import role in the pathogenesis, 
we investigated the distribution of members of the small heat shock protein family (sHsp), 
proteins with chaperone activity, in control brains and in the pathological lesions of AD.  
  
Chapter 4 
Our immunohistochemical data show that sHsps such as αB-crystallin, Hsp27, Hsp20 and 
HspB2/B3 are associated with AD lesions. We therefore investigated the possible binding 
of these sHsps with various types of Aβ and studied the effects of this binding on Aβ 
aggregation and Aβ-mediated cell death of cerebrovascular cells. 
 
Chapter 5 
HspB8 is a recently discovered member of the sHsp family. Since several members of the 
sHsp family do not only colocalize with AD lesions, but also directly bind Aβ and inhibit 
its aggregation and Aβ-mediated cell death of cerebrovascular cells, we studied the 
distribution of HspB8 in AD. In addition, we investigated if HspB8 could bind to Aβ, and 
affect Aβ aggregation and its biological activity. 
 
Chapter 6 
On the basis of the differential distribution of sHsps in AD and their different effects on 
the bioactivity of various Aβ peptides, we investigated the distribution of sHsps in patients 
with hereditary hemorrhage with amyloidosis of the Dutch type (HCHWA-D). Since 
several members of the sHsp family colocalize with CAA in these patients, we studied the 
possible Aβ-mediated upregulation of sHsps by cultured cerebrovascular cells and 
astrocytes. In addition, we investigated the role of sHsps in cytokine production by both 
cultured cerebrovascular cells and astrocytes. 
 
Chapter 7 
The ε4 allele of apolipoprotein E (ApoE) is a risk factor for AD, whereas the ε2 allele may 
be relatively protective. Both alleles are risk factors for cerebral amyloid angiopathy 
(CAA)-related hemorrhages. Furthermore, it is known that ApoE binds to Aβ and may 
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modify its biological activities. In this chapter we evaluated if susceptibility of Aβ-
mediated cell death is directed by ApoE genotype. 
 
Chapter 8 
Aβ clearance from the brain to blood across the blood-brain barrier is receptor-mediated. 
In this chapter we investigated the distribution of Aβ-receptors in various brain vessels 
and compared the distribution of these receptors between normal, AD and HCHWA-D 
brains. In addition, we investigated the expression of Aβ-receptors on both cultured 
cerebrovascular cells and astrocytes and the effect of Aβ on their expression level. 
Accordingly, we studied the role of these receptors in Aβ uptake and Aβ-mediated cell 
death of both cultured cerebrovascular cells and astrocytes.   
  
Chapter 9 
In this chapter we summarize and discuss the results of this thesis and propose future 
research plans. 
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Abstract 
 
The pathologic lesions of Alzheimer’s disease (AD) are characterized by accumulation of 
protein aggregates consisting of intracellular or extracellular misfolded proteins. The 
amyloid-β (Aβ) protein accumulates extracellularly in senile plaques (SPs) and cerebral 
amyloid angiopathy (CAA), whereas the hyperphosphorylated tau protein accumulates 
intracellularly as neurofibrillary tangles (NFTs). “Professional chaperones”, such as the 
heat shock protein family, have a function in prevention of protein misfolding and 
subsequent aggregation. “Amateur” chaperones, such as apolipoproteins, heparan sulfate 
proteoglycans and complement factors bind amyloidogenic proteins and may affect the 
aggregation process of amyloidogenic proteins and their routing to degradation by the 
proteasome. Both professional and amateur chaperones colocalize with the pathological 
lesions of AD and may affect inflammatory reactions associated with these lesions. In 
addition, chaperones might also be involved in clearance of Aβ from the brain via 
phagocytosis or active transport across the blood-brain barrier. Thus, both professional 
and amateur chaperones may be involved in aggregation, accumulation, persistence and 
clearance of Aβ and tau and in inflammation associated with these lesions, and may 
therefore serve as potential targets for therapeutic intervention.  
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1. Introduction 
 Pathological lesions consisting of intra- and/or extracellular accumulations of 
misfolded proteins are characteristic for neurodegenerative diseases, such as Alzheimer’s 
disease (AD). AD is characterized by three distinct pathological lesions: senile plaques 
(SPs), neurofibrillary tangles (NFTs) and cerebrovascular amyloid angiopathy (CAA) (3). 
Both SPs and CAA are formed by extracellular deposition of aggregated amyloid-beta 
protein (Aβ), whereas NFTs consist of intracellular aggregates of hyperphosphorylated tau 
protein in the cytoplasm of neurons (8, 65). The Aβ protein is a 4kDa proteolytic cleavage 
product (65) of the transmembrane amyloid-β precursor protein (APP). The two major 
forms of Aβ expressed in human brain are Aβ1-40 and Aβ1-42, differing from each other only 
by 2 amino acids. Cerebral production of Aβ is normally balanced by clearance from the 
brain either via active transport across the blood-brain barrier (BBB), or via uptake and 
degradation of Aβ by microglial cells and astrocytes (132, 163, 164). Active transport of Aβ 
is mediated by Aβ-receptors that are able of transporting Aβ, or Aβ in complex with other 
proteins, across the BBB (165). In contrast to normal brain, the cerebral Aβ balance is 
disturbed in AD brains, resulting in accumulation and aggregation of Aβ.  
Aβ aggregation results in the formation of Aβ oligomers, protofibrils and 
eventually mature fibrils. Both Aβ oligomers and protofibrils that accumulate in the brain 
parenchyma (SPs) (166, 167), as well as in the outer portion of the media of vessels (CAA), 
are considered the most toxic forms of Aβ resulting in degeneration of neurons and of 
cells of the vessel wall, such as smooth muscle cells and pericytes. In addition, Aβ 
aggregates do not clear from the brain as efficiently as soluble Aβ, and thus directly lead to 
increased levels of Aβ in the brain (168). Furthermore, deposition of Aβ in SPs is 
accompanied by attraction and activation of both microglial cells and astrocytes (4, 122, 
169). Activation of these cell types results in increased secretion of pro-inflammatory 
cytokines, eventually initiating a robust inflammatory reaction.  
In the pathological lesions of AD, “amateur chaperones” co-deposit with Aβ and 
tau, such as apolipoprotein E (ApoE), heparan sulfate proteoglycan (HSPGs), complement 
factors, α1-antichymotrypsin, α2-macroglobulin, serum amyloid P, intercellular adhesion 
molecule-1, tissue-type plasminogen activators, gelsolin and gangliosides. In addition, 
“professional chaperones” such as the heat shock proteins (HSP) are associated with the 
pathogenesis of AD. In general, all these proteins do not only colocalize with the AD 
lesions but also bind Aβ and affect its aggregation, accumulation and deposition in the 
brain. Aβ-binding proteins may also regulate receptor-mediated clearance of Aβ from 
brain via transport across the BBB or via phagocytosis by microglial cells and astrocytes. 
Finally, Aβ-binding proteins might contribute to the inflammatory process observed in 
association with the pathological lesions of AD. We will review these various aspects of 
amateur and professional chaperones in the pathogenesis of AD. 
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2. Aβ-binding proteins in extracellular interaction with Aβ. 
 
2.1 Apolipoproteins 
The apolipoprotein family consists of proteins that combine with lipids in order to 
form different classes of lipoprotein particles. In human brain, several members of this 
protein family are expressed, such as apolipoprotein E (ApoE), apolipoprotein J (ApoJ) and 
apolipoprotein D (apoD). ApoE is a major determinant of lipid transport and metabolism 
and is expressed in brain by astrocytes, microglia, pericytes and smooth muscle cells (170-
174). In human, three common isoforms are expressed; apoE2, apoE3 and apoE4, which 
are all products of alleles at a single gene locus (175, 176). Apolipoprotein J, also known as 
clusterin or SP-40/40, is a highly conserved heterodimeric secreted glycoprotein expressed 
in brain by epithelial and neuronal cells (177). ApoD is a glycoprotein associated with 
high-density lipoproteins in human plasma, and also has a high expression level in human 
brain (178), but neither its physiological role nor its ligand have been identified.  
For the common, late-onset form of AD, several genetic risk factors have been 
described. Yet, until now only the presence of the ε4 allele of ApoE is confirmed as a 
genetic risk factor in multiple independent studies, whereas the ε2 allele appears to be 
protective against AD (179-182). Since ApoE immunoreactivity was found in extracellular 
amyloid deposits in subjects with AD, it has been suggested that ApoE might have an 
effect on amyloidogenesis (89, 90), which is supported by data on the association of ApoE 
with both fibrillar and soluble Aβ, isolated from AD brains (91-93). In vitro studies 
provided evidence for a direct interaction of ApoE with Aβ, and the formation of stable 
complexes (84, 94). Binding of ApoE to Aβ is, however, ApoE isoform-dependent 
(ε2>ε3>>ε4) (95, 96). In addition, ApoE4 also promotes the conversion of soluble Aβ into 
β-sheet-rich amyloid more than ApoE3 (97, 98, 183). Recently, we demonstrated that 
production levels of ApoE are also isoform specific (ε2>ε3>ε4), and that cultured human 
brain pericytes (HBPs) with an ApoE4 genotype were more vulnerable to Aβ-mediated 
cytotoxicity than cerebrovascular cells with other ApoE genotypes (174). Thus, apart from 
the ApoE isoform, absolute ApoE levels might also direct Aβ aggregation. This hypothesis 
was strengthened by the observation that ApoE provides a dose-dependent protective 
effect against Aβ in vivo (184). In addition, only physiologically secreted ApoE affected 
Aβ-mediated toxicity, whereas recombinant, naive, ApoE was ineffective. Indeed, the 
binding of ApoE to Aβ may be modulated by the degree of lipidation of ApoE (95). These 
data suggest that the degree of lipidation of ApoE may strongly affect its biological 
function. 
The effect of ApoE on Aβ deposition in vivo has been extensively studied in several 
transgenic (Tg) mouse models. In contrast to its effect on Aβ in vitro, where a consistent 
accelerating effect of ApoE on Aβ aggregation is observed, the data obtained in these Tg 
mouse studies are less equivocal. Both Aβ immunoreactivity and amyloid formation was 
dramatically reduced in 6 months-old PDAPP/ApoE knock-out mice compared to PDAPP 
mice carrying the ApoE gene (97). Similarly, in 22 months-old APPV717F Tg mice absence 
of ApoE significantly reduced Aβ immunoreactivity and amyloid formation (98). 
Furthermore, CAA and associated microhemorrhages were suppressed in APPSwe and 
PDAPP Tg mouse models when bred onto an ApoE knock-out background (185). A 
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possible contribution of ApoE in plaque formation was recently demonstrated by 
administration of a synthetic peptide, Aβ12-28P, which blocked the formation of 
ApoE/Aβ-complexes and reduced the Aβ load and plaque density (186). In contrast to the 
effects of murine ApoE, both human ApoE3 and ApoE4 suppressed Aβ deposition in 9 
months-old APPV717F Tg mice (187). When these mice aged until 15 months, however, 
ApoE4 induced a 10-fold higher deposition of fibrillar Aβ than ApoE3 (188). Consistent 
with these latter results, human ApoE4 accelerated Aβ deposition in APPSwe Tg mice 
relative to human ApoE3 (189). Intracerebral injection of lenti-ApoE4 increased Aβ 
deposition in PDAPP mice lacking ApoE, whereas other ApoE isoforms were less 
effective, although in mice expressing mouse ApoE, injection of ApoE2 reduced the Aβ 
burden in the brain (190). In addition, when human ApoE3 or ApoE4 were knocked-in in 
Tg2576 mice, Aβ deposition was reduced compared to mice carrying endogenous ApoE at 
9 months, and at 15 months substantial CAA was observed in the mice with human 
ApoE4, but not with human ApoE3, and in either case parenchymal Aβ was sparse (191). 
Thus isoform- and species-specific differences in ApoE direct the aggregation or clearance 
of Aβ. In addition, as stated above, the degree of lipidation of ApoE may be crucial to its 
interaction with Aβ and subsequent its biological effects. In mice deficient for ABCA1, 
ApoE is relatively delipidated and as a result ApoE was retained in insoluble fractions of 
the brain and Aβ load was increased in mice carrying additional Tg-SwDI (192). 
Furthermore, it is suggested that the presence of ApoE facilitates internalization and 
degradation of Aβ from brain parenchyma by astrocytes (193), and human ApoE may 
reduce Aβ deposition in mouse brain by facilitating Aβ transport across the BBB (187). 
Besides colocalization of ApoE with Aβ in AD brains, ApoE is also found within 
neurons containing NFTs (89), where it is able to interact directly with tau protein (194). 
Furthermore, ApoE has an isoform-dependent effect on tau phosphorylation, since ApoE3 
binds to tau in vitro, whereas ApoE4 fails to bind tau (195). In addition, an ApoE4-
dependent increase in phosphorylated tau has been observed (196-198).  
ApoE is not the only apolipoprotein that might play a role in AD pathogenesis, 
since apolipoprotein J and D are also found in AD lesions (199, 200). ApoJ was 
demonstrated to colocalize with fibrillar deposits of amyloid and it is suggested that it 
prevents misfolding and aggregation of soluble Aβ (201-203). In addition, ApoD levels are 
increased in the hippocampus of AD patients and in apoE-deficient mice (204, 205). In 
conclusion, the apolipoprotein family, especially ApoE, seems to facilitate Aβ aggregation 
in vitro. In general, ApoE plays an important role in the formation of fibrillar Aβ deposits 
in the brain. By accelerating the Aβ aggregation process towards mature fibril formation, 
(human) ApoE probably prevents the formation of toxic Aβ intermediates, such as 
oligomers and protofibrils, and might thus have a protective function towards 
development of AD. In addition, ApoE may facilitate the Aβ clearance from the brain (see 
paragraph 4). 
 
2.2 Heparan Sulfate Proteoglycans (HSPG) 
 Proteoglycans are macromolecules with a wide variety of functions ranging from 
simple physical support, to various effects on cell adhesion, motility, proliferation, 
differentiation and even tissue morphogenesis. The proteoglycans are composed of linear 
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sulfated polysaccharides (glycosaminoglycans, GAGs), consisting of disaccharide units, 
covalently bound to a core protein. One of the members of this protein superfamily is the 
heparan sulfate proteoglycan (HSPG) family, characterized by polymers of repeating 
disaccharides, N-acetylglucosamine and glucuronic acid, which can be subsequently 
modified by sulfatation (99, 206). HSPGs can be subdivided into a family of extracellular 
matrix proteins, including perlecan, agrin and collagen XVIII, and a family of cell surface 
proteins, including syndecans and glypicans (99, 100).  
Ever since GAGs were demonstrated in amyloid deposits, the proteoglycans 
became of interest in amyloidogenesis. The presence of HSPGs in SPs, CAA and NFTs in 
AD brains was already demonstrated in the late eighties (86, 101, 102). Only when 
antibodies became available that could identify the various HSPG subtypes, it was 
described that perlecan colocalized with all three lesions characteristic of AD brains (102, 
207, 208). However, we were not able to confirm these findings (106, 209). Furthermore, 
it was shown that in both diffuse and classic SPs several other HSPGs were found, such as 
agrin, glypican 1 and syndecan 1-3, whereas collagen XVIII is only present in classic SPs 
and CAA (103-105, 105, 106).  
The occurrence of HSPGs in SPs and CAA suggests that HSPGs interact with Aβ, 
thereby contributing to development or persistence of SPs or CAA. HSPGs isolated from 
Engelbreth-Holm-Swarm tumor, prevented proteolytic breakdown of aggregated Aβ 
(107). In addition, both agrin and perlecan directly interacted with Aβ, and promoted 
conversion of non-fibrillar Aβ into fibrillar Aβ (103, 108-110). Although the interaction 
between HSPGs and Aβ is likely predominantly mediated by the sulfate moieties of the 
GAGs, a role for the protein backbone in Aβ aggregation could not be excluded (210, 211). 
Since sulfated GAGs were also demonstrated in NFTs in AD brains (85), it was suggested 
that these macromolecules might also play a role in tangle development. Indeed, sulfated 
GAGs may induce the formation of paired helical filaments, by stimulating tau 
phosphorylation (212).  
Since heparan sulfates bind to Aβ and interfere with its fibrillogenesis, they are 
interesting candidates for therapeutic intervention (213). GAG mimetics are able to 
inhibit this binding and may block the formation of β-pleated sheets and adherence of Aβ 
to the cell surface (214). The use of GAG mimetics is already being tested in mouse 
models, where they reduced progression of inflammation-associated amyloidosis (111). 
The efficiency of one of these compounds is currently tested in a human phase III trial.  
In conclusion, HSPGs do not only colocalize with Aβ and tau, but they might 
contribute to the development of these lesions. The role of HSPGs in Aβ aggregation 
might even be a protective one. HSPGs might prevent the persistence of toxic Aβ forms, 
e.g. oligomers or protofibrils, and transform them into more harmless aggregates, i.e. the 
classic senile plaques, containing mature Aβ fibrils that are less toxic than the 
intermediate aggregates. The ability to recognize such different proteins may originate 
from the heterogeneous structure of the heparan sulfate chains. The negatively charged 
HS chains are structurally heterogeneous and bind a diverse repertoire of proteins, such as 
amyloid A, protease-resistant prion protein, α-synuclein and tau, providing HSPGs with 
the ability to interact with a wide range of intracellular and extracellular amyloidogenic 
proteins (206).  
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2.3 Complement factors 
The complement system is an ancient host defense mechanism, which is involved 
in boosting antibody activity. The system consists of a group of soluble serum proteins C1-
C9 and is activated either by immunoglobulin M or G bound to a foreign particle or 
directly by microorganisms. Proteins such as Hageman Factor, C4 binding protein, CDS46, 
CD59 and C1 inhibitor regulate the complement system. In AD, the complement system is 
over-expressed and activated (215). The Aβ protein itself activates this system and 
complement factor concentrations are increased in AD brains (114-116). Aβ induces C3 
and C4 in AD, and elevated levels of the membrane attack complex (MAC), composed of 
C5-C9 are observed (124, 216). In addition, factors such as Hageman Factor, C1q, C3 and 
C5-9 are commonly found in SPs and NFTs (114, 117, 118). C1q is not only associated 
with Aβ deposits, it also binds fibrillar Aβ which activates the complement system (217). 
In contrast, the complement inhibitor (C1 INH) is downregulated in AD (125, 126). Thus, 
an activated complement system seems to be a general feature observed in AD. However, 
the contribution of complement to the pathogenesis of AD is controversial.  
On the one hand, it is suggested that complement activation protects against Aβ-
induced toxicity and even contributes to reducing the accumulation of Aβ in SPs (127). 
Transgenic mice expressing complement inhibitors develop increased AD-pathology, 
whereas increased complement C3 production was associated with a reduction of Aβ 
deposition (127). Thus, the complement activation in the brain may be beneficial in AD 
and possibly also other neurodegenerative diseases (218-220).   
On the other hand, complement activation may lead to accelerated 
neurodegeneration. Activation of complement in an antibody-independent fashion is 
achieved by binding of aggregated, but not soluble, Aβ to C1q (121-124). This latter 
finding suggests that in AD aggregated Aβ might induce chronic complement activation. 
C1 may bind to fibrillar Aβ deposits and precede microglial activation. Both Aβ and pro-
inflammatory stimuli are able to activate microglia, which results in increased Aβ and 
cytokine production by microglia (221). Furthermore, cultured human microglial cells 
show an increase in cytokine production after co-stimulation of Aβ with C1q and serum 
amyloid P (SAP) (119). This suggests that microglia may get triggered by both Aβ and SP-
associated factors such as C1q, which might result in the secretion of pro-inflammatory 
cytokines and Aβ, both accelerating neurodegeneration.   
 Neuroinflammation is a common feature observed in AD. Epidemiologic studies 
dealing with anti-inflammatory agents suggest that neuroinflammation plays an early role 
in AD development, and anti-inflammatory therapy might lower the risk of developing 
AD (222, 223). However, the role of the complement system, as a part of the inflammatory 
process, in the pathogenesis of AD remains to be elucidated, since it may have both 
positive and negative effects. In AD, the initial positive effects of inflammation might be 
shifted towards the more negative effects resulting in chronic inflammation and 
acceleration of the progression of the disease.    
 
 
 
 
Chapter 2
  28
2.4 Professional chaperones 
Heat shock proteins (Hsp) are professional chaperones. They are highly conserved 
proteins constitutively expressed in most cells under normal conditions, where they play a 
role in the cellular metabolism and in protective mechanisms during cell stress (224). The 
heat shock proteins can be divided into 2 different families based on size and function: 
Hsps, such as Hsp100, Hsp90, Hsp70, Hsp60, and the small heat shock proteins (sHsps). 
Hsps with a molecular weight of 60 kD or more possess a ATP-binding site and are 
actively involved in the process of refolding of misfolded proteins (225). Small Hsps, with 
a molecular weight of 40 kD or less, lack this ATP-binding site and assist the Hsps in their 
function of the refolding misfolded proteins (226).  The role of Hsps in misfolded protein 
recognition and refolding is illustrated in figure 1. 
 
 
2.4.1 Heat shock proteins 
It is not surprising that in AD, where misfolded protein molecules accumulate, 
both Hsp90 and Hsp70 synthesis is increased. Several members of the Hsp70 family 
directly interact with intracellular Aβ, but only recently Hsp70 was identified as a 
protector against intracellular Aβ accumulation (227, 228). Besides, immunoreactivity of 
both Hsp90 and 70 is found in SPs, which suggests that these professional chaperones may 
not only interact with misfolded protein within the cell (229-232). In addition, it is also 
postulated that up-regulation of Hsp90 and Hsp70 may suppress the formation of NFTs by 
partitioning tau into a productive folding pathway and thereby preventing tau aggregation 
(233). Recently, it was demonstrated that the chaperone CHIP-Hsc70 complex conjugates 
ubiquitin to hyperphosphorylated tau, which might enhance cell survival by elimination 
Hsp/sHsp
Hsp/sHsp
 
Figure 1. The role of heat shock proteins (Hsp) and small heat shock proteins (sHsps) in recognition and
refolding of unfolded and misfolded proteins. Unfolded or misfolded proteins are recognized by Hsps
and sHsps. Together with these unfolded or misfolded protein, Hsp and sHsps form a complex. In
addition, Hsps recover unfolded or misfolded proteins back to their native form using ATP. If unfolded
or misfolded protein are not recognized by the Hsp/sHsps, these unfolded or misfolded proteins are
capable of forming aggregates. 
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of soluble hyperphosphorylated tau (234). These data suggest that the cell increases 
production of the Hsps to cope with the presence of misfolded proteins such as 
hyperphosphorylated tau and accumulating Aβ. Somehow, this protective mechanism 
seems to fail, however. In line with this hypothesis it was shown that the actin and 
tubulin specific chaperone Hsp60 is decreased in AD, resulting in a decrease of 
cytoskeletal proteins in AD-affected neurons (235). Thus, both production and function of 
Hsps might be disturbed in AD, which might result in the accumulation of misfolded 
proteins.  
 
2.4.2 Small heat shock proteins 
Small Hsps function as molecular chaperones that can prevent proteins from 
adopting an incorrect conformation (236). The sHsp family is characterized by the 
presence of an α-crystallin domain, a stretch of 80-100 amino acids in the C-terminal half 
of the proteins (237). So far, the sHsp family comprises ten sHsps, including αB-crystallin, 
Hsp27, Hsp20, HspB8 and HspB2/B3 (238). Although sHsps are predominantly expressed 
in muscle cells, several family members are also found in human brain.  
In AD, αB-crystallin and Hsp27 are upregulated and expressed by astrocytes 
surrounding SPs and NFTs (239-242), whereas Hsp20, HspB2 and HspB8 colocalize with 
Aβ in SPs and CAA (243, 244). Although αB-crystallin or Hsp27 do not colocalize with Aβ 
in SPs, direct interaction between Aβ and these sHsps in addition to Hsp20 and HspB8 has 
been demonstrated (239, 245-247). In addition, high-affinity binding of αB-crystallin and 
Aβ has been observed in the lenses from people with AD (248). Furthermore, αB-
crystallin is able to prevent mature Aβ fibril formation retaining it in a non-fibrillar, but 
likely a protofibrillar state, which is highly toxic to neurons (249). Recently, we 
demonstrated that αB-crystallin, Hsp20 and HspB8 inhibit Aβ-mediated toxicity towards 
cerebrovascular cells, probably by preventing aggregation of Aβ at the cell surface (244, 
245). In addition, it was shown that Hsp27 directly binds to hyperphosphorylated tau and 
thus protects against cell death (250).  
Hsps are directly involved in the formation and persistence of misfolded protein 
aggregates. They are upregulated in several neurodegenerative diseases, such as AD, 
Creutzfeldt-Jakob disease and Parkinson’s disease, probably as a reaction to the formation 
of misfolded proteins (241, 251-254). However, despite of increased intracellular levels, 
they are unable to completely prevent accumulation of Aβ in AD. This suggests that 
despite of the increased synthesis in neurodegenerative diseases, their production is still 
insufficient as a result of aging transcription or translation machinery, or that there is 
decreased chaperone activity. In aged rats, this phenomenon of decreased chaperone 
activity was illustrated by a significant decrease of Hsp90 function (255), resulting in 
diminished hepatic chaperone capacity. Also the increasing amount of damaged or 
misfolded proteins as a result of defects in protein degradation, or even Hsp damage, 
might lead to a total decrease in chaperone activity in aged cells (256). Thus, the state of 
misfolded protein recognition and repair systems might be of great importance in the 
development of neurodegenerative diseases.        
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2.5 Miscellaneous proteins 
Apart from the above-described proteins, several other molecules are also 
associated with the pathological lesions of AD. Acute phase proteins, such as α1-
antichymotrypsin (ACT), α2-macroglobulin (α2M) and SAP, are all associated with Aβ 
deposition (257-260). ACT is a serine protease inhibitor of the serpin family, produced in 
the liver and abundantly found in serum. In AD, ACT levels are upregulated and binding 
of ACT with Aβ induces Aβ fibrillogenesis (261-263). Furthermore, when ACT is 
overexpressed in transgenic mice, an increased plaque load in the brains of these mice and 
even impaired spatial learning is observed (262, 263). α2M also binds Aβ, although, in 
contrast to ACT, this binding prevents Aβ fibril formation and fibril-associated 
neurotoxicity (264, 265). Since α2M is a protease inhibitor, α2M promotes the protease-
mediated degradation of α2M/Aβ-complexes, and contributes to clearance of Aβ from the 
brain (discussed in 3) (266, 267). The glycoprotein SAP belongs to the pentraxin family, 
and is a common component of all known types of amyloid fibrils. In addition, SAP is 
upregulated in AD and protects amyloid fibrils from proteolysis in vitro. Upregulation of 
SAP is especially found in brain areas affected by AD (268, 269). Furthermore, SAP 
induces Aβ fibril formation and Aβ/SAP complexes are able to activate complement (270-
273). 
Intercellular adhesion molecule-1 (ICAM-1) is a member of the immunoglobulin 
supergene family and associates with SPs in AD brains (274, 275). Elevated levels of 
ICAM-1 are observed in AD patients, and ICAM-1 upregulation is found in activated 
microglial cells associated with SPs (276, 277).   
Tissue-type plasminogen activator (tPA) regulates activation of plasminogen into 
plasmin and is expressed in various regions of the brain, especially in the hippocampus 
(278). Several reports suggested an important role for tPA in AD, since the tPA-system 
might be involved in Aβ turnover (279, 280). Fibrillar forms of Aβ stimulate tPA activity 
in vitro, whereas in AD patients, a reduction of tPA activity is observed in the affected 
areas of AD (279, 281). 
The actin-regulatory protein, gelsolin, is found both intracellularly and in plasma 
(282, 283). Plasma gelsolin binds Aβ and not only inhibits its Aβ fibrillization, but is also 
capable of degrading preformed Aβ fibrils (284, 285). Furthermore, gelsolin inhibits Aβ-
mediated neurotoxicity (286). 
 One of the major gangliosides in the brain is GM1. It is suggested that negatively 
charged residues on the neutral oligosaccharide core of gangliosides is required for Aβ 
binding to the cell membrane (287). Soluble Aβ binds GM1 and the formed complexes 
accelerate Aβ fibrillogenesis by acting as a seed for Aβ (288). In the presence of GM1, Aβ 
is more neurotoxic than Aβ alone, and cholesterol-rich membranes demonstrate 
accelerated Aβ binding due to the formation of GM1 clusters (289, 290). Since GM1 is a 
major component of lipid rafts, and recent studies suggest that Aβ accumulation in these 
lipid rafts is an early event in AD development, GM1 might play an important role in the 
early steps in AD pathogenesis (291, 292).  
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In summary, many different proteins are associated with Aβ aggregates in the AD 
brain and may contribute to the aggregation of Aβ and its biological functions. In 
addition, they might also play a role in Aβ clearance from the brain (see paragraph 4). 
 
 
Table 1. Summary of the expression of chaperones in AD brains, and their interaction and effects on Aβ 
and tau. 
 SP/ 
CAA 
NFT Direct interaction Effects on Aβ or tau in general 
Apolipoproteins 
ApoE 
ApoJ 
 
+ 
+ 
 
+ 
? 
 
Aβ / tau 
Aβ 
 
} fibrillar Aβ /~ hyperph. Tau  
~ Aβ aggregation 
HSPGs 
Perlecan 
Agrin 
Glypican 1 
Syndecan 1-3 
Collagen XVIII 
GAGs 
 
± 
+ 
+ 
+ 
+ 
+ 
 
± 
- 
- 
- 
- 
+ 
 
Aβ 
Aβ 
? 
? 
? 
Aβ / tau 
 
HSPGs: 
~ proteolytic breakdown Aβ 
} non-fibrillar  fibrillar Aβ 
} phosphorylation tau 
Complement Factors 
Hageman Factor 
C1q 
C3/C4 
C5-9 
 
+ 
+ 
+ 
+ 
 
+ 
+ 
+ 
+ 
 
? 
Aβ 
Aβ 
? 
 
Aβ activates complement in AD.  
C3 ~ Aβ deposition 
Heat shock proteins 
Hsp90 
Hsp70 
 
+ 
+ 
 
? 
? 
 
tau 
Aβ/tau 
 
~ tau aggregation 
~ tau aggregation 
Small Hsps 
αB-crystallin 
Hsp27 
Hsp20 
HspB2/B3 
HspB8 
 
- 
- 
+ 
+ 
+ 
 
- 
± 
- 
+ 
- 
 
Aβ 
Aβ/tau 
Aβ 
- 
Aβ 
 
~ Aβ fibril formation 
~ Aβ fibril formation 
~ Aβ fibril formation 
no effect 
~ Aβ fibril formation 
Acute phase proteins  
α1-antichymotrypsin 
α2-macroglobulin 
serum amyloid P 
 
+ 
+ 
+ 
 
- 
- 
+ 
 
Aβ 
Aβ 
Aβ 
 
} Aβ fibrillization 
 
} Aβ fibrillization 
Adhesion molecules 
ICAM-1 
 
+ 
 
- 
 
? 
 
 
Miscellaneous compounds 
tPA 
Gelsolin 
 
- 
- 
 
- 
- 
 
Aβ  
Aβ 
 
~ Aβ fibril formation 
} Aβ fibrillization 
SP, senile plaques; CAA, cerebral amyloid angiopathy; NFT, neurofibrillary tangles; HSPGs, heparan 
sulphate proteoglycans; Aβ, amyloid-beta; Hsp, heat shock proteins; Apo, apolipoproteins; SAP, serum 
amyloid P; ICAM-1, intercellular adhesion molecule-1; tPA, tissue-type plasminogen activator; GAGs, 
glycosaminoglycans; LDLR, low density lipoprotein receptor; LRP-1, LDL receptor protein-1; BBB, 
blood-brain barrier. Expression of chaperones in a specific lesion is illustrated as follows: present (+), by 
conflicting reports (±), absence (-) and unknown (?).  } = inhibtion or downregulation, ~ = induction or 
upregulation. 
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3. Aβ-binding proteins and intracellular interactions with Aβ 
Intracellular accumulation of Aβ might already start in the ER or in the Golgi 
apparatus of the cell (293-295). Although the exact role of intracellular Aβ in vivo is 
unclear, there is evidence that it might play a role in the pathogenesis of AD, since 
intracellular Aβ is linked to neuronal damage (296, 297). Recently, intracellular 
accumulation of Aβ in neurons of transgenic mice was correlated with impairments in 
synaptic plasticity (298). Thus, intraneuronal accumulation of Aβ in those brain areas 
affected earliest in AD suggests a possible relation between intracellular Aβ and 
development of AD (296). 
 Proteins interacting with both extracellular Aβ and intracellular APP have been 
extensively studied. In contrast, only a few proteins that interact with intracellular Aβ, 
and might affect its intracellular fate, are known so far. The endoplasmic reticulum 
amyloid beta-peptide-binding protein (ERAB) binds intracellular Aβ, and mediates 
neurotoxicity in neuronal cells by forming an intracellular target for Aβ (299). In addition, 
the mitochondrial enzyme amyloid-β alcohol dehydrogenase (ABAD) also binds Aβ inside 
neurons, resulting in the production of free radicals (300). However, if these intracellular 
Aβ-binding proteins affect aggregation of Aβ within the cells remain unknown.  
The first lines of defense against misfolded and aggregated proteins are the 
professional chaperones, which counteract these processes and are able to stimulate 
clearance of misfolded proteins by the proteosome. Newly synthesized proteins are folded 
by several other proteins, such as immunoglobulin-binding protein (BiP)/glucose-
regulated protein (GRP78) and calnexin. GRP78 is a member of the Hsp70 protein family 
and interacts with intracellular APP. GRP78 regulates APP and Aβ secretion by 
interfering between APP and β-/γ-secretases within the cell (301). These data suggest that 
Aβ-binding proteins are able to affect intracellular Aβ accumulation and secretion. 
Despite the role of sHsps in the recognition of misfolded proteins and their binding to Aβ 
in vitro, intracellular interaction of these proteins with Aβ remains to be investigated. In 
addition, verification of the importance of intracellular Aβ is controversial since Aβ-
antibodies may bind to other proteolytically derived APP fragments or intermediate 
degradation products. 
 
4. Aβ-binding proteins and Aβ clearance 
Professional and amateur chaperones are involved in aggregation, accumulation 
and persistence of Aβ in AD. However, these Aβ-binding proteins may also play a role in 
the clearance of Aβ from the brain. Two major pathways result in Aβ clearance. First, Aβ 
is removed from brain to blood via active transport across the BBB. This active transport is 
performed by specialized transporters, so-called “Aβ-receptors” expressed by endothelial 
cells. Second, Aβ is removed from brain via phagocytosis by both microglial cells and 
astrocytes. In both pathways, interaction of Aβ with cell surface Aβ-receptors is crucial, 
therefore Aβ-binding proteins might contribute to Aβ clearance by regulating its binding 
with these Aβ-receptors. 
The low-density lipoprotein receptor-related protein-1 (LRP-1) binds Aβ in a 
complex with ApoE at the abluminal side of the endothelium and degrades these 
ApoE/Aβ-complexes in lysosomes or transports them into the plasma (131, 132). However, 
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LRP-1 also mediates transport of free Aβ across the BBB (168). In contrast to LRP-1, the 
receptor for advanced glycation end products (RAGE) transports Aβ from the circulation 
into the CNS (146). Similar to RAGE, the Aβ-receptor megalin might also be involved in 
the transport of Aβ from blood to brain. However, megalin does not directly bind to Aβ, 
therefore this ApoJ receptor is assumed to transport Aβ as ApoJ/Aβ-complexes (142, 143). 
Clearance of Aβ/ApoE-complexes from the brain might be ApoE isoform-dependent. 
ApoE4 forms less stable complexes with Aβ than ApoE3 or ApoE2, therefore ApoE4 might 
reduce Aβ transport efficiency across the BBB. Furthermore, as described above 
(paragraph 2) ApoE4 may enhance Aβ aggregation more efficiently than ApoE3, which 
also inhibits clearance. On the other hand, the LDL receptor shows a marked preference 
for the ApoE3 and ApoE4 isoforms and binds the ApoE2 isoform poorly (302). In addition, 
given the similarity between the LDL receptor family, other LDL receptors, such as the 
LRP-1 receptor, might display similar specificities towards the ApoE isoforms. 
Furthermore, lipidation of ApoE might also affect the clearance of ApoE and ApoE/Aβ-
complexes from the brain, since LRP preferentially binds lipid-rich forms of ApoE (302). 
These data suggest that Aβ-binding proteins, such as ApoE and ApoJ play an important 
role in transport of Aβ across the BBB, and that both the ApoE isoform and the ApoE 
lipidation state might affect Aβ clearance. In addition to ApoE and ApoJ, the Aβ-binding 
protein α2M also forms complexes with Aβ. Since α2M is a ligand for the LRP-1 
receptors, these complexes might undergo LRP-1-mediated endocytosis and degradation 
or translocation into the plasma (165, 267).  
Stimulation of the transport of Aβ across the BBB demonstrated to be an effective 
therapeutic approach in AD, since several studies demonstrated elevated levels of Aβ in 
the plasma of mice after passive immunization with anti-Aβ antibodies (130, 159) or with 
Fab fragment of an anti-Aβ antibody (303) and the decline in cognitive performance was 
arrested in patients that received vaccination (304). However, the occurrence of severe 
meningoencephalitis in human patients after active immunization with Aβ hampered 
widespread application of this type of therapy. Administration of Aβ-binding proteins that 
demonstrate similar positive effects, but possibly without the severe immune reactions 
associated with antibody therapy, might therefore be an answer. An interesting example 
of such an Aβ-binding protein is gelsolin. This protein has high-affinity for Aβ and 
reduces Aβ levels in a transgenic mouse model of AD (161). Furthermore, administration 
of gelsolin or GM1 in PS/APP mice resulted in decreased Aβ aggregation in the brains 
(161). Both gelsolin and GM1 act as a “peripheral sink” for Aβ. Although both compounds 
did not enter the brain, they lowered soluble Aβ concentrations in the blood, disturbed 
the balance between blood and cerebral Aβ concentrations, and accordingly, pulled Aβ 
out of the brain via Aβ–receptor mediated clearance across the BBB. Therefore, other Aβ-
binding proteins administered in the circulation might also act as “peripheral sinks” (130, 
161).  
The pathological lesions of AD are associated with an activated complement 
system and local inflammation. Both activated microglial cells and activated astrocytes are 
associated with Aβ deposition, and may internalize Aβ fragments via phagocytosis (88, 
305, 306). Activation of the complement system is amongst others achieved by Hsps such 
as Hsp60 and Hsp70, that are able to induce phagocytosis by microglia and, thus, clearance 
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of Aβ (260, 307, 308). In addition, the absence of ApoE reduces the internalization and 
degradation of Aβ by astrocytes in the brain, demonstrating that ApoE is directly involved 
in the clearance of Aβ from brain via phagocytosis by microglial cells and astrocytes (193). 
tPA might also contribute to clearance of Aβ, since it accelerated Aβ clearance from 
transgenic mouse brains (281). Thus, since Aβ-chaperones contribute to activation of the 
complement system or activation of microglial cells and astrocytes, these proteins might 
contribute to the clearance of Aβ from the brain via phagocytosis. 
 
5. Aβ-binding proteins: their role in inflammation in AD  
Neuroinflammation in AD comprises both activation of microglial cells and 
astrocytes, and activation of the complement system. Aβ deposits in the brain are 
associated with activated microglia and astrocytes, but also with elevated levels of 
complement (163, 164, 215). Apart from Aβ, several Aβ-binding proteins such as Hsp60 
and Hsp70, which are also associated with the pathological lesions of AD, are capable of 
activating the complement system (260). SAP not only colocalizes with SPs and interacts 
with aggregated Aβ, SAP oligomers also bind and activate C1 (272). Both C1 and SAP may 
bind to fibrillar Aβ deposits in vivo and precede microglial activation, since cultured 
human microglial cells show an increase in cytokine production after co-stimulation of Aβ 
with C1q and SAP (119). This suggests that not only Aβ, but also Aβ-binding proteins, 
which are associated with SPs and CAA in AD, are capable of activating the complement 
system and thus contribute to neuroinflammation in AD.  
In contrast, some Aβ-binding proteins might also prevent neuroinflammation. 
ApoE demonstrates to have an anti-inflammatory effect by suppressing microglial and 
astrocytic activation (309-312). ApoE deficient mice demonstrate increased levels of IL-6 
and TNFα after LPS stimulation, suggesting a role of ApoE in inflammatory gene 
regulation (313). In addition, ApoE isoform-dependent (ε2<ε3<ε4) differences in nitric 
oxide (NO) levels have been observed in microglia cells (314). Transgenic mice expressing 
the ApoE4 protein isoform show a greater NO production than mice expressing the 
ApoE3 protein isoform. These data indicate that ApoE4 might have a less efficient anti-
inflammatory affect, and thus, might accelerate the development of AD. 
As exemplified by ApoE, Aβ-binding proteins might be useful tools to prevent 
complement activation. Recently, it was demonstrated that the semi-synthetic 
proteoglycan analogue dextran sulfate blocks activation of the complement cascade (315). 
In addition, chondroitin sulfate proteoglycans are also known to bind to C1q and prevent 
the formation of the C1 complex in vitro (316). By doing so, chondroitin sulfate 
proteoglycans also inhibit normal complement function. Furthermore, heparin has long 
been regarded as a potential complement inhibitor (317).  
It is, however, not clear if complete inactivation of complement is beneficial for 
AD patients. Under normal conditions, complement plays an important role in the 
clearance of abnormal protein deposits. Therefore, activation of complement might be a 
successful strategy to reduce accumulation of abnormal protein deposits, as demonstrated 
in Aβ immunization studies (154). However, excessive or chronic complement activation 
and the ensuing inflammation causes tissue damage and should be avoided to achieve a 
successful therapeutic approach.   
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6. Concluding remarks     
Chaperones such as the heat shock protein family, apolipoproteins, HSPGs, 
complement factors and several other proteins all affect aggregation, persistence and 
clearance of misfolded protein aggregates characteristic of neurodegenerative diseases 
(Fig. 2). This suggests that these chaperones form interesting therapeutic targets in 
production
Aβ
aggregation
protofibrils mature fibrils
aggregation
Soluble Aβneuron
Hsp, sHsps, tPA,
Complement factors
- -
ApoE, ACT, SAP
HSPGs, Gelsolin,
++
Proteolytic breakdown of Aβ
HSPGs
-
Hsps, sHsps, tPA
+
`` ````
Clearance of Aβ
Complement factors
+
ApoE, α2M, ApoJ
+
Transport via Aβ-receptors across the blood-brain barrier Phagocytosis by microglia and astrocytes  
Figure 2. The putative role of chaperones in amyloid-β (Aβ) fibril formation, proteolytic breakdown and
clearance from the brain. In Alzheimer’s disease, soluble Aβ, predominantly produced in neurons, is
converted into β-sheet rich protofibrils and eventually forms mature Aβ fibrils. The conversion from
soluble Aβ to protofibrils and fibrils, which accumulate in senile plaques and cerebral amyloid
angiopathy, is enhanced by chaperones as Apolipoprotein E (ApoE), Gelsolin, α1-antichymotrypsin
(ACT) and several heparan sulphate proteoglycans (HSPGs), which function as catalysts.  In contrast,
the heat shock protein family, tissue-type plasminogen activator (tPA) and complement factors prevent
the transition of soluble Aβ into protofibrils mature fibrils. Furthermore, heat shock proteins and tPA
stimulate the proteolytic breakdown of (proto)fibrils, whereas the HSPGs prevent this breakdown.
Finally, the clearance of Aβ from the brain across the blood-brain barrier is stimulated by ApoE, ApoJ
and α2-macroglobulin (α2M), whereas complement factors stimulate phagocytosis-mediated clearance
of Aβ by activated microglia and astrocytes.  
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prevention and treatment of neurodegenerative diseases. Administration of several of 
these chaperones already showed an inhibiting effect on the development of toxic 
aggregates and a positive effect on the clearance of these aggregates in vivo.  However, the 
normal functions of these chaperones are numerous and in some cases even unknown, just 
as their in vivo expression levels under normal and pathological conditions. For instance, 
overexpression of professional chaperones, such as the Hsps, to prevent aggregation of 
misfolded proteins will have to be evaluated carefully, since they also interact with other 
chaperones and are dependent on this interaction to fulfill some of their functions. This 
strategy may therefore result in instability of the cell-stress mechanism, which may cause 
the system to collapse. A solution may be found in the overexpression of several 
chaperones, which may be required to achieve an impact on the progression of the 
disease. 
Another pitfall in the use of professional chaperones as therapeutic agents is their 
ability to bind misfolded proteins and keep them in an intermediate conformation. This 
type of conformation might even be more toxic than the aggregated state, since co-
incubations of αB-cystallin with Aβ are more toxic to neurons than Aβ alone (249). 
Furthermore, heat shock proteins are most likely to be involved in early development of 
neurodegenerative diseases, given their natural function. Yet, the role of this protein 
family in maturation of the neurodegenerative lesions remains to be elucidated.  
In the process of clearance of Aβ from the brain, the Aβ-binding partners might 
play important roles in both the receptor-mediated clearance of Aβ across the BBB, but 
also as a ‘peripheral sink’ for Aβ. Both ApoE isotype and local concentrations in the brain 
might regulate Aβ transport across the BBB, but since this transport is receptor-mediated, 
other Aβ-binding proteins might also fulfill such a role. In addition, transport of 
aggregated Aβ across the BBB is less efficient than soluble Aβ. Thus, by preventing self-
aggregation of Aβ, binding proteins contribute to the clearance of Aβ from the brain. As a 
therapeutic strategy, Aβ-binding proteins serving as a ‘peripheral sink’, such as gelsolin, 
seem promising (161). However, although serum Aβ levels rose after treatment with this 
protein, effects on SPs and CAA remains to be elucidated.     
In conclusion, studying the role of chaperones in the development of 
neurodegenerative diseases might provide us with a better understanding of the 
mechanisms underlying the formation and accumulation of toxic aggregates in 
neurodegenerative diseases, which, eventually, may lead to the design of more optimal 
therapeutic strategies for those disorders.   
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Abstract 
 
The small heat shock protein family (sHsps) comprises molecular chaperones able to 
interact with incorrectly folded proteins. Alzheimer’s disease (AD) is characterized by 
pathological lesions such as senile plaques (SPs), cerebral amyloid angiopathy (CAA) and 
neurofibrillary tangles, predominantly consisting of the incorrectly folded proteins 
amyloid-β (Aβ) and tau, respectively. The aim of this study was to investigate the 
association of the chaperones Hsp20, HspB2, αB-crystallin and Hsp27 with the 
pathological lesions of AD brains. For this purpose, a panel of well-characterized 
antibodies directed against these sHsps was used in immunohistochemistry and 
immunoblotting. We observed extracellular presence of Hsp20, Hsp27 and HspB2 in 
classic SPs, and Hsp20 presence in diffuse SPs. In addition, extracellular presence of 
HspB2 was observed in CAA. Both Hsp27 and αB-crystallin were also observed in 
astrocytes associated with both SPs and CAA. Furthermore, none of the sHsps were 
observed in neurofibrillary tangles in AD brains. We conclude that specific sHsp species 
may be involved in the pathogenesis of either SPs or CAA in AD. 
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Introduction 
 
The family of small heat shock proteins (sHsp) comprises molecular chaperones that are 
responsible for protein complex assembly and suppression of protein aggregation, or that 
assist in refolding of partially denatured proteins (236). All sHsps contain a highly 
conserved C-terminal ‘α-crystallin domain’ of 80-100 residues (318). In humans, the sHsp 
family comprises 10 members (238), among which include αB-crystallin (319), Hsp27 
(320) , Hsp20 (321) and HspB2 (322). These sHsps are expressed, to a variable extent, in 
heart, striated muscle and various other tissues (323). Since sHsps regulate protein 
aggregation, they might play an important role in the pathogenesis of disorders that are 
characterized by aberrant protein folding such as Alzheimer’s disease (AD).  
AD is a neurodegenerative disorder, characterized by several pathological lesions: 
senile plaques (SPs), neurofibrillary tangles (NFTs) and cerebral amyloid angiopathy 
(CAA) (3). The major component of SPs and CAA is the amyloid-β peptide (Aβ) (65). If 
the α-helix structure of the native Aβ peptide is destabilized, oligomeric or multimeric 
aggregates with β-sheet conformation are formed (113). NFTs largely consist of aggregated 
hyperphosphorylated tau protein (8).  
Deposition of Aβ in SPs and CAA, and of tau in NFTs is a complex process, which 
does not only include the abnormal folding of the involved proteins itself, but is regulated 
by a number of factors. The deposition of both Aβ and tau seems to be influenced by 
binding of other proteins. Apolipoprotein E and complement C1q may regulate Aβ and 
tau aggregation and Aβ clearance (95, 121). The balance between factors that enhance 
protein aggregation on the one hand, or facilitate protein clearance from the brain on the 
other, may determine if Aβ will accumulate and, finally, aggregate in the brain.  Given 
their function as a molecular chaperone, members of the sHsp family may be involved in 
this complex process.  
 Both αB-crystallin and Hsp27 are expressed in normal brain. αB-crystallin is 
expressed in oligodendroglia and subpial astrocytes (239, 253), and accumulation of αB-
crystallin has been demonstrated in proliferating astrocytes, microglia, oligodendrocytes 
and degenerated neurons in various neurological diseases (239, 253, 324, 325). Hsp27 is 
expressed in meningeal and parenchymal vessel walls, and in astrocytes of the white 
matter (241). In AD brains, Hsp27 expression is observed in proliferating and 
degenerating astrocytes, NFTs and hippocampal neurons (241). Furthermore, increased 
expression of both αB-crystallin and Hsp27 has been found in AD brains (241, 254). The 
presence of other sHsps in human brain remains to be elucidated. In this study, we 
investigated the association of several sHsp with the pathological lesions of AD brain 
using a panel of well-characterized antibodies.    
  
Materials and methods 
 
Autopsy material 
Tissue samples from the occipital neocortex and hippocampus were obtained after rapid 
autopsy and immediately frozen in liquid nitrogen from 9 AD patients (age 77.4 ± 9.8 
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years; post mortem delay 4.2 ± 1.5 hours), 7 of them with moderate to severe CAA, and 
from 8 control cases, without neurological disease (age 82 ± 8.5 years; post mortem delay 4 
± 1.2 hours). Table 1 provides an overview of the diagnosis, Braak & Braak score, CERAD 
score, CAA grade, age, post-mortem interval, gender, apolipoprotein E genotype and 
agonal status of the patients used in this study. The agonal status of the patient was 
categorized into three categories; I: an agonal status lasting less than 24 hours prior to 
death; II: an agonal status lasting between 1 and 7 days prior to death; III: an agonal status 
lasting more than 7 days prior to death. Diagnosis and grading of AD patients was 
performed according to the criteria established by Braak & Braak and CERAD (326, 327). 
CAA grading was established by quantification of the number of Aβ-positive vessels in 
one microscopic field (magnification 2.5x). At least 4 microscopic fields of both the 
occipital cortex and the gyrus temporalis medius were analyzed and categorized as 
follows: 0 (-, no CAA), 0-10 (+, sparse CAA), 10-20 (++, moderate CAA) and >20 (+++, 
severe CAA) vessels affected by Aβ deposition.   
Immunohistochemistry 
In table 2 the antibodies used in this study are listed. Serial cryo-sections (4 μm) were 
used to examine the presence of the various sHsps in AD brains. Sections were air-dried 
and fixed in acetone for 5 minutes. Endogenous peroxidase activity was blocked using 
acetone containing 0.15% H2O2 for 5 minutes. Sections were preincubated for 30 minutes 
with 20% animal serum, the type of which was determined by the specific secondary 
Table 1. Overview of patients included in this study.  
Patient 
number 
Diagnosis Grade 
(Braak) 
Grade 
(CERAD) 
Grade 
CAA 
Age PMI 
(hrs.) 
Gender ApoE Agonal status 
1 AD VI +++ +++ 69 3 M 4\4 III 
2 AD VI +++ ++ 89 3 F 3\4 II 
3 AD VI +++ ++ 63 3 F 3\3 II 
4 AD VI +++ ++ 89 4 F 4\4 III 
5 AD VI +++ +++ 81 4 F 3\3 III 
6 AD VI +++ ++ 67 7 M 3\4 III 
7 AD VI +++ +++ 77 3 M 3\4 III 
8 AD V +++ + 87 5 F 3\3 II 
9 AD VI +++ + 75 5 M 4\4 II 
10 Control 0 0 - 91 4 F 3\4 II 
11 Control I 0 - 68 3 M 2\3 III 
12 Control 0 0 - 71 6 F 3\3 I 
13 Control I 0 - 81 3 M 3\3 III 
14 Control II ++ - 84 5 F 2\3 III 
15 Control III ++ - 83 4 F 3\4 I 
16 Control 0 0 - 84 4 F 3\3 III 
17 Control III + + 92 6 F 3\3 III 
Overview of the patients used in this study. AD = Alzheimer’s disease, PMI = post mortem interval (hrs. 
= hours), ApoE = apolipoprotein E genotype. The agonal status of the patients was categorized into three 
categories; I: an agonal status lasting less than 24 hours prior to death; II: an agonal status lasting 
between 1 and 7 days prior to death; III: an agonal status lasting more than 7 days prior to death. 
Grading of AD (Braak and CERAD scores) and of CAA was performed as described in the methods.  
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antibody used. Then, sections were incubated overnight at 4oC with primary antibody 
(Table 2). We used biotin-labeled horse anti-mouse antibodies (Vector Laboratories, 
Burlingame, CA, USA) as secondary antibody in case of primary mouse monoclonal 
antibodies, and biotin-labeled goat anti-rabbit antibodies (Vector) in case of primary 
rabbit polyclonal antibodies. Subsequently, sections were incubated with the avidin-
biotin complex according to the manufacturer’s description (Vector). Between incubation 
steps, sections were extensively washed using phosphate-buffered saline (PBS). 
Diaminobenzidine (DAB) was used as chromogen. Subsequently, copper sulfate (0.5% in 
saline solution) was applied to enhance staining. Sections were washed with tap water and 
stained with hematoxylin for 3 minutes, and then sections were washed again with tap 
water for 10 minutes. After dehydration with ethanol, sections were treated with xylol 
and mounted with Permount (Fisher Scientific, New Jersey, USA). For Congo red staining, 
10 μm serial sections were used and fixed in acetone. Increasing concentrations of ethanol 
(0-80%) were used to dehydrate the sections. Finally, sections were preincubated with 3% 
NaCl in 80% ethanol and incubated in the same solution containing 0.5% Congo red and 
counterstained with hematoxylin. Every fifth section in the series was stained with 
antibody 6C6. Expression of sHsps in astrocytes and microglial cells was investigated by 
comparing serial sections and by double-immunostaining for both sHsps and the astrocyte 
marker 6F2 or the microglial marker KiM1p, respectively. 
 HspB2 presence was studied using a polyclonal anti-HspB2 antibody raised against 
rat recombinant HspB2 protein; the specificity of this antibody has previously been 
demonstrated in pigs (328). Anti-HspB2 specificity in human brains was demonstrated by 
absorption of anti-HspB2 antibody (for this experiment used at a dilution of 1:8000) with 
20 μg recombinant HspB2. The specificity of the antibodies directed against Hsp20 (VDK-
20, 20-11), αB-crystallin (RCB-Mab, Pab-aBcr) and Hsp27 (SPA-800, 1426) was 
demonstrated by pre-incubation of antibody with 20 μg recombinant antigen for 2 hours 
that resulted in the loss of signal in immunohistochemistry.  
 
Table 2. Primary antibodies used in this study. 
Primary 
antibody 
Antigen Species  
raised in 
Dilution Source 
(reference) 
6C6 Aβ Mouse 1:1000 Elan Pharma. San Francisco, CA, USA 
40-4 Aβ Rabbit 1:2000 Dr.Van Nostrand, Stony Brook, NY, USA 
8763-250 Tau Rabbit 1:2000 Abcam Limited, Cambridge, UK 
AT8 Hyperphos. Tau Mouse 1:200 Innogenetics, Gent, Belgium 
RCB-Mab αB-crystallin Mouse 1:100 Riken Cell Bank, Tsukuba, Japan 
Pab-aBcr αB-crystallin Rabbit 1:500 Den Engelsman et al. (334) 
SPA-800 Hsp27 Mouse 1:2000 Stressgen, Victoria, Canada 
1426 Hsp27 Rabbit 1:2000 Abcam Limited, Cambridge, UK 
VDK-p20 Hsp20 Rabbit 1:4000 Van de Klundert et al. (41) 
20-11 Hsp20 Mouse 1:50 Adv.Immunochem., Long Beach, CA, USA 
F34 HspB2 Rabbit 1:2000 Verschuure et al. (328) 
6F2 GFAP Mouse 1:20 Sanbio, Uden, The Netherlands 
KiM1p Microglia Mouse 1:5000 Kindly provided by Dr. M.R.  
Parwaresch, University of Kiel, Germany 
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Quantification of immunohistochemical stainings 
Staining for the different anti-sHsp antibodies was evaluated by assessment of 
staining of amyloid-laden cortical vessels, of diffuse and classic SPs and of NFTs, in both 
occipital neocortex and hippocampus. For each AD patient, the number of sHsp-positive 
AD lesions in 8-13 microscopical fields (magnification 100x) per serial section were 
analyzed. The average percentage of sHsp-positive AD lesions was determined for all 
patients. Amyloid-laden vessels and diffuse SPs were identified by 6C6 staining, classic 
SPs by both 6C6 and Congo red staining and NFTs by tau staining.  
 Possible differences in the total number of Hsp20-positive SPs, Hsp20-positive 
classic SPs, Hsp27-positive classic SPs or HspB2-positive amyloid-laden vessels between 
groups with different CERAD score and Braak & Braak score were tested by ANOVA, 
whereas the correlations with age or postmortem interval (PMI) was performed using the 
two-tailed Pearson’s correlation test. 
 
Double-immunostaining 
For double-immunostaining, sections were fixed and pre-incubated as described above. 
Sections were simultaneously incubated with the primary antibodies of interest (table 2). 
Subsequently, sections were simultaneously incubated either with Swine anti-rabbit-FITC 
and biotin-labeled horse anti-mouse or sheep-anti-mouse-FITC and biotin-labeled goat-
anti-rabbit (all Vector), depending on the primary antibodies used. Finally, slides were 
incubated with avidin-labeled Texas Red (Vector) for 45 minutes. Antibodies were diluted 
in PBS/0.1% BSA, which also served as a negative control. After each incubation, slides 
were extensively washed with PBS. Sections were mounted in Vectashield (Vector). The 
polyclonal and monoclonal antibodies that were available for αB-crystallin, Hsp27, and 
Hsp20 gave similar results in double-immunofluorescence with anti-Aβ or anti-tau 
antibodies. Immunofluorescence staining was analyzed using a confocal laser-scanning 
microscope (Leica, Wetzlar, Germany).  
 
Western blotting 
Immunoblot analysis was performed on eight AD and eight control brain tissue extracts 
from the occipital neocortex. Tissue samples were homogenized in phosphate-buffered 
saline containing 1% SDS and protease inhibitors (CompleteTM Mini, Roche, Mannheim, 
Germany) and incubated for 1 hour at 37 0C. Equal amounts of protein were loaded and 
fractionated on 15% polyacrylamide gels. Non-specific protein binding was blocked by 
preincubation with Odyssey-blocking buffer according to manufacture’s guidelines (LI-
COR, Westburg, Leusden). Binding of primary antibodies was visualized by using goat 
anti-mouse IRDye 800 or goat anti-rabbit/Alexa 680 (LI-COR). Analysis was performed 
using the Odyssey infrared imaging system (LI-COR). The intensity of the western blot 
bands was quantified. Possible differences in the intensity of the western blot bands 
between control and AD brains were tested by t-test. 
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Results 
 
Presence of Hsp20 in control and Alzheimer’s disease brains 
In control brains, Hsp20 staining was observed in astrocytes in the white matter and 
occasionally in the grey matter (Fig. 1a). Weak immunoreactivity was also observed in 
large parenchymal (Fig. 1j) and leptomeningeal vessels (data not shown). In AD brains, 
both classic and diffuse SPs were intensely stained with the anti-Aβ antibodies used, in 
both neocortex (Fig. 1b, c) and hippocampus (data not shown). Moderate to severe CAA 
was observed in 7 out of 9 patients by Aβ staining (Fig. 1d) and Congo red staining (not 
shown). A comparison between anti-Aβ (6C6) and anti-Hsp20 staining (using either VDK-
p20 or 20-11) revealed that 73% of all SPs in the occipital neocortex and 47% of the SPs in 
the hippocampus were positively stained for Hsp20 (Fig. 1b, g and c, h: Table 3). 
Furthermore, 23% of the classic SPs in the occipital neocortex and 42% in the 
hippocampus were positively stained for Hsp20 (Table 3). Besides, reactive astrocytes 
surrounding SPs or CAA were immunopositive for Hsp20 (Fig.1d, i). In cerebral vessels 
unaffected by Aβ deposition (Fig 1e), Hsp20 staining was weak (Fig. 1j). In normal aged 
controls, both diffuse and classic SPs were also immunoreactive for Hsp20 (Fig 1f). NFTs 
were not stained for Hsp20 (data not shown). Specificity of the anti-Hsp20 reactivity in 
human brains was demonstrated if the anti-Hsp20 antibody (Fig 1k) was pre-absorbed 
with recombinant Hsp20 (Fig 1l). We did not observe a correlation between the 
percentage of Hsp20-positive diffuse and classic SPs or the percentage of Hsp20-positive 
classic SPs with post mortem interval (p > 0.05). However, the percentage of Hsp20- 
positive classic SPs in either hippocampus or neocortex correlated with age (p < 0.05). 
Neither Braak & Braak nor CERAD score affected the Hsp20 staining patterns in both 
neocortex and hippocampus of the patients. 
Comparison of Hsp20 levels in occipital neocortex between control and AD 
patients (each n = 8) was performed using western blot analysis and subsequent 
quantification. Although this analysis demonstrated a trend towards increased Hsp20 
presence in AD brains compared to control brains, the differences were not significant 
(Fig 4).  
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Figure 1. Immunohistochemical staining of control brain and SPs, CAA and normal leptomeningeal
vessels in neocortex of AD brain for Hsp20. Serial sections: b, g; c, h; d, i; e, j; k, l. Hsp20 was
demonstrated in reactive astrocytes in normal brain parenchyma (a, arrow). The anti-Aβ (mAb 6C6)
stained SPs (b (arrows), c) and CAA (d). Hsp20 was demonstrated in SPs (g (arrows), h) and in
reactive astrocytes associated with the SPs (h, arrow). Hsp20 staining (i) was absent from vessels
affected by Aβ deposition (d). Reactive astrocytes associated with CAA were stained for Hsp20 (i,
arrow). Vessels unaffected by Aβ (e, arrow) were not stained for Hsp20 (j). Hsp20 positive SPs were
also found in aged controls (f). Specificity of the polyclonal anti-Hsp20 (VDK-p20) antibody was
demonstrated by pre-absorption of the antibody with recombinant Hsp20 (k, l). Staining of SPs with
anti-Hsp20 (k) is absent after pre-absorption (l). Original magnification a ×400, b and g ×125, c-j ×250,
k-l ×200. 
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Figure 2. Immunohistochemical staining of control brain and SPs, CAA and normal leptomeningeal
vessels in the neocortex of AD brain for HspB2 (a, c, e, g, h, i). Serial sections: b-c; d-e; f-g; h-i. HspB2
stained reactive astrocytes (a, arrow) and smooth muscle cells in large vessels in normal brain (a, open
arrow). The anti-Aβ antibody 6C6 stained both classic (d, open arrow) and diffuse SPs (b, d), and CAA
(f). HspB2 was demonstrated in classic SPs (c, e, open arrows) and CAA (g, c, arrow). Furthermore,
HspB2 was absent in small parenchymal vessels (e, arrow). Specificity of the anti-HspB2 antibody was
demonstrated by pre-absorption of the antibody with recombinant HspB2 (h, i). Staining of CAA with
anti-HspB2 (h) is absent after pre-absorption (i). Original magnification a-i ×250, b and c ×75 . 
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Presence of HspB2 in control and Alzheimer’s disease brains 
Presence of HspB2 in control brains was limited to smooth muscle cells in large 
leptomeningeal vessels and an occasional astrocyte (Fig. 2a) or microglial cell in the brain 
parenchyma. In AD neocortex and hippocampus anti-HspB2 antibodies stained all classic 
SPs (Fig. 2b, d), whereas 85% and 100% of vessels affected by Aβ deposition (Fig 2c, e) in 
the neocortex and hippocampus, respectively, were stained. HspB2 was not observed in 
unaffected parenchymal vessels (Fig 2d, e; Table 3). Furthermore, NFTs and diffuse SPs 
were not stained for HspB2 (data not shown). Specificity of the anti-HspB2 reactivity in 
human brains was demonstrated when staining in CAA (Fig 2h) was compared to staining 
with anti-HspB2 antibody that was pre-absorbed with the recombinant HspB2 (Fig 2i). No 
correlation was observed between the percentages of HspB2-positive CAA and either age 
or post mortem interval (p > 0.05). Braak & Braak or CERAD score did not affect HspB2 
presence of the patients in both neocortex and hippocampus (p > 0.05). Comparison of 
HspB2 levels in neocortex of control and AD patients (n = 8) was performed using western 
blot analysis. Again, we observed a trend towards increase of HspB2 presence in AD 
brains compared to control brain, but the observed differences were not significant (p > 
0.05) (Fig 4).  
 
A C E
B D F
 
Figure 3. Immunohistochemical staining of Aβ (a, b), αB-crystallin (c, d) and Hsp27 (e, f) in normal
leptomeningeal and parenchymal vessels (a, c, e, open arrow) and CAA (b, d, f) in serial sections (a, c, e; b,
d, f) of the neocortex of AD brains. Anti-αB-crystallin antibodies stained oligodendroglia cells throughout
the cortex (c, arrow) and reactive astrocytes associated with CAA (d, arrow). Anti-Hsp27 antibodies were
immunoreactive with parenchymal vessels (e, arrow) and occasionally with reactive astrocytes associated
with CAA (f, arrow). Original magnification a, c, e ×250, b, d, f ×150. 
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Presence of αB-crystallin and Hsp27 in control and Alzheimer’s disease brains 
In control brains, αB-crystallin staining was observed in oligodendroglial cells (Fig. 3c). 
Furthermore, leptomeningeal vessels as well as astrocytes in the white matter were also 
stained (data not shown). In AD, anti-αB-crystallin antibodies stained reactive astrocytes 
and activated microglia associated with virtually all SPs (data not shown) and with CAA 
(Fig. 3d). However, αB-crystallin did not colocalize with Aβ in SPs (data not shown) or 
CAA (Fig. 3d). 
In control brains, Hsp27 staining was limited to leptomeningeal and large 
parenchymal vessels (fig 3e), and an occasional astrocyte and microglial in the white 
matter (data not shown). In AD, Hsp27 staining was observed in a subpopulation of 
astrocytes and microglia cells associated with SPs and CAA (Fig. 3f). Furthermore, 
colocalization was observed with Aβ in 15% and 35% of the classic SPs in neocortex and 
hippocampus, respectively (Table 3). We did not observe a correlation between the 
percentage of Hsp27-positive classic SPs and either age or post mortem interval (p > 0.05). 
Braak & Braak or CERAD score did not affect the Hsp27 presence in both neocortex and 
hippocampus of the patients (p > 0.05).  
Two antibodies (8763-250 and AT8) directed against the tau protein demonstrated 
strong staining of tangles and dystrophic neurites in both neocortex and hippocampus in 
AD brains (data not shown). Neither αB-crystallin nor Hsp27 were demonstrated in NFTs 
(data not shown). Specificity of both anti-αB-crystallin and Hsp27 reactivity in human 
brains was demonstrated when staining in reactive astrocytes was compared to staining 
with antibodies that were pre-absorbed with recombinant protein (data not shown). 
Finally, comparison of Hsp27 and αB-crystallin levels in neocortex of control and AD 
patients (n = 8) was performed using western blot analysis. A non-significant trend 
towards increased Hsp27 and αB-crystallin presence in AD brains compared to control 
brains was observed (p > 0.05) (Fig 4).  
Table 3. Summary of the percentages (mean (SD)) of (classic) senile plaques or Aβ-affected vessels that 
were stained for a specific sHsp. 
 Hsp20-pos.  
all  SPs 
Hsp20-pos.
cl. SPs 
Hsp27-pos.
cl. SPs 
αB-crystallin- 
pos. all SPs 
HspB2-pos. 
cl. SPs 
HspB2-pos.  
Aβ-affected 
Vessels 
Occipital 
neocortex 
73 (24) 23 (17) 15 (6) 0 100 85 (14) 
Hippocampus 47 (24) 42 (20) 35 (8) 0 100 100  
The results are mean percentages of 8-13 microscopical fields per serial section of 9 AD patients. SPs 
(senile plaques), cl. (classic), pos. (positive), SD (standard deviation).   
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Discussion 
In this study, we describe the association of sHsps with SPs and CAA in AD brains and 
their expression in reactive astrocytes and leptomeningeal vessels of the human brain. 
Hsp20 was demonstrated in diffuse and classic SPs in AD brains. HspB2 was associated 
with classic SPs in AD brains and was also present in smooth muscle cells in 
leptomeningeal vessels and reactive astrocytes. Strikingly, HspB2 was also strongly 
expressed in CAA, whereas other sHsps, including αB-crystallin, Hsp20 and Hsp27, were 
not observed in CAA. In addition to these novel findings, we confirmed previous studies 
in which the expression of αB-crystallin and Hsp27 was observed in reactive astrocytes 
associated with SPs (239-241, 252, 324, 325). Furthermore, all sHsps analyzed in this study 
were absent from NFTs in AD brains.  
Small heat shock proteins function as molecular chaperones that prevent proteins 
from adopting an incorrect conformation (238). The pathological lesions of AD consist of 
the incorrectly folded proteins Aβ and tau. Our data suggest that Hsp20 is predominantly 
associated with non-fibrillar Aβ (diffuse SPs), whereas HspB2 is associated with fibrillar 
Aβ (classic SPs and CAA). Although increased expression of sHsps was demonstrated in 
AD brains (241, 254), our western blot analysis only demonstrated non-significant trends 
towards increased sHsp presence in AD compared to control brains. Apparently, sHsp 
protein levels in brain samples might be too low to discriminate between AD and control 
brains using western blot analysis. Direct interaction between sHsps with Aβ remains to 
be demonstrated in other models, yet our data suggest that both HspB2 and Hsp20 may 
play a role in the deposition of Aβ in AD brains, albeit at different levels of the Aβ 
aggregation process and in association with different pathological lesions in the AD brain.  
Recently, Shimura and co-workers demonstrated the association of Hsp27 with 
hyperphosphorylated tau protein from AD brain (250). We, however, could not confirm 
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Figure 4. Western blot analysis of Hsp20, HspB2, αB-crystallin and Hsp27 levels in AD brain.
Immunoblot analysis of brain tissue extracts from the occipital neocortex of AD brains for Hsp20
(antibody 20-11, 17 kD), HspB2 (antibody F34, 20 kD), αB-crystallin (antibody RCB-Mab, 20 kD) and
Hsp27 (antibody SPA-800, 23 kD) are demonstrated. 
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the association of Hsp27 (and any of the other sHsps tested) with tau in NFTs. Since we 
only analyzed full-blown NFTs, our findings do not exclude a possible interaction 
between Hsp27 and tau in early stages of NFT formation. Hsp27 and also αB-crystallin 
expression were observed in glial tau inclusions in non-AD tauopathies such as 
corticobasal degeneration and frontotemporal dementia with parkinsonism linked to 
chromosome 17 (324, 325), indicating that these sHsps may affect intracellular tau 
aggregation in glial cells. This suggests that the accumulation of tau protein in either 
neuronal or glial cells is differentially regulated and that the interaction between tau and 
sHsps may strongly depend on - and be regulated by - the specific cell type involved in 
different neurodegenerative disorders.   
Previous reports demonstrated that Hsp27 and αB-crystallin are upregulated in AD 
brains and directly interact with Aβ in vitro (246, 247). Here, we could demonstrate the 
co-localization of Hsp27, but not of αB-crystallin, with Aβ in a subset of SPs, suggesting 
that the in vitro interaction between Aβ and Hsp27, but not of αB-crystallin, may, to a 
minor degree, contribute to the extracellular cerebral deposition of Aβ in vivo. A recent 
report demonstrated coaggregation of αB-crystallin with Aβ in the cytoplasm of deep 
cortical lens fibre cells of AD patients, suggesting that αB-crystallin can regulate 
intracellular Aβ aggregation (248). Based on our observations, these interactions seem to 
be restricted to the lens, where αB-crystallin is a ubiquitous protein, and does not seem to 
occur in the brains of AD patients, since we were not able to demonstrate intracellular 
expression of αB-crystallin in neurons, which are a major source of Aβ production in the 
brain. 
Given their intracellular role in protein folding, the extracellular presence of 
HspB2 and Hsp20 in AD brains is remarkable. Extracellular distribution of sHsps might be 
due to specific secretion or to cellular degeneration and subsequent release of the sHsps in 
the extracellular space. Extracellular appearance of sHsps in human sera and in 
extracellular granular deposits within the vascular media has been described (329, 330). 
Moreover, Hsp20 may act extracellularly as a regulator of platelet function in plasma 
(331). Thus, extracellular appearance of sHsps as a result of secretion might actively 
contribute to the accumulation of Aβ in AD lesion by binding to Aβ and affect its 
aggregation process. Alternatively, since various cells types in the AD brain, such as 
vascular smooth muscle cells, pericytes, endothelial cells and neurons degenerate as a 
reaction to Aβ accumulation (21, 22), cytoplasmic proteins such as sHsps might be 
released into the extracellular space as a result of cell death. In addition, cell-stress 
induced by Aβ might increase the production of the sHsps in neurons and reactive 
astrocytes before degeneration occurs, contributing to sHsps levels. Therefore, 
accumulation of extracellular sHsps in SPs and CAA might occur as a result of cell death 
induced by Aβ. Given their ability to directly interact with Aβ, sHsps might then be 
trapped in these Aβ-containing lesions. We observed quantitative differences in the 
association of, for example, Hsp20 with SPs in the neocortex and in the hippocampus. 
Differences in the microenvironment of neocortex and hippocampus, e.g. in the region-
specific cellular responses to Aβ, might contribute to these observed differences.  
Inflammation plays an important role in the pathogenesis of AD. Reactive 
astrocytes and microglia are found in and around classic SPs, as well as around 
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extracellular NFTs (28, 241, 254, 330, 332) and CAA (333). Our observation of the 
increased presence of Hsp27 and αB-crystallin in astrocytes suggests that a stress response 
occurs in these reactive cells (241, 254). This stress response apparently also includes 
increased presence of Hsp20. Strikingly, reactive astrocytes expressing Hsp20 were also 
observed surrounding CAA, possibly as part of a stress response to the vascular deposition 
of Aβ. Reactive astrocytosis has been described in association with CAA in Hereditary 
Cerebral Hemorrhage with Amyloidosis-Dutch type (332) and in Iowa-type Hereditary 
Cerebral Amyloid Angiopathy (28), but to our knowledge not in association with CAA in 
AD brains. Our findings suggest that astrocytes may become activated around CAA, e.g. 
due to mild hypoxia caused by local suboptimal vascular function, which does not affect 
other markers of astrogliosis such as glial fibrillary acidic protein (GFAP) or αB-crystallin.  
In conclusion, based on the observation that Hsp20 is associated with diffuse SPs, 
we suggest that Hsp20 has a particular affinity for non-fibrillar Aβ. In contrast, HspB2 is 
associated with classic SPs and CAA, and thus seems to have a higher affinity for fibrillar 
Aβ. Our study suggests that the various members of the sHsp family have a different 
affinity for aggregated peptides and that Hsp20 and HspB2 might be actively involved in 
the accumulation of Aβ in SPs or CAA, respectively. Furthermore, these data are in line 
with our previously proposed hypothesis that the pathogenesis of CAA and senile plaques 
is different, e.g. with respect to the involvement of Aβ-associated proteins (110). Finally, 
the exact role of sHsps in the deposition, aggregation or clearance of Aβ in Alzheimer’s 
disease brains needs further elucidation but may provide a target for interference with this 
disease. 
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Abstract 
 
Small heat shock proteins Hsp20 and HspB2/B3 co-localize with Aβ deposition in senile 
plaques and cerebral amyloid angiopathy in Alzheimer’s disease brains, respectively. It 
was the aim of our study to investigate if these and other sHsps bind to wild-type Aβ1-42 or 
the more toxic Aβ1-40 carrying the ‘Dutch’ mutation (22Glu´Gln) (D-Aβ1-40), affect Aβ 
aggregation and thereby influence Aβ cytotoxicity. Binding affinity between sHsps and Aβ 
was investigated by surface plasmon resonance. Aβ aggregation was studied by using 
circular dichroism spectroscopy and electron microscopy. Furthermore, we used cultured 
cerebrovascular cells to investigate the effects of sHsps on Aβ-mediated cytotoxicity. 
Hsp20, Hsp27 and αB-crystallin, but not HspB2/B3, bound to Aβ (both D-Aβ1-40 and Aβ1-
42), and reduced or completely inhibited aggregation of D-Aβ1-40 into mature fibrils, but 
did not affect Aβ1-42 aggregation. Furthermore, these sHsps were effective inhibitors of the 
cerebrovascular toxicity of Aβ (both D-Aβ1-40 and Aβ1-42) in vitro. Binding affinity of the 
sHsps to D-Aβ1-40 correlated to the degree of inhibition of Aβ-mediated cytotoxicity, and 
the potential to reduce Aβ β-sheet and fibril formation. With Aβ1-42 a similar correlation 
between binding affinity and cytotoxicity was observed, but not with its aggregation state. 
In conclusion, sHsps may regulate Aβ aggregation and serve as antagonists of the 
biological action of Aβ, but the extent of their interaction depends on the type of sHsp and 
Aβ peptide. 
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Introduction 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized pathologically by 
senile plaques, neurofibrillary tangles (NFTs) and cerebral amyloid angiopathy (CAA). 
The major component of senile plaques and CAA is the amyloid-β protein (Aβ), a 4 kDa 
polypeptide (65) proteolytically cleaved from the amyloid-β precursor protein (APP) (66, 
335). In addition, CAA is the major pathological finding in patients with hereditary 
cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D) (26), where a 
mutation at amino acid 22 of Aβ induces extensive deposition in small leptomeningeal 
arteries and cortical arterioles, often leading to fatal hemorrhages. In vessels affected by 
CAA, both smooth muscle cells and pericytes degenerate as a result of Aβ deposition (21). 
Conformational changes of Aβ may lead to its aggregation into oligomers, 
protofibrils and mature fibrils (336). Aβ is particularly neurotoxic when it is in such an 
aggregated state (166, 167). In contrast, the soluble form of Aβ, rather than the aggregated 
fibrils, is toxic towards cultured cerebrovascular cells (337).  Furthermore, only Aβ1-40 
containing the ‘Dutch’ mutation (Glu22Gln) (D-Aβ1-40) and wild-type Aβ1-42, but not wild-
type Aβ1-40, induced degeneration of cerebrovascular cells (338, 339) by a mechanism 
which seemed to be based on aggregation of Aβ at the cell surface (340, 341).    
Besides Aβ, senile plaques and CAA contain several Aβ-associated proteins, that 
may affect the biological function of Aβ (119), amongst which are the small heat shock 
proteins (sHsps). Small Hsps represent a family of proteins functioning as molecular 
chaperones that can prevent other proteins from adopting a conformation other than its 
native three-dimensional structure, which might be toxic for the cell (236). The human 
sHsp family comprises 10 sHsps (238), including αB-crystallin, Hsp27, Hsp20, HspB2 and 
HspB3. Based on differences in oligomerization properties, the sHsps can be divided into 
two categories: one consisting of Hsp27, Hsp20 and αB-crystallin, and the other of HspB2 
and HspB3. Hsp27, Hsp20 and αB-crystallin are highly expressed by muscle cells and form 
co-oligomers with each other in these cells. In contrast, although HspB2 and B3 are only 
scarcely expressed in muscle cells, they form together a unique and independent co-
oligomer complex in these cells (323).  In brain, sHsps are expressed in reactive astrocytes 
(241, 242) and direct interaction between αB-crystallin and Hsp27 with Aβ has been 
demonstrated in vitro (246-248). Recently, we demonstrated that Hsp20 and HspB8 are 
expressed in senile plaques, whereas HspB2/B3 is expressed in CAA (342, 343). In 
addition, we demonstrated that HspB8 interacts with Aβ and inhibits Aβ-mediated 
toxicity towards cerebrovascular cells (343). Given their specific role in regulating correct 
protein folding and the widespread misfolding of Aβ in AD, we investigated if sHsps bind 
to Aβ, affect Aβ aggregation and, as a consequence, affect Aβ-mediated cytotoxicity. 
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Materials and Methods 
 
Materials 
Both Aβ1-40 peptide (96% pure, HPLC analysis) containing the Glu22Gln mutation (D-Aβ1-
40) and wild-type Aβ1-42 (95% pure, HPLC analysis) were obtained from Biosource (Etten-
leur, The Netherlands). Aβ40-1 peptide (99% pure, HPLC analysis) was obtained from 
American Peptide Company (Sunnyvale, CA, USA). Lyophilized peptides were dissolved 
in sterile water, at 250 μM and stored at –80oC. 
 
Expression and purification of recombinant proteins 
The coding regions of the various sHsps were cloned into the following vectors: pET8c 
(rat Hsp20), pET3a (human B2/B3 and human Hsp27), pET16 (human αB-crystallin). 
Since it was demonstrated that HspB2 and HspB3 form functional heterogeneous 
complexes of 150 kDa (323), both proteins were expressed together in one vector. The 
sHsps were expressed in the respective vectors in BL21 (DE3) competent cells (Invitrogen 
Corporation, Carlsbad, CA, USA). A culture inoculated from a single colony was 
incubated for 4 hours at 37oC. Protein production was induced by addition of isopropyl-
thio-b-D-galactopyranoside at a final concentration of 0.5 mM. After 4 hours, cells were 
harvested in TGE (50 mM Tris pH 8.0, 50mM Glucose, 1mM EDTA) and lysed by repeated 
freeze-thaw cycles and sonification (344). Insoluble proteins were removed by 
centrifugation. All sHsps were purified over a DEAE-Sepharose Fast Flow column 
(Pharmacia, Freiburg, Germany) using a linear gradient from 0 up to 1 M NaCl in TNE 
(25mM Tris, 1M NaCl, 2mM EDTA) buffer. In addition, a SourceQ column (Amersham, 
Uppsala, Sweden) was used with a linear gradient from 0 up to 1 M NaCl in TNE buffer 
for further purification. A Superose 6HR 10/30-size exclusion column (Pharmacia) was 
used to determine sHsp molecular weight. Purity of the preparation was as follows: 
Hsp20: 80%, HspB2/B3: 75%, Hsp27: 90% and αB-crystallin:  95%. 
 
PAGE gel 
Native PAGE gel analysis was performed on lyophilized Aβ peptides, dissolved in sterile 
water at 250 μM, or dissolved in Na-Acetate (pH 5.0, as used for surface plasmon 
resonance experiments; see 2.4.). Equal amounts of protein were loaded and fractionated 
on a SDS-free 12% PAGE gel. Fractionated proteins were visualized using Commassie 
Brilliant Blue. Analysis was performed using the Odyssey infrared imaging system (LI-
COR Biosciences GmbH, Bad Homburg, Germany).  
 
Surface plasmon resonance (SPR)  
SPR experiments were performed using a BIAcore 2000 (Uppsala, Sweden) biosensor 
instrument. Sensor chips and protein coupling chemicals were purchased from Biacore 
AB. D-Aβ1-40, wild-type Aβ1-42 and Aβ40-1 peptide (3 μl Aβ, 1 μg/μL, in 300 μl 10 mM Na-
Acetate, pH 5.0) were coupled to the surface of the sensor flow cell. Then, the procedure 
for coupling proteins to the sensor chips was performed as recommended by the 
manufacturer using N-ethyl-N’- (dimethylaminopropyl) carbodiimide, N-
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hydroxysuccinimide and blocking the excess of activated groups by 1 M ethanolamine, pH 
8.5. Kinetic measurement was performed at 25 oC with a flow rate of 10 μL/min in HBS-
EP buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20). 
Surface coverage of the immobilized proteins; BSA (4.6 ng/mm2), D-Aβ1-40 (2.8 ng/mm2), 
Aβ1-42 (3.4 ng/mm2) and Aβ40-1 (4.2 ng/mm2), therefore surface coverage was in the same 
order of magnitude for all proteins. 
 Interaction of sHsps with D-Aβ1-40 (50 μl), wild-type Aβ1-42 or Aβ40-1 was performed using 
6 different concentrations of sHsp (5-50 μM). Regeneration of the sensor surface was 
performed with 20 μL of 10 mM NaOH. Interaction of sHsps with D-Aβ1-40, wild-type Aβ1-
42 or Aβ40-1 was compared with bovine serum albumin (BSA) as a negative control. The 
kinetic evaluation software (BIAcore), with correction for the negative control, was used 
to generate overlay plots of 6 concentrations of analyte to determine the relative 
dissociation constant KD (expressed in M). Furthermore, all experiments were performed 
in duplicate per chip, and at least two different sensor chips were used to exclude chip-to-
chip variations.     
 
Circular Dichroism (CD) Spectroscopy  
D-Aβ1-40 (50 μM) or Aβ1-42 (50 μM) was incubated either with or without Hsp20, 
HspB2/B3, Hsp27 or αB-crystallin (10 μM, molar ratio sHsp:D-Aβ1-40, 1:5) in 50 mM Tris-
HCl buffer with 150 mM NaCl (pH 7.4) at 37oC for 0 hours, 3 hours, 24 hours or 6 days. 
Subsequently, CD spectra were recorded in a Jasco J-810 Spectropolarimeter (Jasco Co., 
Tokyo, Japan) at 4oC. Far UV CD spectra were recorded using a cuvette with 1 mm path 
length at 1 nm intervals between 195 and 240 nm. The spectra were taken as the average 
of 15 scans recorded at a speed of 20 nm/min. CD spectra ranging from 212 nm up to 222 
nm were analyzed using the Wilcoxon matched pairs test. Centrifugation of the samples 
for10 minutes at 13,000 rpm had no effect on the CD spectra, compared to untreated 
samples. 
 
Electron microscopy (EM) 
D-Aβ1-40 or wild-type Aβ1-42 was incubated with or without Hsp20 (molar ratio 1:1), 
HspB2/B3 (1:1), Hsp27 (1:1), αB-crystallin (1:5), in either 20 mM HEPES (pH 7.4) or 50 
mM Tris-HCl buffer with 150 mM NaCl (pH 7.4) for 3 days. To study the morphology of 
Aβ aggregates the resulting samples were diluted in ultra pure water (1:5) and 5 μl aliquots 
were allowed to for 5 minutes on formvar-coated Ni-grids at 37oC. Grids were washed 
with ultra pure water and air-dried. For EM, samples were negatively stained with 3% 
filtered uranyl acetate solution. Both HEPES and 50 mM Tris-buffer demonstrated similar 
results.  
 
Immunofluorescence staining 
Cells cultured on eight-well chamber slides, were incubated with 25 μM D-Aβ1-40, with or 
without Hsp20 (molar ratio sHsps:D-Aβ1-40, 1:1 or 1:25), HspB2/B3, Hsp27 (molar ratio 1:1 
or 1:5) and αB-crystallin (molar ratio 1:5 or 1:50), for 3 days. Cells were washed once with 
phosphate-buffered saline (PBS) and then fixed with periodate-lysine-paraformaldehyde 
(PLP) for 10 minutes. The cell preparations were simultaneously incubated either with 
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mouse monoclonal anti-αB-crystallin antibody (Riken Cell Bank, Tsukuba, Japan) (334) 
and polyclonal rabbit anti-Aβ antibody (40-4) (generous gift from Dr. W.E. Van Nostrand, 
Stony Brook, NY, USA), or with polyclonal anti-Hsp20 antibody (344) or a polyclonal 
anti-HspB2 antibody (328) in combination with monoclonal antibody anti-Aβ (6C6, 
generous gift from Dr. D. Schenk, Elan Pharmaceuticals, San Francisco, CA). For 
immunohistochemical analysis of Hsp27 levels in HBPs, a mouse monoclonal anti-Hsp27 
antibody was used (Stressgen, Victoria, Canada). Subsequently, cells were simultaneously 
incubated with FITC-labeled swine anti-rabbit and biotin-labeled horse anti-mouse 
antibodies (both from Vector Laboratories, Burlingame, CA, USA). Finally, slides were 
incubated with avidin-labelled Texas Red and with Topro-3 for nuclear staining (Vector) 
for 45 minutes. Antibodies were diluted in PBS/0.1% BSA, which also served as a negative 
control. After each incubation, slides were extensively washed with PBS. 
Immunofluorescence staining was analyzed using a confocal laser-scanning microscope 
(Leica, Wetzlar, Germany).  
 
Cell culture 
Human brain pericytes (HBP) and human leptomeningeal smooth muscle cells (HLSMC) 
were isolated and characterized as described previously (339, 345, 346). Cells were 
maintained in Eagle’s minimal essential medium (EMEM) (Bio Whittaker Europe, 
Verviers, Belgium) supplemented with 10% human serum (Gemini BioProducts, 
Calabasas, CA, USA), 20% newborn calf serum (Life Technologies, Rockville, USA), 0.1% 
basic fibroblast growth factor and 2% penicillin/streptomycin at 37oC and 5% CO2. Cell 
passages 3-15 were used for the experiments; no effect of passage number was observed in 
the experiments. For viability studies, cells were incubated in an eight-well chamber slide 
(Nunc, Roskilde, Denmark) with EMEM and 0.1% BSA (serum-free medium) 
supplemented with 25 μM D-Aβ1-40 or wild-type Aβ1-42 for 6 days (174). Control cells 
incubated with serum-free medium alone, demonstrated normal morphology. Cells were 
co-incubated with sHsps at the indicated doses. Smooth muscle cells incubated with 
scrambled-sequence Aβ1-42 demonstrated neither signs of degeneration nor loss of cell 
viability (347). Cell viability was quantified using a fluorescent 
Live/Dead®Viability/Cytotoxicity Kit according to the manufacturer’s description 
(Molecular Probes, Eugene, OR, USA) and analyzed using a Leica fluorescence 
microscope. The percentage of dead cells was determined from at least four counts per 
well (approximately 800 cells per count), and the experiments were performed in 
duplicate. Each experiment was repeated at least three times. 
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Results 
 
Interaction of sHsp with Aβ using Surface Plasmon Resonance (SPR) 
Binding between the various sHsps and Aβ1-42 or D-Aβ1-40 was studied by surface plasmon 
resonance. No association of bovine serum albumin (BSA) to either Aβ1-42 or D-Aβ1-40 was 
observed on the sensor chip (Fig. 1A), also no association of sHsps with Aβ40-1, coated on 
the sensor chip, was observed. Hsp20 (5-50 μM) (Fig. 1B), αB-crystallin and Hsp27 (data 
not shown) demonstrated a high association and low dissociation from the sensor chip 
coated with D-Aβ1-40, suggesting strong binding to D-Aβ1-40. In contrast, binding of 
HspB2/B3 to D-Aβ1-40 was absent (Fig. 1C). Similar results were obtained for binding 
between the sHsps and Aβ1-42.  From the SPR data, the relative average binding affinity 
was calculated (see Table 1). Affinity of the sHsps for both forms of Aβ decreased in the 
following order: αB-crystallin > Hsp20, Hsp27 >> HspB2/B3. All sHsps demonstrated a 
higher affinity for Aβ1-42 than for D-Aβ1-40. For binding to the sensor chip, both Aβ1-42 and 
D-Aβ1-40 were dissolved in 10 mM Na-acetate.  
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Figure 1. Binding affinity of sHsps for Aβ1-42 and D-Aβ1-40. Interaction of sHsps with D-Aβ1-40 or wild-
type Aβ1-42 was analyzed using 6 different concentrations of sHsps (5-50 μM). Interaction of bovine
serum albumin (BSA, 50 μM) with D-Aβ1-40 was absent, serving as a negative control (A). Hsp20
demonstrated a high association with D-Aβ1-40 on the sensor chip and a low dissociation (B), whereas
association of HspB2/B3 with both peptides was absent (C). Both amyloid-beta peptides, dissolved at 25
μM in MilliQ and 10 mM Na-acetate (pH 5.0), were analyzed using native PAGE gel analysis before
coupling to the surface of the sensor flow cell. In both buffers, Aβ1-42 and D-Aβ1-40 demonstrated mainly
soluble monomeric Aβ (D). Injection point of sHsps or BSA (S) onto the sensor chip (association), and
injection point washing buffer (T) (dissociation). RU (resonance unit). 
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To check if the peptides were in a monomeric state, we compared Aβ1-42 and D-Aβ1-40 from 
freshly diluted stock solution (dissolved at 25 μM in MilliQ) with the peptides diluted in 
Na-acetate (pH 5.0), by analysis of a native PAGE gel. In both solutes, Aβ1-42 appeared as 
one band, whereas D-Aβ1-40 appeared as two bands, a major band (representing 
approximately 94% of the protein content) and a minor band with apparent higher 
molecular weight (6%) (Fig. 1D), suggesting that most of the peptides were initially in a 
monomeric state. 
 
Effect of sHsps on β-sheet formation of Aβ    
Binding of sHsps to Aβ might affect the formation of Aβ to form β-sheets. Therefore, 
quantitative changes in secondary structure of D-Aβ1-40 or Aβ1-42 either in the presence or 
absence of Hsp20, Hsp27, HspB2/B3 or αB-crystallin, were studied by circular dichroism 
(CD) spectroscopy. Analysis of 50 μM D-Aβ1-40, varying from 0 hours up to 6 days, resulted 
in a shift of a signal minimum (t= 0 hours) at approximately 200 nm, characteristic of a 
peptide in random coil conformation (Fig. 2A) to a minimum at 218 nm and a maximum 
at 195 nm after 6 days, a pattern that is characteristic for a peptide in β-sheet 
conformation (348). After 6 days of co-incubation of D-Aβ1-40 (50 μM) with Hsp20 (10 
μM) the CD spectrum showed a mixture of random coil and β-sheet formation, suggesting 
that Hsp20 reduced β-sheet formation by Aβ (Fig. 2B). In contrast, co-incubation of 50 
μM D-Aβ1-40 with 10 μM HspB2/B3 (Fig. 2C) resulted in essentially a similar CD spectrum 
as D-Aβ1-40 alone, suggesting a lack of interference with β-sheet formation. After 6 days of 
co-incubation of 50 μM D-Aβ1-40 with 10 μM Hsp27 (Fig. 2D) a mixture of random coil 
and β-sheet formation was observed, although the spectrum shows more β-sheet 
formation compared to co-incubations with Hsp20. Co-incubation of 50 μM D-Aβ1-40 with 
10 μM αB-crystallin, however, also resulted in a mixture of random coil and β-sheet 
formation after 6 days (Fig. 2E), although the signal suggested the highest amount of 
random coil of all co-incubations analyzed. The co-incubation of D-Aβ1-40 with αB-
crystallin also shows a spectrum indicative of less random coil formation compared to D-
Aβ1-40 at 0 hours (Fig. 2E). CD spectra of D-Aβ1-40 co-incubated with Hsp20, Hsp27 or αB-
crystallin for 6 days, resulted in a significant reduction in β-sheet formation (p = 0.001), 
compared to D-Aβ1-40 alone. In contrast, co-incubation of HspB2/B3 after 6 days had no 
significant effect on β-sheet formation (p = 0.15), compared to D-Aβ1-40 alone. CD analysis 
of Hsp20 (Fig. 2B), HspB2/B3 (Fig. 2C), Hsp27 (Fig. 2D) and αB-crystallin (Fig. 2E) alone 
(10 μM) all demonstrated a minor signal with a minimum from approximately 207 nm to 
220 nm. 
 Analysis of incubation of 50 μM Aβ1-42, resulted in a complete shift to β-sheets within 3 
hours (Fig. 2F), although a trend towards β-sheets was already visible within 30 minutes 
(data not shown). Co-incubation of 50 μM Aβ1-42 with 10 μM Hsp20 had no effect on the 
CD-spectrum compared to Aβ1-42 alone (Fig. 2G). In essence, similar results were obtained 
with co-incubations of HspB2/B3 (Fig. 2H), Hsp27 (Fig. 2I) and αB-crystallin (Fig. 2J), 
suggesting that co-incubation of Aβ1-42 with sHsps had no effect on Aβ1-42 β-sheet 
formation.  
 
Chapter 4
  59
 
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
nm
nm
nm
nm
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
0h
0h
0h
0h
6d
24h
24h
24h
3h
6d
6d
24h
6d
3h
Hsp20
D-Aβ1-40
D-Aβ1-40/Hsp20 wt-Aβ1-42/Hsp20
wt-Aβ1-42
Wavelength (nm)Wavelength (nm)
Wavelength (nm)Wavelength (nm)
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
wt-Aβ1-42/Hsp27
6d
24h
3h0h
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
Wavelength (nm)
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
Wavelength (nm)
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
wt-Aβ1-42/αB-crystallin
nm
nm
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
Wavelength (nm)
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
D-Aβ1-40/αB-crystallin
nm
0h 6d
24h
αB-crystallin
0h
3h
24h
6d
D-Aβ1-40/Hsp27
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
Wavelength (nm)
nm
6d
Hsp27
0h
24h
A
B
D
E
F
G
I
J
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
wt-Aβ1-42/HspB2/B3
-40
-30
-20
-10
0
10
20
190 200 210 220 230 240
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
Wavelength (nm)
nm
D-Aβ1-40/HspB2/B3
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
nm
Wavelength (nm)
HspB2/B3
0h
24h
6d
0h 3h
24h
6d
C H
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
M
ol
ar
 e
lli
pt
ic
ity
 re
si
du
e 
x1
03
Figure 2. Analysis of the effects of sHsps on Aβ aggregation by circular dichroism spectroscopy.
Conformation of 50 μM D-Aβ1-40 (A to E) or Aβ1-42 (F to J) either without (A and F) or with co-incubation
of Hsp20 (B, G), HspB2/B3 (C, H), Hsp27 (D, I) and αB-crystallin (E, J), molar ratio 1:5 (sHsp:Aβ). sHsps
(10 μM) alone were also analyzed, Hsp20 (B), HspB2/B3 (C), Hsp27 (D) and αB-crystallin (E). Peptides
were dissolved in Tris-HCl buffer 50 mM, 150 mM NaCl, pH 7.4, and incubated for 0 hours, 3 hours, 24
hours or 6 days at 37oC as indicated.  
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Effect of sHsps on ultrastructural morphology of Aβ aggregates 
The above-described experiment suggests that sHsps might affect Aβ aggregation and the 
formation of mature Aβ fibrils. Therefore, we aimed to confirm the effects of sHsps on Aβ 
aggregation by using alternative, independent techniques. To examine the effects of sHsps 
on the structure of D-Aβ1-40 aggregates we co-incubated peptides for either 3 days at 37oC 
and analyzed the morphology of Aβ aggregates qualitatively by electron microscopy (EM). 
As expected, incubation of 25 μM D-Aβ1-40 for 3 days resulted in the formation of an 
extensive network of predominantly mature fibrils (Fig. 3A). In contrast, co-incubation of 
D-Aβ1-40 with Hsp20 (molar ratio sHsp:D-Aβ1-40, 1:1), did not result in the formation of the 
extensive networks as observed with D-Aβ1-40 alone. Instead, dispersed small irregular 
groups of fibrils were observed (Fig. 3B). Co-incubation with HspB2/B3 (Fig. 4C), in a 
molar ratio of 1:1, resulted in the formation of dispersed irregular groups of electron-
dense Aβ fibrils.  
 
 
A B C D E
D-Aβ1-40
D-Aβ1-40
Hsp20 Hsp27HspB2/B3 αB-crystallin
Aβ1-42
F G H I J
Aβ1-42
Hsp20 Hsp27HspB2/B3 αB-crystallin
Figure 3. Analysis of the effects of sHsps on Aβ fibril formation using electron microscopy. Ultrastructural
analysis of 25 μM D-Aβ1-40 incubated at 37oC for 3 days resulted in large Aβ aggregates (A) predominantly
containing mature fibrils. In contrast, co-incubation of 25 μM D-Aβ1-40 with 25 μM Hsp20 (molar ratio
Hsp20: D-Aβ1-40, 1:1) at 37oC for 3 days resulted in low numbers of dispersed small irregular groups of
fibrils (B). Co-incubation of 25 μM D-Aβ1-40 with 25 μM HspB2/B3 (C), molar ratio 1:1, yielded much
higher numbers of such groups of electron-dense fibrils, whereas co-incubation with Hsp27 (D) resulted
in fibrils similar to co-incubation with Hsp20, although higher numbers of fibrils were observed. Only co-
incubation with αB-crystallin (molar ratio sHsps:Aβ, 1:25) showed protofibril-like structures (E), clearly
visible at higher magnification (E, inset). In ultrastructural analysis of 25 μM Aβ1-42 incubated at 37oC for 3
days predominantly mature Aβ fibrils were observed (F). Similar mature fibrils were observed in co-
incubations of Aβ1-42 with Hsp20 (G), HspB2/B3 (H), Hsp27 (I) and with αB-crystallin (J) (molar ratio
sHsp:Aβ1-42, 1:1). Magnification: A-J: 7500 x; E, inset: 75000 x. Scale bar A-J; 1μm, E, inset; 100nm.
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Co-incubation with Hsp27 (Fig. 3D), in a molar ratio of 1:1, resulted in fibrils 
morphologically similar to those resulting from the co-incubation with Hsp20. In 
contrast, co-incubation of αB-crystallin with D-Aβ1-40 resulted in the absence of a mature 
fibril network (Fig 3E). Only protofibril-like structures were observed (Fig. 3E, inset), that 
were not formed in the presence of any of the other sHsps. Results obtained after 6 days of 
incubation, were similar to that after 3 days incubation.  
Analysis of Aβ1-42 already resulted in dispersed small groups of fibrils after 3 hours 
of incubation, whereas an extensive network of mature fibrils was formed after 3 days 
(Fig. 3F), confirming the CD analysis and suggesting that this peptide fibrillizes faster than 
D-Aβ1-40. Aggregated Aβ1-42 was not observed in freshly dissolved peptide. When Aβ1-42 
was co-incubated with Hsp20, Hsp27 or αB-crystallin no aggregates could be observed 
after 3 hours of treatment, whereas co-incubation of HspB2/B3 with Aβ1-42 resulted in 
similar dispersed groups of fibrils as shown with Aβ1-42 alone. After 3 days of co-
incubation with Hsp20 (Fig. 3G), HspB2/B3 (Fig. 3H), Hsp27 (Fig. 3I) and αB-crystallin 
(Fig. 3J) extensive networks of mature fibrils were observed, similar to the treatments 
with Aβ1-42 alone (Fig. 3F). Results obtained after 6 days of incubation, were similar to that 
after 3 days incubation. In incubation of sHsps alone, no visible fibril structures were 
observed.   
 
Effect of sHsps on Aβ accumulation at the cell surface 
Incubation of HBPs with D-Aβ1-40 results in accumulation of Aβ at the cell surface, as 
demonstrated previously by us (340). Therefore, we investigated if sHsps mediate their 
effect by interfering with Aβ accumulation at the cell surface. When cultured HBPs were 
incubated with D-Aβ1-40 (Fig. 4A and B, cross-section) accumulation of Aβ at the cell 
surface was observed. Using CSLM the effects on Aβ accumulation at the cell surface 
could be analyzed qualitatively (Fig. 4). Accumulation of Aβ at the cell surface in the 
presence of Hsp20 was dose-dependent. Incubation with the lowest dose of Hsp20 (molar 
ratio 1:25) resulted in accumulation of both D-Aβ1-40 and Hsp20 at the cell surface (Fig. 4C 
and D). In contrast, after incubation with the highest dose of Hsp20 (molar ratio 1:1) the 
cell surface area covered by both immunoreactive Aβ and Hsp20 decreased (Fig. 4E and 
F). Administration of Aβ with HspB2/B3 for 3 days (molar ratio 1:1 or 1:5) had no effect 
on Aβ association with the cell surface (Fig. 4G and H). Furthermore, no effect on Aβ 
association with the cell surface was observed when cells were treated with both D-Aβ1-40 
and Hsp27 (molar ratio between 1:1 and 1:5) for 3 days (Fig. 4I, J). Treatment with both 
D-Aβ1-40 and αB-crystallin (1:1 up to 1:125) resulted in a decreased cell surface area 
covered by both immunoreactive Aβ and αB-crystallin as observed in co-incubations of 
D-Aβ1-40 with Hsp20 (molar ratio 1:1)(Fig. 4K and L). In absence of Aβ, no staining of 
sHsps on the cell surface was observed. In co-incubations of Aβ1-42 with the various sHsps, 
essentially similar effects on Aβ accumulation on the cell surface were observed (data not 
shown). 
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Figure 4. Staining for sHsps and Aβ at the surface of cultured HBPs. HBP were incubated with 25 μM D-
Aβ1-40 (A and B, cross section) and co-incubated with 1 μM Hsp20, molar ratio (sHsps:Aβ) 1:25 (C, D) and
1:1 (E, F), for 3 days. HBP were co-incubated with 25 μM D-Aβ1-40 and 25 μM of HspB2/B3 (G, H), or
Hsp27 (I, J), or αB-crystallin (K, L), molar ratio 1:1 (sHsps:Aβ), for 3 days. Immunofluorescence staining of
Aβ (40/4, polyclonal, green), Hsp20 (monoclonal, red), HspB2 (polyclonal, red), Hsp27 (monoclonal, red)
and αB-crystallin (monoclonal, red). Magnification x 630. Nuclei are counterstained blue. 
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Effect of sHsps on Aβ-mediated cell death 
Since sHsps bind to Aβ and may affect its aggregation, they may also affect its biological 
activity, e.g. its cytotoxic properties. In order to test this, we analyzed the effects of sHsps 
on Aβ-mediated cell death of human brain pericytes (HBP) and human leptomeningeal 
smooth muscle cells (HLSMC) in a quantitative manner. Incubation of cultured HBPs 
with 25 μM D-Aβ1-40 for 6 days reduced cell viability to approximately 50%, whereas in 
control incubations approximately 8% of the cells were dead (Fig. 5A). Aβ treatment 
resulted in visible signs of cellular degeneration, with cell contours becoming blurred, 
although all cells remained attached to the culture dish. Incubation with 25 μM of the 
inverted sequence (Aβ40-1) had no effect on cell death, compared to the control incubations 
(Fig. 5A). Co-incubation of D-Aβ1-40 with varying concentrations of Hsp20 resulted in a 
dose-dependent decrease in the number of dead cells (Fig. 5A).  
 
At a concentration of 25 μM Hsp20 (molar ratio sHsps:D-Aβ1-40, 1:1) complete inhibition 
of cell death was obtained and the morphology of the cells was indistinguishable from 
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Figure 5. Analysis of the effects of sHsps on Aβ-induced cytotoxicity towards human brain pericytes
(HBPs). Effects of small heat shock proteins (sHps) on cell death in HBP cultures after incubation with
D-Aβ1-40 (A-C) or Aβ1-42 (D-E) (both 25 μM), for 6 days are shown. The concentration of applied sHsp is
shown as the molar ratio of sHsp:Aβ. Several sHsps protected D-Aβ1-40 or Aβ1-42 –mediated cell death in a
dose-dependent manner. Hsp20 was an effective inhibitor (A and D), whereas HspB2/B3 and Hsp27 (B
and E) resulted in no or only poor protection against Aβ-mediated cell death. αB-crystallin also
demonstrated inhibition of Aβ–mediated cell death (C and F). In incubation of HBP with 25 μM Aβ40-1,
for 6 days, no effects on cell death as compared to the control were observed (A). Statistical analysis was
performed using Student’s t-test. The level of significance of the difference with D-Aβ1-40 or Aβ1-42 is
indicated as follows: *p< 0.05; **p< 0.01; p> 0.05 is not indicated. Mean ± S.E.M. are shown. 
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control cells. In contrast, similar molar ratios of HspB2/B3 or Hsp27 were not active (Fig. 
5B). Co-incubation with αB-crystallin inhibited D-Aβ1-40-mediated toxicity at a 1:5 molar 
ratio (Fig. 5C). Incubation with sHsps alone did not affect the number of dead cells 
compared to controls. Similar results were obtained with cultured HLSMCs (data not 
shown). In previous reports, it was described that αB-crystallin could induce 
neurotoxicity in samples counting otherwise non-toxic, low concentrations of Aβ (249). 
However, neither αB-crystallin nor Hsp20 (up to 75 μM) induced cerebrovascular cell 
death in combination with otherwise harmless concentrations (1 μM) of D-Aβ1-40 (data not 
shown).  
Incubation of HBP with 25 μM Aβ1-42 for 6 days resulted in a less robust cell death 
than with D-Aβ1-40, since approximately 75% of the cells survived this treatment (Fig. 5D). 
However, in comparison to its effect on D-Aβ1-40-mediated cell death, Hsp20 was more 
effective in inhibiting the toxic effects of Aβ1-42: addition of 1:5 Hsp20/Aβ1-42 already 
resulted in complete inhibition of cell death (Fig. 5D). Furthermore, in contrast to the 
absence of any effect on D-Aβ1-40-mediated cell death, both HspB2/B3 and Hsp27 
significantly inhibited Aβ1-42-mediated cell death at a molar ratio of 1:1 (Fig. 5E). Finally, 
αB-crystallin was also more effective in inhibiting Aβ1-42-mediated cell death; at a molar 
ratio of 1:50, complete cell rescue was achieved (Fig. 5F). 
Since αB-crystallin was the most effective inhibitor of Aβ toxicity, we investigated 
whether delayed supplementation with this sHsp could abrogate the toxicity of previously 
administered Aβ. Addition of 25 μM αB-crystallin to the culture medium, starting 4 to 48 
hours after exposure to 25 μM D-Aβ1-40 was followed by a time-dependent decrease in 
protection of Aβ-mediated cell death (data not shown). When αB-crystallin was not 
added within 24 hours after Aβ, cells were protected from degeneration only to a minor 
degree or, not at all.  
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Discussion  
In this report we demonstrated that the sHsps Hsp20, Hsp27 and αB-crystallin, but not 
HspB2/B3, bind strongly to Aβ (both D-Aβ1-40 and Aβ1-42) and affect its aggregation. 
Furthermore, Hsp20, Hsp27 and αB-crystallin inhibited cerebrovascular Aβ (both D-Aβ1-40 
and wild-type Aβ1-42) toxicity, probably by reducing the accumulation of Aβ at the cell 
surface. Finally, Hsp20, Hsp27 and αB-crystallin clearly inhibited aggregation of D-Aβ1-40, 
whereas their effects on Aβ1-42 were less pronounced. 
The potential of the various sHsps to inhibit D-Aβ1-40 toxicity towards 
cerebrovascular cells was correlated to the relative binding affinity of the sHsps to D-Aβ1-
40, their effect on Aβ β-sheet formation and mature fibril formation, and their ability to 
reduce accumulation of Aβ at the cell surface (summarized in Table 1). For instance, αB-
crystallin binds with high affinity to D-Aβ1-40, reduces its β-sheet formation and inhibits 
mature fibril formation and accumulation of D-Aβ1-40 at the cell surface, resulting in 
protection against D-Aβ1-40-mediated toxicity towards cerebrovascular cells. In contrast, 
HspB2/B3 failed to bind to D-Aβ1-40, did not, or only marginally, affect its β-sheet 
formation, mature fibril formation and accumulation at the cell surface, and consequently, 
inhibition of D-Aβ1-40 toxicity was absent. In contrast, however, such correlation between 
binding affinity, Aβ aggregation and cytotoxicity, was not directly evident for Aβ1-42. Aβ1-42 
formed β-sheets more rapidly than D-Aβ1-40, but this process was not detectably 
influenced by any sHsp, whereas all sHsps bind to Aβ1-42 (except HspB2/B3) and  – to a 
varying degree – inhibited Aβ1-42 –mediated cytotoxicity. 
In figure 6 we propose a schematic mechanism that may explain our findings. It is 
well-known that Aβ aggregates step-wise from monomers via oligomers and protofibrils 
into mature fibrils (349). Previous studies (350) suggested that mature fibrils do not 
interact with the cell surface of perivascular cells. Furthermore, our data on αB-crystallin 
suggest that protofibrils also do not interact with cerebrovascular cells. Thus, it is most 
likely that Aβ-mediated cell death is initiated by the association of Aβ monomers or 
oligomers with the cell surface. The observation that sHsps hardly affect aggregation of 
Aβ1-42 in solution might be due to its rapid aggregation, compared to D-Aβ1-40. In addition, 
fast aggregation of Aβ1-42 might result in lower amounts of toxic Aβ oligomers and less 
pronounced cell death compared to D-Aβ1-40 and, thus, more efficient inhibition of cell 
death by sHsps. Once associated with the cell surface, Aβ may continue to aggregate into 
mature fibrils. However, aggregation of Aβ does not seem to be the critical event in 
executing cell death since the various sHsps inhibit Aβ1-42-mediated cell death without 
affecting peptide aggregation. Furthermore, previous work (351) demonstrated that Aβ 
fibrillization at the cell surface can be uncoupled from cell death, suggesting that peptide 
fibrillization is an epiphenomenon. Therefore, sHsps seem to inhibit Aβ-mediated cell 
death by inhibiting the association of the peptide to the cell surface, thereby preventing 
cell death. The inhibitory effects on Aβ aggregation in solution may not be relevant to the 
process of cell death, however.   
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Figure 6. A schematic overview of the putative role of sHsps in Aβ aggregation. Aβ aggregates step-wise 
from monomers via oligomers and protofibrils into mature fibrils (349) (       ). Neither mature fibrils nor 
protofibrils seem to interact with the cell surface. Likely, Aβ-mediated cell death is initiated by the 
association of Aβ monomers or oligomers with the cell surface (       ). Once associated with the cell surface 
Aβ may continue to aggregate into mature fibrils. Although sHsps, especially αB-crystallin in the case of D-
Aβ1-40, may inhibit Aβ aggregation in solution (     ) it is most likely that the sHsps inhibit Aβ-mediated cell 
death by inhibiting the association of the peptide to the cell surface. However, sHsps such as Hsp20 and 
Hsp27 may affect, to a certain degree, the formation of D-Aβ1-40 mature fibrils (     ). Aβ1-42 aggregates faster 
in solution than D-Aβ1-40 (          ), which may explain why sHsps hardly affect aggregation of this peptide in 
solution.  
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   The mechanism by which Hsp20 and Hsp27 act on Aβ seemed to differ from that 
of αB-crystallin. Co-incubation of D-Aβ1-40 with Hsp20 or Hsp27 marginally reduced fibril 
formation, and did not result in the formation of Aβ protofibril-like structures as observed 
after co-incubation with αB-crystallin. Thus, although all sHsps share the ”α-crystallin 
region” (352), the interaction with Aβ might by dominated by subtle differences within 
this α-crystallin region between sHsps, or in other domains of the sHsps. For instance, the 
natural missense mutation R120G within the α-crystallin region of αB-crystallin decreases 
its chaperone activity (353), whereas naturally occurring mutations at amino acid 141 in 
the C-terminal domain (outside the α-crystallin region) of HspB8 significantly reduce its 
chaperone activity (354). Remarkably, all sHsps were more effective in reducing cell death 
caused by Aβ1-42 rather than D-Aβ1-40. Thus, either the N-terminal sequence or the amino 
acid residues around position 22 within Aβ, or both, could be involved in interactions 
with sHsps. In sporadic AD, CAA is to some extent observed in approximately 80% of all 
patients. In HCHWA-D, however, CAA is the most prominent lesion and directly 
involved in disease progression. We observed a higher binding affinity, and a more 
effective reduction in Aβ-mediated cell death of sHsps for the wild-type Aβ1-42, compared 
to the Aβ1-40 with the Dutch mutation. Thus, sHsps might be more efficient in preventing 
vascular Aβ accumulation in sporadic AD, compared to patients with HCHWA-D. 
 
 
 
 
 
Table 1. Summary of the interactions of sHsps and Aβ. 
 Analysis  αB-crystallin Hsp20 Hsp27 HspB2/B3 
Aβ1-42 1.12 ± 0.5 × 10-9 7.81 ± 4.5 × 10-7 1.14 ± 0.6 × 10-6 ND Binding affinity 
for Aβ (relative KD 
in M, mean ± SE) 
SPR 
D-Aβ1-40 1.73 ± 1.3 × 10-7 1.07 ± 0.4 × 10-6 1.41 ± 0.5 × 10-6 ND 
Aβ1-42 Not Significant Not Significant Not Significant Not 
Significant 
Reduction of β-
sheet formation 
CD 
 
D-Aβ1-40 Significant Significant Significant Not 
Significant
Aβ1-42 - - - - Reduction of 
mature Aβ fibril 
formation1 
EM 
D-Aβ1-40 +++ ++ ++ + 
Aβ1-42 1:50 1:5 1:1 >>1:1 Molar ratio 
(sHsps:Aβ) at 
which complete 
inhibition of Aβ-
mediated cell 
death is achieved 
Viability 
assay D-Aβ1-40 1:5 1:1 >>1:1 >>1:1 
1Effects on β-sheet formation or fibril formation is categorized in the following order: +++ (strong effect),  ++ (moderate 
effect), + (minor effect), - (no effect). SPR (surface plasmon resonance), CD (circular dichroism spectroscopy), EM 
(electron microscopy), ND (no detectable binding), SE (standard error).   
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Our SPR data are in line with the previously reported high-affinity binding and co-
aggregation of Aβ with αB-crystallin and Hsp27. Furthermore, our study confirmed 
previous data that αB-crystallin induced the formation of Aβ protofibril-like structures 
(249). Protofibrils are neurotoxic (167) and αB-crystallin indeed enhanced Aβ 
neurotoxicity (249). In contrast to these observations, we showed that the Aβ protofibril-
like structures that resulted after co-incubation of Aβ with αB-crystallin are not toxic to 
cerebrovascular cells but that, on the contrary, αB-crystallin was an effective inhibitor of 
Aβ-mediated cerebrovascular toxicity. Therefore, the mechanisms of Aβ toxicity and the 
regulation of this effect by Aβ-binding proteins might vary between different target cell 
types (110). 
Although the usual function of sHsps is intracellular surveillance of protein 
folding, our present data suggest that these proteins may have extracellular activity as 
well. Indeed, other studies suggested that sHsps may be observed at the cell surface (355) 
or extracellularly (329, 330). Furthermore, extracellular Hsp20 may act as a regulator of 
platelet function in plasma (331) and we recently demonstrated that both Hsp20 and 
HspB2 appear extracellularly and colocalize with the pathological hallmarks of AD brains. 
Hsp20 colocalizes with Aβ in senile plaques and HspB2 was found in CAA (342). This 
indicates that Hsp20 has a particular affinity for non-fibrillar Aβ, whereas HspB2 seems to 
have a higher affinity for fibrillar Aβ. This may explain our observations that Hsp20 
interacted with soluble Aβ and inhibited its aggregation, whereas HspB2/B3 neither 
bound soluble Aβ nor affected its aggregation. Possibly, HspB2/B3 interacts with (partly) 
aggregated Aβ.  
Aβ-associated proteins, such as Apolipoprotein E (356), bind Aβ in vivo, and affect 
its aggregation and accumulation in the brain and may play a role in the clearance of Aβ 
from brain tissue (357). As described for Apolipoprotein E, sHsps may facilitate clearance 
of Aβ from the cerebral cortex by inhibiting the aggregation of Aβ into insoluble mature 
fibrils (357). Therefore, optimization of the interaction between Aβ and sHsps may be a 
potential target for therapeutic intervention of AD aimed at stimulation of Aβ clearance 
from the brain.  
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Abstract 
 
Alzheimer’s disease is characterized by pathological lesions, such as senile plaques (SPs) 
and cerebral amyloid angiopathy (CAA), both predominantly consisting of a proteolytic 
cleavage product of the amyloid precursor protein (APP), the amyloid-β peptide (Aβ). 
CAA is also the major pathological lesion in hereditary cerebral hemorrhage with 
amyloidosis of the Dutch type (HCHWA-D), caused by a mutation in the gene coding for 
the Aβ peptide. Several members of the small heat shock protein family, such as αB-
crystallin, Hsp27, Hsp20 and HspB2, are associated with the pathological lesions of AD, 
and direct interaction between small heat shock proteins (sHsps) and Aβ has been 
demonstrated in vitro. HspB8, also named Hsp22 of H11, is a recently discovered member 
of the sHsp family, which has chaperone activity and is observed in neuronal tissue. 
Furthermore, HspB8 affects protein aggregation, which has been shown by its ability to 
prevent formation of mutant huntingtin aggregates. The aim of this study was to 
investigate whether HspB8 is associated with the pathological lesions of AD and 
HCHWA-D and whether there are effects of HspB8 on Aβ aggregation and Aβ-mediated 
cytotoxicity. We observed presence of HspB8 in classic SPs in AD brains. In addition, 
HspB8 was found in CAA in HCHWA-D brains, but not in AD brains. Direct interaction 
of HspB8 with Aβ1-42, Aβ1-40 and Aβ1-40 with the Dutch mutation was demonstrated by 
surface plasmon resonance. Furthermore, co-incubation of HspB8 with D-Aβ1-40 resulted 
in complete inhibition of D-Aβ1-40-mediated death of cerebrovascular cells, likely 
mediated by a reduction both in β-sheet formation of D-Aβ1-40 and its accumulation at the 
cell surface. In contrast, however, with Aβ1-42, HspB8 neither affected β-sheet formation 
nor Aβ-mediated cell death. We conclude that HspB8 might play an important role in 
regulating Aβ aggregation and, therefore, the development of classic SPs in AD and CAA 
in HCHWA-D. 
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Introduction 
Senile plaques (SPs) and amyloid angiopathy (CAA) are both characteristics of 
Alzheimer’s disease (AD) brains. The major component of these lesions is the amyloid-β 
protein (Aβ), a 4 kDa polypeptide (65) proteolytically cleaved from the amyloid-β 
precursor protein (APP) (66, 335). Furthermore, CAA is the major pathological finding in 
patients with hereditary cerebral hemorrhage with amyloidosis of the Dutch type 
(HCHWA-D) (26), where Aβ1-40 containing the ‘Dutch’ mutation (Glu22Gln) (D-Aβ1-40) 
induces a highly toxic form of Aβ that is deposited in brain vessels, leading to cerebral 
hemorrhage. Aβ accumulation and deposition in human brain vessels results in 
degeneration of smooth muscle cells and pericytes (358). The Aβ protein occurs in varies 
forms, ranging from relatively soluble monomers to oligomers, protofibrils and mature 
fibrils (336). Aβ fibrils are particularly neurotoxic (166, 167), whereas the soluble form of 
Aβ is toxic towards cultured cerebrovascular cells (337).  Both D-Aβ1-40 and wild-type Aβ1-
42, but not wild-type Aβ1-40, induce degeneration of cerebrovascular cells (338, 339) by a 
mechanism which seems to be based on aggregation of Aβ at the cell surface (340, 341).    
Aβ is not only subject to self-aggregation, several other proteins are also known to 
interact with Aβ. These Aβ-associated proteins might not only affect Aβ accumulation and 
deposition, but also its clearance from the brain (90). In vivo, Aβ accumulates in SPs and 
CAA, lesions that also contain several Aβ-associated proteins, such as apolipoprotein E 
and small heat shock proteins (sHsps) (89, 342). The sHsp family includes proteins that 
function as molecular chaperones and thus prevent other proteins from adopting an 
incorrect conformation (236). The human sHsp family comprises 10 sHsps (238), including 
αB-crystallin, Hsp20, Hsp27, HspB2/B3 and HspB8. Direct interaction between αB-
crystallin and Hsp27 with Aβ was demonstrated in vitro (246, 247) and these sHsps are 
also expressed in reactive astrocytes surrounding senile plaques (241, 242, 342). 
Furthermore, both Hsp20 and HspB2 bind Aβ and co-deposit with Aβ in SPs and CAA, 
respectively (342), and therefore may play a role in the process of Aβ aggregation and 
deposition.    
HspB8 is a recently discovered member of the sHsp family that contains a typical 
α-crystallin region and interacts with other sHsps, like Hsp27 (238, 359, 360). Its 
chaperone activity has been demonstrated in vitro, and, HspB8 blocks aggregation of 
polyglutamine proteins in vivo (354, 361). Apart from presence of HspB8 in both skeletal 
muscle and smooth muscle (362), HspB8 has also been observed in several neuronal cell 
types (363, 364). Given the interaction of HspB8 with other sHsps, the neuronal 
expression of HspB8, and its ability to prevent protein aggregation, we investigated if 
HspB8 may associate with Aβ in AD and HCHWA-D brains, thereby affecting its 
biological properties.  
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Materials and Methods 
 
Autopsy material 
Tissue samples from the occipital neocortex were obtained after rapid autopsy and 
immediately frozen in liquid nitrogen from 9 AD patients (age 80 ± 7.0 years; post mortem 
delay 4.0 ± 1.2 hours), 5 of them with moderate to severe CAA, and from 4 control cases, 
without neurological disease (age 76 ± 7.7 years; post mortem delay 4.3 ± 1.3 hours). 
Furthermore, tissue samples from the occipital neocortex of 5 patients with HCHWA-D 
(age 55.2 ± 3.3 years; post mortem delay 3.4 ± 1.8 hours) were obtained. Table 1 provides 
an overview of the diagnosis, Braak & Braak score, CERAD score, CAA grade, age, post-
mortem interval, gender and apolipoprotein E genotype of the patients used in this study. 
Diagnosis and grading of AD patients was performed according to the criteria established 
by Braak & Braak and CERAD (326, 327). CAA grading was established by quantification 
of the number of Aβ-positive vessels in one microscopic field (magnification 2.5x). At least 
4 microscopic fields of both the occipital cortex and the gyrus temporalis medius were 
analyzed and categorized by the number of vessels affected by Aβ deposition as follows: 0 
(-, no CAA), 0-10 (+, sparse CAA), 10-20 (++, moderate CAA) and >20 (+++, severe CAA).   
 
 
Table 1. Overview of patients included in this study.  
Patient 
number 
Diagnosis Grade 
(Braak) 
Grade 
(CERAD) 
Grade 
CAA 
Age PMI (h) Gender ApoE 
1 AD V +++ + 81 5 F 3/3 
2 AD VI +++ +++ 69 3 M 4/4 
3 AD V-VI +++ +++ 78 5 F 3/4 
4 AD V +++ + 87 6 F 3/3 
5 AD VI +++ ++ 89 3 F 3/4 
6 AD VI +++ + 75 5 M 4/4 
7 AD VI +++ +++ 77 3 M 3/4 
8 AD VI +++ ++ 89 4 F 4/4 
9 AD VI +++ + 75 3 M 3/3 
10 HCHWA-D I/II 0 +++ 55 1 F 3/4 
11 HCHWA-D I/II 0 +++ 59 4 M 3/3 
12 HCHWA-D - 0 +++ 51 3 M ND 
13 HCHWA-D - 0 +++ 53 3 F ND 
14 HCHWA-D - 0 +++ 58 6 M ND 
15 Control - 0 - 84 4 F 3/3 
16 Control I 0 - 81 4 M 3/3 
17 Control - 0 - 71 6 F 3/3 
18 Control I 0 - 68 3 M 2/3 
AD = Alzheimer’s disease, PMI = post mortem interval (h = hours), ApoE = apolipoprotein E genotype, 
ND = not determined. Grading of AD (Braak and CERAD scores) and of CAA was performed as 
described in the methods. 
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Immunohistochemistry 
To examine the presence pattern of HspB8 in AD and HCHWA-D brains, serial cryo-
sections (4 μm) were used. Sections were fixed and treated as described in previous reports 
(342). An overview of the antibodies used in this study is given in Table 2. HspB8 
presence was studied using a goat polyclonal anti-HspB8, ab4149 (Abcam, Cambridge, 
UK) and a rabbit anti-HspB8 antibody (328) raised against rat recombinant HspB8 protein. 
The antibody specificity in human brains was demonstrated by pre-absorption of the anti-
HspB8 antibodies (for this experiment used at a dilution of 1:8000) with 20 μg 
recombinant HspB8 for 2 hours at 4oC.  
 
Double immunostaining 
For double immunostaining, sections were fixed and pre-incubated as described above. 
Sections were simultaneously incubated with the primary antibodies of interest (see Table 
2). Subsequently, sections were co-incubated either with Swine anti-rabbit-FITC and 
biotin-labeled horse anti-mouse or sheep-anti-mouse-FITC and biotin-labeled goat-anti-
rabbit (all from Vector Laboratories, Burlingame, CA, USA), depending on the primary 
antibodies used. Finally, slides were incubated with avidin-labeled Texas Red (Vector) for 
45 minutes. Antibodies were diluted in PBS/1% BSA, which also served as a negative 
control. After each incubation, slides were extensively washed with PBS. Sections were 
mounted in Vectashield (Vector). Immunofluorescence staining was analyzed using a 
confocal laser-scanning microscope (Leica, Wetzlar, Germany).  
 
Peptides 
Both Aβ1-40 peptide (96% pure, HPLC analysis) containing the Glu22Gln mutation (D-Aβ1-
40) and wild-type Aβ1-42 (95% pure, HPLC analysis) were obtained from Biosource (Etten-
leur, The Netherlands). Both Aβ40-1 peptide (95% pure, HPLC analysis) and Aβ1-40 peptide 
(96% pure, HPLC analysis) were obtained from American Peptide (USA). Lyophilized 
peptides were dissolved in sterile water, at 250 μM and stored at –80oC. 
 
 
 
Table 2. Primary antibodies used in this study. 
Primary 
antibody 
Antigen Species 
raised in 
Dilution Source 
(Reference) 
6C6 Aβ Mouse 1:1000 Elan Pharma. San Francisco, CA, USA 
40-4 Aβ Rabbit 1:2000 Dr.Van Nostrand, Stony Brook, NY, USA 
8763-250 Tau Rabbit 1:2000 Abcam Limited, Cambridge, UK 
AT8 Hyperphos. 
Tau 
Mouse 1:200 Innogenetics, Gent, Belgium 
J92 HspB8 Rabbit 1:2000 Verschuure et al.(328) 
ab4149 HspB8 Goat 1:2000 Abcam, Cambridge, UK 
6F2 GFAP Mouse 1:20 Sanbio, Uden, The Netherlands 
KiM1p Microglia Mouse 1:5000 Kindly provided by Dr. M.R. Parwaresch, 
University of Kiel, Germany 
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Expression and purification of recombinant proteins 
The coding region of HspB8 was cloned into the vector pET16b. HspB8 was expressed in 
BL21 (DE3) competent cells (Invitrogen Corporation, Carlsbad, CA, USA). A culture 
inoculated from a single colony was incubated at 37oC for about 4 hours. Protein 
production was induced at an OD600 of 0.5 by the addition of isopropyl-thio-β-D-
galactopyranoside at a final concentration of 0.5 mM. Cells were harvested in TNE (50 
mM Tris pH 8.0, 10 mM NaCl, 1mM EDTA) and lysed by sonification after 4 hours (344). 
Insoluble proteins were removed by centrifugation. HspB8 was purified over a DEAE-
Sepharose Fast Flow column (Pharmacia, Freiburg, Germany) using a linear gradient from 
10 mM to 1 M NaCl in TNE buffer. A Superose 6HR 10/30-size exclusion column 
(Pharmacia) in TNE was used to determine sHsp complex size. Purity of the preparation 
was estimated at 83% by SDS-PAGE gel.  
 
Surface plasmon resonance (SPR) interaction studies 
SPR experiments were performed using a BIAcore 2000 (Uppsala, Sweden) biosensor 
instrument. Sensor chips and protein coupling chemicals were purchased from Biacore 
AB. Both D-Aβ1-40, wild-type Aβ1-42 peptide (3 μl Aβ, 1 μg/μL, in 300 μl 10 mM Na-acetate, 
pH 5.0) were coupled to the surface of the sensor flow cell. As recommended by the 
manufacturer, proteins were coupled to the sensor chips using N-ethyl-N’- 
(dimethylaminopropyl) cabodiimide, N-hydroxysuccinimide and blocking the excess of 
activated groups by 1 M ethanolamine, pH 8.5. Kinetic measurement was carried out at 25 
oC with a flow rate of 10 μL/min in HBS-EP buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 
3 mM EDTA, 0.005% surfactant P20). Interaction of HspB8 with D-Aβ1-40 (50 μl), wild-
type Aβ1-42 and wild-type Aβ1-40 was analyzed using 5 different concentrations per HspB8 
(10-50 μM). Regeneration of the sensor surface was performed with 20 μL of 10 mM 
NaOH. Interaction of HspB8 with D-Aβ1-40, wild-type Aβ1-42 or wild-type Aβ1-40 was 
compared with BSA as a negative control. The kinetic evaluation software (BIAcore), with 
correction for the negative control, was used to generate overlay plots of 5 concentrations 
of analyte to determine the dissociation constant Kd (expressed in M). Furthermore, all 
experiments were carried out in duplo per chip, and at least two different sensor chips 
were used to exclude chip-to-chip variations.      
 
PAGE gel 
Native PAGE gel was used on lyophilized Aβ peptides, dissolved in sterile water at 250 
μM, or dissolved in Na-acetate (pH 5.0, as used for surface plasmon resonance 
experiments). Equal amounts of protein were loaded and fractionated on a SDS-free 12% 
PAGE gel. Fractionated proteins were visualized using Commassie Brilliant Blue. Analysis 
was performed using the Odyssey infrared imaging system (LI-COR Biosciences GmbH, 
Bad Homburg, Germany).  
 
Cell culture 
Human brain pericytes (HBP) and human leptomeningeal smooth muscle cells (HLSMC) 
were isolated and characterized as described previously (339, 345, 346). Cells were 
maintained in Eagle’s minimal essential medium (EMEM) (Bio Whittaker Europe, 
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Verviers, Belgium) supplemented with 10% human serum (Gemini BioProducts, 
Calabasas, CA, USA), 20% newborn calf serum (Life Technologies, Rockville, USA), 0.1% 
basic fibroblast growth factor and 2% penicillin/streptamycin at 37oC and 5% CO2. Cell 
passages 3-15 were used for the experiments. For degeneration studies, cells were 
incubated in an eight-well chamber slide (Nunc, Roskilde, Denmark) with EMEM and 
0.1% bovine serum albumin (BSA) (serum-free medium) supplemented with 12.5 μM D-
Aβ1-40, 25 μM wild-type Aβ1-42 or 25 μM Aβ40-1 for 6 days (174). Control cells incubated 
with serum-free medium alone, demonstrated normal morphology. Cells were co-
incubated with HspB8 at the indicated doses. Cell viability was quantified using a 
fluorescent Live/Dead®Viability/Cytotoxicity Kit according to the manufacturer’s 
instructions (Molecular Probes, Eugene, OR, USA) and analyzed using a Leica 
fluorescence microscope. The percentage of dead cells was determined from at least four 
counts per well (approximately 800 cells per count), and the experiments were performed 
in duplicate. Each experiment was repeated at least three times. Smooth muscle cells 
incubated with scrambled-sequence Aβ1-42 demonstrated neither signs of degeneration nor 
loss of cell viability (347). 
 
Immunofluorescence staining of Aβ and HspB8 on the cell surface 
Cells cultured on eight-well chamber slides, were incubated with 12.5 μM D-Aβ1-40 or 25 
μM wild-type Aβ1-42, with or without HspB8 (molar ratio HspB8:D-Aβ1-40, 1:1 or 1:25), for 
3 days. Cells were washed once with phosphate-buffered saline (PBS) and then fixed with 
periodate-lysine-paraformaldehyde (PLP) for 10 minutes. The cell preparations were then 
simultaneously incubated with monoclonal antibody anti-Aβ (6C6, generous gift from Dr. 
P. Seubert, Elan Pharmaceuticals, San Francisco, CA) and rabbit polyclonal anti-HspB8. 
Subsequently, cells were simultaneously incubated with FITC-labeled swine anti-rabbit 
and biotin-labeled horse anti-mouse antibodies (both from Vector). Finally, slides were 
incubated with avidin-labeled Texas Red and with Topro-3 for nuclear staining (Vector) 
for 45 minutes. Antibodies were diluted in PBS/1% BSA, which also served as a negative 
control. After each incubation, slides were extensively washed with PBS. 
Immunofluorescence staining was analyzed using a confocal laser-scanning microscope 
(Leica, Wetzlar, Germany).  
 
Circular Dichroism (CD) Spectroscopy  
D-Aβ1-40 (50 μM) or wild-type Aβ1-42 (50 μM) was incubated either with or without HspB8 
(10 μM, molar ratio HspB8:D-Aβ1-40, 1:5) in 50 mM Tris-HCl buffer with 150 mM NaCl 
(pH 7.4) at 37oC for 0 hours, 3 hour, 24 hours or 6 days. Subsequently, CD spectra were 
recorded in a Jasco J-810 Spectropolarimeter (Jasco Co., Tokyo, Japan) at 4oC. Far UV CD 
spectra were recorded using a cuvette with 1 mm path length at 1 nm intervals between 
195 and 240 nm. The spectra were taken as the average of 15 scans recorded at a speed of 
20 nm/min.  
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Results 
 
Presence of HspB8 in control, AD and HCHWA-D brains 
In control brains, HspB8 staining was observed in astrocytes in both grey and white 
matter and in cerebrovascular cells of large parenchymal vessels, such as smooth muscle 
cells and endothelial cells, (Fig. 1A). In aged control patients an occasional classic SP, 
stained with the anti-Aβ antibody and reactive astrocyte surrounding SPs demonstrated 
HspB8 immunoreactivity (Fig. 1B). The identity of the HspB8-positive astrocytes was 
confirmed by double staining (Fig. 1C, D). Staining was also observed in oligodendroglia, 
as defined by morphology, and microglia (Fig. 1E, F). In diffuse SPs, however, HspB8 
staining was absent. Specificity of both anti-HspB8 antibodies was demonstrated when 
staining of classic SPs (Fig. 1G) in AD brains was reduced by using anti-HspB8 antibody 
pre-absorbed with recombinant HspB8 (Fig. 1H). 
In both AD and HCHWA-D brains, anti-HspB8 also stained oligodendroglia, microglia 
and reactive astrocytes in both white and grey matter. In addition, weak HspB8 staining 
was also observed in cells of normal parenchymal vessels (Fig. 1M,N). Furthermore, 
HspB8 was absent in NFTs (data not shown). In both AD and HCHWA-D brains, classic, 
diffuse SPs and CAA in the neocortex of these patients were stained with the anti-Aβ 
antibody (Fig. 1I, J and K, L) and Congo red. Comparison of the staining obtained with 
Congo red, anti-Aβ (6C6) and both anti-HspB8 antibodies revealed immunoreactivity of 
anti-HspB8 in classic SPs in all AD patients (Table 1), whereas diffuse SPs were not 
stained in both AD and HCHWA-D brains (Fig. 1I, J, M, N). In AD brains, in CAA 
localization of the anti-HspB8 immunoreactivity was similar as to control vessels but with 
much higher intensity (Fig. 1O). In contrast to CAA in AD, anti-HspB8 staining was 
observed in CAA in HCHWA-D brains (Fig. 1P). Furthermore, reactive astrocytes 
surrounding both SPs and CAA, were HspB8 immunopositive.  
 
Interaction of HspB8 with Aβ using Surface Plasmon Resonance (SPR) 
HspB8 colocalises with Aβ in the pathological lesions of both AD and HCHWA-D brains, 
therefore we investigated whether direct interactions occur between HspB8 and wild-
type Aβ1-42, wild-type Aβ1-40 or D-Aβ1-40, using surface plasmon resonance. To check if the 
peptides were in a monomeric state, we compared freshly diluted stock solutions of Aβ1-42, 
Aβ1-40 and D-Aβ1-40 (dissolved at 25 μM in MilliQ) with the peptides diluted in 10 mM Na-
acetate (pH 5.0), and analysed them by native PAGE gel. In both solutions, Aβ1-42 (Fig. 2A) 
and Aβ1-40 (data not shown) appeared as a single band, whereas D-Aβ1-40 appeared as a 
major band (approximately 94% of the protein content) and a minor band with apparent 
higher molecular weight (6%) (Fig. 2A), suggesting that most of the peptides were initially 
in a monomeric state. Binding of bovine serum albumin (BSA) to Aβ1-42, Aβ1-40 and D-Aβ1-
40 was absent (Fig. 2B). HspB8 demonstrated high association with and minor dissociation 
from D-Aβ1-40 (Fig. 2C), Aβ1-42 (Fig. 2D) and Aβ1-40 (Fig. 2E). From the obtained SPR data, 
dissociation constants were calculated (Fig. 2F). HspB8 binding to D-Aβ1-40 had the highest 
binding affinity in comparison to the other two Aβ peptides.  
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Figure 1. Immunohistochemical staining of HspB8 in neocortex of control, AD and HCHWA-D brain.
HspB8 was demonstrated in the vessel wall (A) in control brains. Expression of HspB8 was also found in
classic SPs in control brains (B). Reactive astrocytes (C, GFAP) also demonstrated HspB8
immunoreactivity (A, B, D, arrows). In addition, HspB8 antibody (F) stained microglia (E, KIM1p).
Specificity of the anti-HspB8 antibody (J92) was demonstrated by pre-incubation of the antibody with
recombinant HspB8 (G, H). Staining of SPs with anti-HspB8 is absent after pre-incubation. The anti-Aβ
(mAb 6c6) stained SPs (I, J) and CAA (K, L) in control, AD and HCHWA-D brains. HspB8 was observed
in astrocytes associated with SPs in AD brains (M). In AD brains, HspB8 staining was observed in classic
SPs (M, arrow), but absent from diffuse SPs (M, open arrow). HspB8 staining was absent from diffuse
SPs in HCHWA-D brains (N, arrow). In normal vessels in AD and HCHWA-D brains, weak HspB8
staining was observed (M, N, arrow*). In CAA in AD brains, HspB8 staining was absent (O), whereas in
CAA in HCHWA-D brains, HspB8 immunoreactivity was observed (P). Serial sections; G, H; I, M; J, N;
K, O; L, P. Original magnification A, B, G-P × 250 and C-F × 400. 
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Figure 2. Binding affinity of HspB8 for wild-type Aβ1-42, wild-type Aβ1-40 and D-Aβ1-40. Aβ peptides,
dissolved in MilliQ at 25μM and 10 mM Na-Acetate (pH 5.0), were analyzed using native PAGE gel before
coupling to the surface of the sensor flow cell. In either buffer, wild-type Aβ1-42 was only present as a
single band, whereas for D-Aβ1-40 an additional band representing a higher molecular weight form was
observed (approximately 6% of the total protein content, arrow) (A). Interaction of bovine serum albumin
(BSA) with D-Aβ1-40 was absent, serving as a negative control (B). Interaction of HspB8 with D-Aβ1-40 (C),
wild-type Aβ1-42 (D) and wild-type Aβ1-40 (E) was performed using 5 different concentrations of sHsps (10-
50 μM). HspB8 binds to D-Aβ1-40, wild-type Aβ1-42 and wild-type Aβ1-40 (F). The results in the table are
mean KD value determined using 5 different concentrations of HspB8 and standard error of at least 3
different experiments. The injection point of HspB8 or BSA (T) onto the sensor chip (association), and
injection point of the washing buffer (S) (dissociation) are indicated. Abbreviations: KD (dissociation
constant), RU (resonance unit) and SE (standard error).  
 
Chapter 5
  79
Effects of HspB8 on Aβ-mediated cell death 
HspB8 was observed in CAA in HCHWA-D brains, whereas it was absent in CAA in AD. 
Binding of HspB8 to Aβ, as demonstrated by SPR, might affect the biological activity of 
Aβ. Therefore, we investigated the effects of HspB8 on Aβ-mediated cell death of human 
brain pericytes (HBP) and human leptomeningeal smooth muscle cells (HLSMC). 
Incubation of cultured HBPs with 12.5 μM D-Aβ1-40 for 6 days reduced cell viability to 
approximately 50%, whereas in control cells approximately 8% cell death was observed 
(Fig. 3A).  
 
 
 
Co
ntr
ol
Aβ 40
-1
 25
 μM
D-
Aβ 1-
40
 12
.5 μ
M
Hs
pB
8 2
5 μM
Hs
pB
8 1
:5
Hs
pB
8 1
:3
Hs
pB
8 1
:1
Hs
pB
8 2
:1
Aβ 1-
42
 25
 μM
Hs
pB
8 1
:25
Hs
pB
8 1
:1
0
25
50
12.5 μM D-Aβ1-40
25 μM Aβ1-42
%
 d
ea
d 
ce
lls
*
**
**
*
co
ntr
ol
D-
Aβ 1-
40
 1
2.5
 μM 0 ho
urs
3 h
ou
rs
7 h
ou
rs
24
 ho
urs
48
 ho
urs
0
25
50
75
%
 d
ea
d 
ce
lls
12.5 μM D-Aβ1-40 / 25 μM HspB8
**
*
*
A
B
%
 d
ea
d 
ce
lls
%
 d
ea
d 
ce
lls
 
Figure 3. Analysis of the effects of HspB8 on Aβ-induced cytotoxicity towards human brain pericytes
(HBPs). Effects of HspB8 on cell death in HBP cultures after incubation with D-Aβ1-40 (12.5 μM), wild-
type Aβ1-42 (25 μM) or Aβ40-1 (25 μM) for 6 days are shown. The concentration of HspB8 is shown as the
molar ratio of sHsp:Aβ (A). HspB8 protected cells from D-Aβ1-40–mediated cell death in a dose-dependent
matter. Inhibition by HspB8 of wild-type Aβ1-42 –mediated cell death was absent (A). Addition of 25 μM
HspB8 to the culture medium, starting 0 to 48 hours after exposure to 12.5 μM D-Aβ1-40 demonstrated a
time-dependent decrease in protection of D-Aβ1-40-mediated cell death (B). Statistical analysis was
performed using a Student’s t-test. The level of significance of the difference with D-Aβ1-40 or Aβ1-42 is
indicated as follows: *p< 0.05; **p< 0.01; p> 0.05 is not indicated. Mean ± S.E.M. are shown. 
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Although after treatment with D-Aβ1-40 the cells morphologically demonstrated signs of 
cellular degeneration, with cell contours becoming blurred, all cells remained attached to 
the culture dish. Exposure of cerebrovascular cells to 25 μM of Aβ40-1 had no effect on cell 
death (data not shown). Co-incubation of D-Aβ1-40 with varying amounts of HspB8 
resulted in a dose-dependent decrease in the number of dead cells (Fig. 3A). At a 
concentration of 25 μM HspB8 (molar ratio sHsp:D-Aβ1-40, 2:1) the morphology of the 
cells was indistinguishable from control cells, and D-Aβ1-40-mediated toxicity was 
inhibited entirely. Treatment with HspB8 alone did not affect the number of dead cells 
compared to control cells (Fig. 3A).  
Exposure of HBP to 25 μM wild-type Aβ1-42 for 6 days resulted in a less robust cell death, 
since approximately 40% of the cells had died after this treatment (Fig. 3A). Unlike its 
effect on D-Aβ1-40-mediated cell death, HspB8 was ineffective in inhibiting the toxic 
effects of Aβ1-42; even after addition of 1:1 HspB8/Aβ1-42 no inhibition of cell death was 
achieved. Similar results were obtained with cultured HLSMCs treated with both Aβ 
peptides and HspB8 (data not shown). Incubation of 25 μM wild-type Aβ1-40 for 6 days had 
no effect on cell death, as also demonstrated by others (341). 
Since HspB8 was an effective inhibitor of D-Aβ1-40 toxicity, we investigated whether 
delayed supplementation with this sHsp after the administration of Aβ could abrogate D-
Aβ1-40-mediated toxicity. Addition of 25 μM HspB8 to the culture medium, starting 0 to 48 
hours after exposure to 12.5 μM D-Aβ1-40 demonstrated a time-dependent decrease in 
protection of D-Aβ1-40-mediated cell death (Fig. 3B). When HspB8 was added 24 hours or 
more after D-Aβ1-40, cells were only protected to a minor degree or not protected from 
degeneration at all.  
 
Association of HspB8 with Aβ on the cell surface 
The viability experiments showed that HspB8 is able of inhibiting D-Aβ1-40-mediated 
degeneration of cerebrovascular cells. Incubation of HBPs with D-Aβ1-40 or wild-type Aβ1-
42 resulted in accumulation of Aβ at the cell surface, as demonstrated previously (340), 
whereas this phenomenon was absent with wild-type Aβ1-40 (341). In cultures of HBPs 
that were co-incubated with D-Aβ1-40 and HspB8 for 3 days (molar ratio HspB8:D-Aβ1-40, 
1:1 or 1:25) co-localization of both proteins could be observed using confocal laser 
scanning microscopy (Fig. 4). Accumulation of Aβ protein at the cell surface was 
dependent on the dose of HspB8. Incubation of a low dose of HspB8 (molar ratio 1:25) 
resulted in accumulation of both D-Aβ1-40 and HspB8 at the cell surface (Fig. 4A, B), 
whereas incubation at molar ratio of 1:1 resulted in a decrease of Aβ association with the 
cell surface and consequently, immunoreactive HspB8 as well (Fig 4C, D). Cross-section 
analysis, of HBPs co-incubated with D-Aβ1-40 and HspB8 for 3 days (molar ratio HspB8:D-
Aβ1-40, 1:25), using confocal laser scanning microscopy suggested that both proteins were 
co-located at the cell surface of HBPs (Fig 4E). HspB8 staining was absent when cells were 
incubated with HspB8 only. Co-incubation of Aβ1-42 with HspB8 for 3 days (molar ratio 
HspB8:Aβ1-42, 1:1) had no effect on the accumulation of Aβ1-42 on the cell surface and 
colocalization of HspB8.  
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Effects of HspB8 on secondary Aβ structure 
One of the mechanisms by which the above-described findings can be explained, is 
inhibition of Aβ aggregation by HspB8. Changes in secondary structure of D-Aβ1-40 or Aβ1-
42, either in the presence or absence of HspB8, were studied by circular dichroism (CD) 
spectroscopy. Incubation of 50 μM D-Aβ1-40, varying from 0 hours up to 6 days, resulted in 
a shift of a signal minimum (t= 0 hours) at approximately 200 nm characteristic of a 
peptide in random coil formation (Fig. 5A) to a minimum at 218 nm and a maximum at 
190 nm after 6 days, a pattern characteristic for β-sheet conformation (348). CD analysis of 
HspB8 alone (10 μM) resulted in a minor signal with a minimum from 190 nm to 205 nm 
(Fig. 5B), as observed also by others (361). After 6 days of co-incubation of D-Aβ1-40 (50 
μM) with HspB8 (10 μM) the CD spectrum demonstrated a mixture of random coil and β-
sheet formation, suggesting that HspB8 reduces, but not completely inhibits, β-sheet 
formation of Aβ. Analysis of 50 μM Aβ1-42, varying from 0 hours up to 6 days, 
demonstrated a signal shift similar to D-Aβ1-40 (Fig. 5C). However, the shift to β-sheets was 
already established within 3 hours (Fig. 5C). Treatment with a combination of 50 μM Aβ1-
42 and 10 μM HspB8 demonstrated an essentially similar CD-spectrum compared to Aβ1-42 
alone (Fig. 5D). Co-incubations of a higher molar ratio of HspB8 with either D-Aβ1-40 or 
Aβ1-42 were not analyzed given the interference of the HspB8 signal with the Aβ signal. 
Incubation of wild-type Aβ1-40 did not result in β-sheet formation, as previously 
demonstrated by others (341). 
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Figure 4. Staining for HspB8 and Aβ at the surface of cultured HBPs. HBP were co-incubated with D-
Aβ1-40 and HspB8, molar ratio (HspB8:Aβ) 1:25 (A, B) and 1:1 (C, D), for 3 days. Immunofluorescence
staining of Aβ (6C6, monoclonal, green) and HspB8 (polyclonal, red) is shown. Nuclei are counter
stained blue. HspB8 co-localized with Aβ at the cell surface. Cross-section analysis using confocal laser
scanning microscopy demonstrated co-localization of both proteins at the cell surface of HBPs (E).
Magnification × 630. 
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Discussion 
In this report we demonstrated that HspB8 is associated with classic SPs in AD and 
normal brains and CAA in HCHWA-D brains. Furthermore, a correlation was observed 
between binding affinity of HspB8 for Aβ, reduction of β-sheet formation and inhibition 
of Aβ-mediated cytotoxicity towards cerebrovascular cells. HspB8 demonstrated a higher 
binding affinity for D-Aβ1-40, compared to wild-type Aβ1-42, and was more effective in 
reducing β-sheet formation and cytotoxicity caused by D-Aβ1-40 than by Aβ1-42.  
Several members of the sHsp family co-localize with the pathological hallmarks of 
AD. Both αB-crystallin and Hsp27 are upregulated in AD and observed in proliferating 
astrocytes and microglia associated with SPs in AD (240, 254). Recently, we demonstrated 
that Hsp20 colocalized with Aβ in diffuse SPs in AD, whereas HspB2 was observed in 
CAA (342). These data suggest that sHsps, such as Hsp20 and HspB2 might play a role in 
the accumulation and/or deposition of Aβ in AD brains. Presence of HspB8 has been 
described in skeletal muscle, smooth muscle (362) and in several neuronal cell types (363, 
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Figure 5. Analysis of the effects of HspB8 on Aβ aggregation by circular dichroism spectroscopy.
Conformation of 50 μM D-Aβ1-40 (A, B) or wild-type Aβ1-42 (C, D) either without (A, C) or with (B, D) co-
incubation of HspB8, molar ratio 1:5 (sHsp:Aβ). HspB8 (10 μM) alone was also analyzed (B). Peptides were
dissolved in Tris-HCl buffer 50 mM, 150 mM NaCl, pH 7.4, and incubated for 0 hours, 24 hours or 6 days at
37oC as indicated.  
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364), that may be the cellular source of HspB8 in CAA in HCHWA-D and in classic senile 
plaques in AD. Since CAA in HCHWA-D predominantly consists of D-Aβ1-40 and SPs of 
D-Aβ1-42, the tight binding of HspB8 to D-Aβ1-40 may explain the selective association of 
HspB8 to CAA. Alternatively, it can be suggested that HspB8 preferentially binds to 
fibrillar Aβ, given its association with classic SPs in AD and CAA in HCHWA-D. On the 
other hand, our SPR data indicate that HspB8 also binds to monomeric Aβ and we did not 
observe HspB8 staining of CAA in AD. The higher binding affinity of HspB8 for D-Aβ1-40 
compared to Aβ1-40, may explain why HspB8 co-localizes to CAA in HCHWA-D but not in 
AD. In contrast, although stronger binding of HspB8 to Aβ1-42 compared to Aβ1-40 was 
observed, HspB8 was only observed in classic SPs, but not in diffuse SPs that contain Aβ1-
42, in AD. Thus, neither mutations within Aβ, the C-terminal sequence of Aβ nor its 
aggregation state solely determine the association of HspB8 with the lesions in AD and 
HCHWA-D brains. Therefore, other, yet unstudied, factors probably regulate the 
association of HspB8 with Aβ.  
In vitro interaction between sHsps and Aβ has been described for both αB-
crystallin and Hsp27 (246, 247). Here we demonstrate that HspB8 also binds to distinct 
species of Aβ. Our unpublished observations showed that another member of the sHsp 
family, HspB2, does not bind to Aβ. Whereas all sHsps share an 80 amino acid ”α-
crystallin region”(352), the interaction with Aβ is likely dominated by other regions 
within the sHsps. Support for this hypothesis comes from studies on the interaction 
between HspB8 and mutated huntingtin (Htt43Q) (354). HspB8 inhibited aggregation of 
Htt43Q, but naturally occurring mutations at amino acid 141 in the C-terminal region 
(outside the α-crystallin domain) of HspB8 significantly reduced its chaperone activity. 
Therefore, this C-terminal region might also be involved in the interaction with Aβ.  
HspB8 only inhibited the cytotoxic activity of D-Aβ1-40, but not that of Aβ1-42, 
despite that HspB8 binds to either of the two monomeric peptides. It is possible that the 
capacity of HspB8 to inhibit aggregation of D-Aβ1-40, but not of Aβ1-42, provides an 
explanation for this finding. Furthermore, Aβ1-42 showed faster aggregation in our CD 
analysis, which may result in reduced binding of HspB8 with Aβ1-42 compared to the 
slower aggregating D-Aβ1-40. 
 So far, sHsps have been implied in the process of intracellular protein folding. 
However, here we demonstrate that HspB8 may appear extracellularly and thus might 
have activity outside the cell. Recently, we described extracellular appearance of several 
other members of the sHsp family, such as Hsp20 and HspB2 (342). In addition, other 
groups also reported sHsps at the cell surface or extracellularly, including a role for Hsp20 
in regulation of platelet function in plasma (329-331, 355). The extracellular appearance of 
sHsps in the brain, together with their ability to bind soluble Aβ, suggests that sHsps 
might influence Aβ aggregation and accumulation in the brain of AD and HCHWA-D 
patients. Recently, it was suggested that upregulation of HspB8 may be a potential strategy 
to protect motor neurons from degeneration (364). Although, it is yet unclear if HspB8 
may appear in secreted form, extracellular appearance of Hsp70 has been reported (365). 
Thus, whether the extracellular appearance of the various sHsps is a result of cellular 
degeneration or is initiated by other stimuli, remains to be elucidated.  
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In vivo, Aβ-associated proteins are known to interact with Aβ. The best-studied 
proteins are heparan sulfate proteoglycans (HSPGs)(85, 86), serum amyloid P (SAP)(87), 
apolipoprotein E (ApoE)(84), α1-antichymotrypsin (ACT)(366) and complement factors 
(C1q, C3d and C4d)(88). All these proteins do not only interact with Aβ, they also may 
affect the formation, deposition and accumulation of Aβ in the brain and therefore may 
play a role in the clearance of Aβ from the brain. Since aging is associated with decreasing 
levels of Hsps (367), and since sHsps have an important function in regulating protein 
folding, “quality control” of proper protein folding may start failing, resulting in the 
accumulation of toxic protein aggregates. Thus, sHsps, including HspB8, might aid in 
maintaining both the delicate balance between Aβ production and clearance and the 
balance between Aβ aggregation and disaggregation by controlling its protein folding 
state.  
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Abstract 
 
Hereditary cerebral haemorrhage with amyloidosis of the Dutch type (HCHWA-D) is 
characterized by hemorrhagic strokes and dementia. In HCHWA-D, the amyloid-β 
protein (Aβ) E22Q mutation generates a toxic form of Aβ and results in severe cerebral 
amyloid angiopathy (CAA) and diffuse senile plaques (SPs). Small heat shock proteins 
(sHsps) are molecular chaperones and associated with SPs and CAA in Alzheimer’s disease 
(AD). In our previous report, we demonstrated that HspB8 was associated with CAA in 
HCHWA-D brains, and with classic SPs in AD brains. The aim of this study was to 
investigate whether the sHsps αB-crystallin, Hsp20, Hsp27 and HspB2 are associated with 
the pathological lesions in HCHWA-D brains, whether the cells associated with these 
lesions produce sHsps in vitro, and whether sHsps are involved in the inflammatory 
processes in AD and HCHWA-D. We observed association of Hsp20 and HspB2 with 
CAA, but not with SPs, in HCHWA-D brains, whereas Hsp20 was found in SPs and 
HspB2 in both SPs and CAA in AD brains. The presence of sHsps in CAA and SPs was not 
the result of an Aβ-mediated upregulation as measured in cultured human brain pericytes 
and astrocytes. Surprisingly, Hsp20, HspB2 and HspB8 induced interleukin-6 (IL-6) 
production in pericytes and astrocytes, whereas this effect was not found using αB-
crystallin, Hsp27, or with Aβ1-40, Aβ1-42 and Aβ1-40 with the Dutch mutation. We conclude 
that specific sHsps species may be involved in the development or progression of either 
SPs or CAA in AD and HCHWA-D, and that sHsps that are associated with these lesions 
may be among the mediators of an inflammatory response.    
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Introduction 
 
Senile plaques (SPs) and cerebral amyloid angiopathy (CAA) are neuropathological 
hallmarks of both Alzheimer’s disease (AD) and hereditary cerebral hemorrhage with 
amyloidosis of the Dutch type (HCHWA-D). SPs and CAA predominantly consist of the 
amyloid-beta peptide (Aβ), a 4 kDa proteolytic cleavage product of the amyloid precursor 
protein (APP) (65). HCHWA-D patients are characterized by extensive accumulation of 
Aβ in cerebral vessels resulting in fatal intracerebral hemorrhages (26). The severe CAA, 
present in HCHWA-D patients, is caused by the toxic 22GluGln mutation within the 
Aβ1-40 peptide (D-Aβ1-40) (26). Aβ accumulation and deposition in human brain vessels 
results in the degeneration of both pericytes and leptomeningeal smooth muscle cells 
(358). Both SPs and CAA are associated with complement factors, acute phase proteins 
and cytokines (305). These inflammatory mediators may stimulate Aβ production, 
activation of microglial cells and astrocytes, and induce neurotoxicity (368). In AD, IL-1 
and IL-6 are associated with SPs, and both IL-6 and TNF-α levels are increased in AD 
brains (369, 370), suggesting that, conversely, Aβ accumulation induces cytokine 
production in AD. 
The small heat shock protein (sHsp) family comprises molecular chaperones, 
involved in protein complex assembly and suppression of protein aggregation and assist in 
the refolding of partially denatured proteins (236). In humans, the sHsp family comprises 
10 members, among which αB-crystallin, Hsp27, Hsp20, HspB2/B3 and HspB8, all 
containing a highly conserved C-terminal ‘α-crystallin‘ domain (238, 318-322, 362).  In 
normal brain, presence of αB-crystallin, Hsp27, Hsp20, HspB2/B3 and HspB8 has been 
observed (243, 244). αB-crystallin is present in oligodendroglia cells, astrocytes, microglia, 
and in degenerating neurons in neurological diseases (239, 243, 253, 324, 325). Hsp27, 
Hsp20, HspB8 and HspB2 were found in brain vessels and astrocytes (241, 243, 244). In 
AD, expression of both αB-crystallin and Hsp27 is increased, and colocalization of Hsp27 
with SPs has been observed (241, 243, 254). Recently, association of Hsp20, HspB2 and 
HspB8 with SPs in AD was described, as well as of Hsp20 with CAA (243, 244). 
Interestingly, HspB8 is absent in CAA in AD brain, whereas colocalization with CAA is 
observed in HCHWA-D brains (244). Furthermore, the capacity to affect Aβ aggregation 
and modulate Aβ-mediated cytotoxicity varies among the different sHsps and their 
efficiency is also directed by the particular Aβ sequence (245). 
These data suggest that the various members of the sHsp family might be 
differentially associated with apparently similar lesions, such as CAA and SPs, in 
HCHWA-D compared to AD brains. Therefore, we investigated the distribution of αB-
crystallin, Hsp20, Hsp27 and HspB2 in HCHWA-D brains. Since several sHsps colocalize 
with Aβ in CAA and SPs, and are expressed in astrocytes associated with these lesions, we 
also studied the possible relationship between Aβ and sHsp expression in cultured human 
brain pericytes and astrocytes. Finally, since both sHsps and Aβ accumulate in CAA and 
SPs, and these lesions are associated with inflammatory activity, we investigated the 
possible contribution of sHsps and Aβ to the induction of cytokines by cultured HBPs and 
astrocytes. 
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Materials and methods 
  
Autopsy material 
Tissue samples from the frontal cortex of 5 patients with HCHWA-D (age 55.2 ± 3.3 years; post 
mortem delay 3.4 ± 1.8 hours) was obtained. Table I provides an overview of the diagnosis, Braak 
& Braak score, CERAD score, age, post-mortem interval and gender of the patients used in this 
study. Diagnosis and grading of HCHWA-D patients was performed according to the Braak & 
Braak and CERAD criteria (326, 327).  
 
Immunohistochemistry 
In Table II the antibodies used in this study are listed. Serial cryo-sections (4 μm) were 
used to examine the presence of the various sHsps in HCHWA-D brains. Sections were 
fixed and treated as described in previous reports (243, 244). Presence of sHsps in 
astrocytes and microglial cells was investigated by comparing serial sections and by 
double-immunostaining for both sHsps and the astrocyte marker 6F2 or the microglial 
marker KiM1p, respectively, as described previously (243, 244). 
 
 
Table I. Overview of HCHWA-D patients included in this study. 
Patient 
number 
Grade 
(Braak) 
Grade 
(CERAD) 
Age PMI (hrs.) Gender 
1 I/II 0 55 1 F 
2 I/II 0 59 4 M 
3 - 0 51 3 M 
4 - 0 53 3 F 
5 - 0 58 6 M 
PMI = post mortem interval. Braak and CERAD scores were performed as described in the methods. 
Table II. Primary antibodies used in this study. 
Primary 
antibody 
Antigen Species  
raised in 
Dilution Source 
(reference) 
6C6 Aβ Mouse 1:1000 Elan Pharma. San Francisco, CA, USA 
40-4 Aβ Rabbit 1:2000 Dr.Van Nostrand, Stony Brook, NY, USA 
8763-250 Tau Rabbit 1:2000 Abcam Limited, Cambridge, UK 
AT8 Hyperphos. Tau Mouse 1:200 Innogenetics, Gent, Belgium 
RCB-Mab αB-crystallin Mouse 1:100 Riken Cell Bank, Tsukuba, Japan 
Pab-aBcr αB-crystallin Rabbit 1:500 Den Engelsman et al. (334) 
SPA-800 Hsp27 Mouse 1:2000 Stressgen, Victoria, Canada 
1426 Hsp27 Rabbit 1:2000 Abcam Limited, Cambridge, UK 
VDK-p20 Hsp20 Rabbit 1:4000 Van de Klundert et al. (344) 
20-11 Hsp20 Mouse 1:50 Adv.Immunochem., Long Beach, CA, USA 
SPA-812 Hsp70 Rabbit 1:2000 Stressgen, Victoria, Canada 
F34 HspB2 Rabbit 1:2000 Verschuure et al. (328) 
6F2 GFAP Mouse 1:20 Sanbio, Uden, The Netherlands 
KiM1p Microglia Mouse 1:5000 Kindly provided by Dr. M.R.  
Parwaresch, University of Kiel, Germany 
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Materials 
Aβ1-40 peptide (96% pure, HPLC analysis) containing the Glu22Gln mutation (D-Aβ1-40), 
wild-type Aβ1-42 (95% pure, HPLC analysis) and wild-type Aβ1-40 (98% pure, HPLC 
analysis) were obtained from Biosource (Etten-leur, The Netherlands). Lyophilized 
peptides were dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) and dried overnight. Subsequently, peptides were 
dissolved in DMSO, at 5 mM and stored at –80oC. 
 
Expression and purification of recombinant proteins 
The coding regions of the various sHsps were cloned into the following vectors: pET8c 
(rat Hsp20), pET3a (human B2/B3 and human Hsp27), pET16 (human αB-crystallin, 
human HspB8). Since it was demonstrated that HspB2 and HspB3 form functional 
heterogeneous complexes of 150 kDa (323), both proteins were expressed together in one 
vector. The sHsps were expressed in the respective vectors in BL21 (DE3) competent cells 
(Invitrogen Corporation, Carlsbad, CA, USA). Recombinant sHsps were purified as 
described in previous publications (430,460). Purity of the preparation was estimated as 
follows: Hsp20: 80%, HspB2/B3: 75%, Hsp27: 90%, HspB8: 83% and αB-crystallin:  95%. 
 
Cell culture 
Human brain pericytes (HBP), human leptomeningeal smooth muscle cells (HLSMC) and 
human brain astrocytes were isolated and characterized as described previously (59, 24, 
103, 244). Cerebrovascular cells were maintained in Eagle’s minimal essential medium 
(EMEM) (Bio Whittaker Europe, Verviers, Belgium) supplemented with 10% human 
serum (Gemini BioProducts, Calabasas, CA, USA), 20% newborn calf serum (Life 
Technologies, Rockville, USA), 0.1% basic fibroblast growth factor and 2% 
penicillin/streptomycin at 37oC and 5% CO2. Astrocytes were maintained in 
DMEM/HAM-F10 (1:1) containing 10% (v/v) FCS, 2mM-glutamine, penicillin (100 
IU/ml), and streptomycin (50 μg/ml). Cell passages 3-15 were used for the experiments. 
Control cells incubated with EMEM or DMEM/HAM-F10 and 0.1% bovine serum 
albumin (BSA) (serum-free medium) demonstrated normal morphology.  
 
Western blotting 
Cultured HBPs and human astrocytes, incubated with or without 12.5 μM D-Aβ1-40 for 3 
days, were washed with PBS and solubilized with RIPA lysis buffer. Aliquots of the cell 
lysates were diluted with dithiothreitol (DTT)-containing sample buffer. Equal amounts of 
protein were loaded and fractionated on a 12% SDS-PAGE gel and transferred onto 
nitrocellulose membranes. Unoccupied sites on the membranes were blocked using 
Odyssey blocking buffer (according to the manufacturer’s description). Blots were 
incubated with primary anti-sHsps antibodies, dissolved in a 1:1 dilution of Odyssey 
blocking buffer and PBS, overnight at 4oC (Table II). After washing the blots with PBS 
containing 0.5% Tween20, they were incubated with secondary antibodies (Goat-Alexa 
Fluor 800-labelled anti-mouse or Alexa Fluor 680-labelled goat-anti-rabbit, both from LI-
COR Biosciences GmbH, Bad Homburg, Germany) for 1 hour at room temperature. Blots 
were rinsed twice with PBS containing 0.5% Tween20 and twice with PBS. Finally, 
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analysis was performed using the Odyssey infrared imaging system (LI-COR Biosciences 
GmbH).  
 
ELISA 
Cultured HBPs and astrocytes were incubated with 12.5 μM D-Aβ1-40, Aβ1-42 or Aβ1-40, or 
12.5 μM of sHsps (αB-crystallin, Hsp27, HspB2, Hsp20 and HspB8) for 3 days at 37oC in a 
24 well plate. Cytokine (IL-6, IL-1β and TNF-α) levels in cell culture supernatants were 
measured using commercial enzyme immunoassay kits according to the manufacturer’s 
instructions (PeliPairTM reagent set, Sanquin, Amsterdam, The Netherlands). To exclude 
possible effects of LPS, potentially present in the purified sHsp samples, aliquots of Hsp20, 
HspB2/B3 and HspB8 were heat-inactivated for 15 minutes at 100oC and used as controles. 
At least 4 independent experiments were performed and, after analysis, the data of all 4 
experiments were pooled. Induction of IL-6 production by IL-1β served as positive 
control. Induction of IL-6 production by Aβ or sHsps was expressed as percentage of the 
induction achieved by IL-1β. Statistical analysis was performed using Student’s t-test. The 
level of significance of the difference with control cells is indicated as follows: *p< 0.05; 
**p< 0.01; ***p< 0.001; p> 0.05 is not indicated. 
 
 
Results 
 
Distribution of sHsps in HCHWA-D brains 
In Aβ-unaffected vessels of HCHWA-D brains, immunoreactivity of anti-αB-crystallin, 
anti-Hsp27, anti-HspB2 and anti-Hsp20 antibodies was only observed in large 
leptomeningeal vessels (not shown). In normal middle-sized parenchymal vessels of 
HCHWA-D brains both αB-crystallin (Fig.1A) and Hsp27 (Fig.1B) immunostaining was 
absent, whereas only weak staining with both anti-HspB2 (Fig.1C) and anti-Hsp20 
(Fig.1D) antibodies was observed. Furthermore, αB-crystallin immunoreactivity was 
shown in oligodendroglia cells (Fig. 1A) and few reactive astrocytes in the white matter. 
Both anti-Hsp27 and anti-HspB2 antibody staining was observed in an occasional reactive 
astrocyte and microglia in the white matter (not shown). The anti-Hsp20 antibody stained 
reactive astrocytes of both white and grey matter in HCHWA-D brains (Fig. 1D).  
The anti-Aβ antibody (6C6) stained Aβ-affected vessels in HCHWA-D brains (Fig. 
1E-H). Both αB-crystallin (Fig. 1I) and Hsp27 (Fig. 1J) were absent from CAA. In contrast, 
both anti-HspB2 (Fig. 1K) and anti-Hsp20 (Fig. 1L) staining was observed in CAA. In 
addition, the anti-Aβ antibody (6C6) stained diffuse SPs in HCHWA-D brains (Fig. 2A-D). 
Anti-αB-crystallin (Fig. 2E), anti-Hsp27 (Fig. 2F), anti-HspB2 (Fig. 2G) and anti-Hsp20 
(Fig. 2H) immunoreactivity was absent from diffuse SPs in HCHWA-D brains. No 
immunoreactivity of anti-sHsps antibodies was observed in the sparsely present NFTs (not 
shown).  
Distribution in pathological lesions of αB-crystallin, Hsp20, Hsp27 and HspB2 in 
HCHWA-D brains, and of these sHsps together with HspB8 in AD (243, 244), is 
summarized in Table III. 
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Figure 1. Immunohistochemical staining of sHsps in unaffected vessels and CAA in neocortex of
HCHWA-D brains. Serial sections: E, I; F, J; G, K; H, L. Both Anti-αB-crystallin (A) and anti-Hsp27
(B) antibody staining was absent in control vessels, whereas weak immunoreactivity of both anti-
HspB2 (C) and anti-Hsp20 (D) was observed in middle-sized parenchymal vessels. The anti-αB-
crystallin antibody stained oligodendroglial cells (A, arrow). Reactive astrocytes in brain parenchyma
were stained by the anti-Hsp20 (D, arrow) antibody. The anti-Aβ (mAb 6C6) antibody stained Aβ-
affected vessels in HCHWA-D brains (E-H). Both αB-crystallin (I) and Hsp27 (J) immunoreactivity
was absent from CAA, whereas anti-HspB2 (K) and anti-Hsp20 (L) antibody staining was observed in
Aβ-affected vessels in HCHWA-D brains. Original magnification A-H ×250. 
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Expression of sHsps in cultured HBPs and astrocytes 
To investigate the potential increase of the cellular source of the sHsps observed in CAA 
and SPs, Aβ-mediated production of sHsps was studied in cultured brain pericytes and 
astrocytes using Western blotting. Both cultured HBPs and astrocytes expressed αB-
crystallin, Hsp20, HspB2, Hsp27, HspB8 and Hsp70 (Fig. 3). However, incubation of both 
HBPs and astrocytes with 12.5 μM D-Aβ1-40 for 3 days at 37oC, had no effect on sHsps 
production, although this incubation resulted in slightly increased levels of Hsp70 in both 
HBPs (increase by a factor 1.7) and astrocytes (increase by a factor 4.3), serving as a 
positive control for D-Aβ1-40-induced cell stress (Fig. 3).  
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Figure 2. Immunohistochemical staining of sHsps in SPs in neocortex of HCHWA-D brains.
Corresponding serial sections: A, E; B, F; C, G; D, H. The anti-Aβ (mAb 6C6) antibody stained diffuse SPs
in HCHWA-D brains (A-D). Staining by anti-αB-crystallin (E), anti-Hsp27 (F), anti-HspB2, (G) and anti-
Hsp20 (H) antibodies was absent from diffuse SPs in HCHWA-D brains. Original magnification A-H ×250.
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SHsps induce IL-6 production by cultured cerebrovascular cell and astrocytes 
Both Aβ and sHsps accumulate in pathological lesions such as CAA and SPs. We studied if 
Aβ or sHsps were able to induce the production of cytokines by either cultured human 
brain pericytes or cultured astrocytes. Neither Aβ1-40, Aβ1-42 nor D-Aβ1-40 (12.5 μM) 
induced a significant increase in IL-6 production, in both HBPs and astrocytes, compared 
to control cells (Fig. 4A, B). In addition, incubation of 12.5 μM αB-crystallin or Hsp27 also 
did not induce IL-6 levels above control levels in both HBPs and astrocytes. In contrast, 
incubation of both primary cell types with 12.5 μM Hsp20, HspB2/B3 or HspB8, resulted 
in a significant induction of IL-6 secretion (Fig. 4A, B). In both cell types, incubation of 
12.5 μM Hsp20 resulted in the highest induction of IL-6 secretion. Incubation of HBPs 
with 12.5 μM heat-inactivated Hsp20, HspB2/B3 and HspB8, did not affect IL-6 secretion 
(Fig. 4A). Co-incubation of any of the sHsps with the various species of Aβ did not result 
in a synergistic effect on IL-6 induction (not shown). In cultures of both HBPs and 
astrocytes incubated with Aβ1-40, Aβ1-42 and D-Aβ1-40 or with the sHsps, the concentrations 
of IL-1β and TNF-α remained below the detection level (not shown). 
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Figure 3. Western blot analysis of sHsps expression in both HBPs and astrocytes. Cultured HBPs and
astrocytes were incubated with or without 12.5 μM D-Aβ1-40 for 3 days at 37oC. 12.5 μM D-Aβ1-40 did not
affect production of αB-crystallin, Hsp20, HspB2, Hsp27 and HspB8, by both HBPs and astrocytes.
Increased levels of Hsp70 were observed in both HBPs and astrocytes after incubation with 12.5 μM D-
Aβ1-40 for 3 days.  
 
Table III. Distribution of sHsps in CAA and SPs in AD and HCHWA-D brains. 
 
 CAA Diffuse SPs NFTs 
 AD (243) HCHWA-D AD (243) HCHWA-D  
αB-crystallin - - - - - 
Hsp27 - - +* - - 
Hsp20 - + + - - 
HspB2 + + - - - 
HspB8 (244) - + - - - 
 
Chapter 6
  94
 
Discussion 
In this report, we demonstrate that both Hsp20 and HspB2 are associated with CAA in 
HCHWA-D brains, and that Hsp20, HspB2 and HspB8, which all colocalize with Aβ in 
SPs and CAA in AD (243, 244), induce IL-6 production in both HBPs and astrocytes. 
The small heat proteins are molecular chaperones, specialized in the prevention of 
proteins to adopt an incorrect formation (236). Both SPs and CAA predominantly consist 
of the incorrectly folded protein Aβ. sHsps such as Hsp20, Hsp27, HspB2 and HspB8 are 
associated with these lesions in both AD and HCHWA-D brains, although the sHsps seem 
to have a specific pattern of association. In general, sHsps seem to be preferentially 
associated with fibrillar forms of Aβ (243, 244). Here, we observed association of Hsp20 
and HspB2 with fibrillar Aβ in CAA in HCHWA-D, whereas colocalization with soluble 
forms of Aβ in diffuse SPs was absent. Thus, although sHsps bind monomeric Aβ in vitro 
(245), in vivo sHsps seem to be predominantly associated with fibrillar Aβ.  
sHsps are highly homologous and form mixed complexes with each other and with folding 
intermediates of their protein substrates in vivo (318). Yet, we found specific association 
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Figure 4. IL-6 production by HBPs and human astrocytes.  
Cultured HBPs (A) and astrocytes (B) were incubated with 12.5 μM of Aβ1-40, Aβ1-42, D-Aβ1-40, αB-
crystallin, Hsp27, Hsp20, HspB2/B3, HspB8, or heat-inactivated (HI) Hsp20, HspB2/B3 or HspB8 for 3
days at 37oC. Supernatant was collected and IL-6 concentrations were measured using ELISA. IL-1 β-
induced IL-6 production was set at 100%. Statistical analysis was performed using a Student’s t-test. The
level of significance of the difference with control cells is indicated as follows: *p< 0.05; **p< 0.01; ***p<
0.001; p> 0.05 is not indicated. Mean ± S.E.M. are shown. 
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of some members of the sHsp family with pathological lesions in HCHWA-D and AD 
brains. Interestingly, only sHsps with relatively poor chaperone functions, such as Hsp20, 
HspB2 and HspB8 (318, 344), colocalized with Aβ in CAA and SPs in HCHWA-D and AD 
brains. In contrast, αB-crystallin and Hsp27, both efficient chaperones, were not found in 
these extracellular Aβ accumulations. This might suggest that, given their poor chaperone 
function, Hsp20, HspB2 and HspB8, in contrast to αB-crystallin and Hsp27, interact with 
Aβ aggregates in vivo, but are unable to ‘escape’ from these aggregates after their function 
has been completed. In addition, both Hsp20 and HspB8 are associated with CAA in 
HCHWA-D brains, but not with CAA in AD brains. The 22GluGln mutation within the 
Aβ1-40 peptide causes a higher propensity to aggregate, compared to wild-type Aβ (338). 
Thus, the reason why both Hsp20 and HspB8 remain entrapped in D-Aβ1-40 aggregates 
may be either because they have a less efficient chaperone function towards the D-Aβ1-40 
protein compared to wild-type Aβ or because the D-Aβ1-40 protein aggregates faster than 
wild-type Aβ.  
Interaction of sHsps with Aβ may depend on subtle differences within the “α-
crystallin” region or in other domains. The natural missense mutation R120G, for 
instance, decreases the chaperone function of αB-crystallin and is located within the α-
crystallin region (353). In contrast, a mutation at amino acid 141 in the C-terminal 
domain of HspB8 also results in reduced chaperone activity (354). However, in interaction 
of sHsps with Aβ, the type of Aβ (Aβ1-40 or Aβ1-42) or mutations in the Aβ peptide might be 
of similar importance for the sHsp/Aβ interaction. The N-terminal part of the Aβ peptide 
or the residues around position 22 within Aβ might both direct the specific interaction 
with sHsps. αB-crystallin, Hsp20 and Hsp27 all demonstrate higher binding affinity for 
Aβ1-42, compared to D-Aβ1-40, whereas HspB8 binds D-Aβ1-40 with a higher affinity than 
Aβ1-42 (244, 245). In addition, in vitro binding of HspB2 to Aβ is absent (245). Thus, 
although sHsps are highly homologous by sharing the “α-crystallin region” (352), their 
interaction with the various Aβ peptides varies, and thus might be the cause of a specific 
distribution pattern.  
 We observed presence of sHsps in reactive astrocytes associated with the 
pathological lesions of AD and HCHWA-D (243, 244). On the other hand, sHsp 
accumulation in CAA may suggest a vascular source of sHsps. However, Aβ-mediated 
induction of sHsps in cultured HBPs and astrocytes was not observed. Possibly, the sHsps 
found in CAA and SPs are not locally produced by cells exposed to Aβ. Thus, sHsps 
observed in AD lesions might originate from other cell types that secrete these sHsps (329, 
331, 355) or from astrocytes and cerebrovascular cells, but, then, not by induction by Aβ. 
Yet, both the source of sHsps and how they affect the bioactivity of Aβ in brain remains 
unclear. 
Cytokines such as IL-1β, IL-6 and TNF-α, are all upregulated in AD (305). This 
upregulation is associated with microglial activation, astrogliosis and enhanced secretion 
of other proinflammatory molecules and Aβ (371). Furthermore, studies in transgenic 
animals suggest that Aβ accumulation at the vessel wall is enhanced by inflammation 
(372, 373). Given the direct link between Aβ accumulation in the brain of AD patients 
and inflammation, it is suggested that this Aβ accumulation triggers inflammation (374). 
In AD, a strong inflammatory reaction is associated with SPs, whereas in CAA only 
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activation of the complement system occurs (149). In contrast, activated microglia and 
astrocytes are associated with CAA, but not with SPs in HCHWA-D (26, 375). We 
observed that only those sHsps that occur extracellularly and are associated with Aβ in 
SPs and CAA in AD and HCHWA-D, such as Hsp20, HspB2/B3 and HspB8, induce a 
much more pronounced IL-6 production in cultured HBPs and astrocytes, than Aβ itself 
(Table 3) (243, 244). These data suggest that sHsps, rather than Aβ itself, do not only 
demonstrate specific interactions with Aβ, but may be among the key mediators of the 
inflammatory reaction in AD and HCHWA-D brains. However, Hsp20, HpB2/B3 and 
HspB8 only induced IL-6 secretion. Thus the production of IL-1β and TNF-α, also 
upregulated in AD, might be triggered by alternative mechanisms.  
The biological activity of the various sHsps might be receptor-dependent. Since 
Hsps, such as Hsp70 and Hsp90, are suggested to interact with the Toll-like receptor 4 
(TLR4) and induce nuclear factor-κB and p38mitogen-activated protein kinase via 
activation of the receptor in rat microglia (308). Recently, HspB8 demonstrated to activate 
dendritic cells and induce cytokine secretion, such as IL-6, via the TLR4 (376). Thus, Toll-
like receptors, such as the TLR4, might act as receptors for several members of the sHsp 
family on human brain cells and astrocytes, and upon ligand binding induce the secretion 
of cytokines, although the exact mechanism is not yet known.     
 In conclusion, Hsp20 and HspB2 are associated with CAA in HCHWA-D brains, 
although they are absent in CAA in AD brains. We suggest that mutations within the Aβ 
peptide, such as the Dutch mutation in Aβ, does not only influence Aβ toxicity, but also 
affects binding of Aβ with other proteins, such as the sHsps and heparan sulphate 
proteoglycans (209). In addition, our study suggests that sHsps in SPs and CAA may be 
key mediators of the inflammatory reactions associated with these lesions. Thus, sHsps 
that are observed in the pathological lesions of AD and HCHWA-D might not only play a 
role in the accumulation and deposition of Aβ, but also stimulates the pathology by 
actively contributing to the inflammation process in both AD and HCHWA-D.    
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Abstract 
 
The ε4 allele of ApoE is a risk factor for Alzheimer's disease, whereas the ε2 allele may be 
relatively protective. Both alleles are risk factors for cerebral amyloid angiopathy (CAA)-
related hemorrhages. CAA is associated with degeneration of smooth muscle cells and 
pericytes. Previously, we described that synthetic amyloid-β1-40 peptide (Aβ1-40) with the 
22Glu→Gln ‘Dutch’ mutation caused pericyte death in vitro by a mechanism that involves 
Aβ fibril-like assembly at the cell surface. It is known that ApoE binds to Aβ and may 
modify its biological activities. In the present study we evaluated the effect of ApoE on 
Aβ-mediated toxicity of cerebrovascular cells. We observed that cultured cells with an 
ε4/ε4 genotype were more vulnerable to Aβ than cultures with an ε3/ε3 or ε3/ε4 
genotype. The one cell culture with the ε2/ε3 genotype was relatively resistant to Aβ in 
comparison to other cultures. Furthermore, we observed a dose-dependent protective 
effect of native ApoE against Aβ-mediated toxicity of cerebrovascular cells and, in 
addition, ApoE ε2/ε3 cells secreted more ApoE protein compared to cells with other ApoE 
genotypes, in particular in comparison with ε4/ε4 cells. Thus, the disparity between ApoE 
genotype and Aβ-mediated toxicity might be related to differences in the cellular capacity 
to secrete ApoE. The present data suggest that one mechanism by which ApoE may alter 
the risk for AD is a genotype-dependent regulation of Aβ cytotoxicity, possibly via 
variations in its secretion levels whereby extracellular ApoE may bind to Aβ and thereby 
modify Aβ-mediated cell death. 
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Introduction 
 
Senile plaques (SPs) and cerebral amyloid angiopathy (CAA) are two of the 
neuropathological hallmarks of Alzheimer's disease (AD). The amyloid-β protein (Aβ), 
which consists of 40-42 amino acids, is the major constituent of both SPs and CAA. 
Apolipoprotein E (ApoE) has been identified as a major risk factor for the sporadic late-
onset form of AD. The ApoE gene has three alleles, ε2, ε3 and ε4, the most frequent of 
which is the ε3 allele. Inheritance of one or two copies of the ε4 allele is associated with a 
dose-dependent increased risk for AD, and an earlier age of onset of AD (42, 43), although 
even individuals homozygous for ε4 may reach high age without cognitive impairment 
(44). On the contrary, the ε2 allele seems to have a protective effect against AD (45). 
Surprisingly however, both the ε2 and the ε4 allele are associated with an increased risk 
for CAA or CAA-related hemorrhages (46-48, 377). 
 Inheritance of one or two copies of the ApoE ε4 allele is associated with a higher 
load of SPs and CAA (47, 50). In vitro studies have shown that ApoE is able to bind to Aβ 
(51, 378): native ApoE3 binds Aβ more efficiently than ApoE4 (53). ApoE may also 
accelerate the formation of Aβ fibrils (51, 54, 55). In mice transgenic for human amyloid 
precursor protein (APP) and deficient in ApoE, the amount of amyloid, but not that of Aβ 
immunoreactivity, was strongly reduced in comparison with transgenic APP/ApoE+/+ mice 
(379), suggesting that ApoE plays a critical role in facilitating Aβ deposition. In contrast to 
these studies, early Aβ deposition is suppressed in mice transgenic for both APP and 
human ApoE on an ApoE knock-out background (380). These results show that the role of 
ApoE and its specific isoforms in Aβ fibrillogenesis, deposition, or clearance still remains 
unclear. 
 Previously, we described the toxicity of various Aβ peptides towards cultures of 
human brain cerebrovascular smooth muscle cells (SMCs) and pericytes (HBPs) (381-383). 
We demonstrated that non-aggregated wild-type Aβ1-42 and Aβ1-40 carrying the Glu→Gln 
mutation at position 22 of Aβ, as in hereditary cerebral hemorrhage with amyloidosis - 
Dutch type (HCHWA-D), caused degeneration of cultured SMCs and HBPs. Either cell 
type secreted significant amounts of ApoE (384). Given the well-described interactions 
between ApoE and Aβ, we investigated if endogenously produced ApoE could interfere in 
an isoform-dependent manner with the Aβ-mediated cytotoxicity towards cultured 
human cerebrovascular cells. Therefore, in this study we performed a comparative 
analysis of the cytotoxic effect of Aβ on cultures of HBPs and SMCs with different ApoE 
genotypes.  
 
Materials and Methods 
 
Reagents  
Aβ with the “Dutch” mutation (22 Glu→Gln, D-Aβ1-40, 89% pure) was purchased from 
Biosource (Etten-Leur, The Netherlands). Human recombinant ApoE produced in 
baculovirus in Sf insect cells was obtained from PanVera (Madison, WI). ApoE obtained 
from the conditioned medium of transfected human embryonic kidney 293 cells was 
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generously provided by dr. G.W. Rebeck (Georgetown University). Affinity-purified 
polyclonal anti-Aβ antibodies were prepared as described (385). Monoclonal anti-ApoE 
antibody was purchased from Innogenetics (Antwerpen, Belgium). Anti-LDL receptor 
related protein (LRP) (β-chain) antibody was obtained from American Diagnostica Inc. 
(Stamford, CT). Anti-Aβ antibody used for CAA grading was purchased from Dako 
(Glostrup, Denmark). 
 
Cells 
Pericytes were isolated from human brain tissue and smooth muscle cells (SMCs) from 
leptomeningeal vessels from a number of AD patients and neurologically unaffected 
individuals, obtained after autopsy as described previously (386-388) (Table 1). Diagnosis 
and grading of AD patients was performed according to the criteria established by Braak & 
Braak (389) and CERAD (390) (391). CAA grading was established by quantification of the 
number of Aβ-positive vessels in one microscopic field (magnification 2.5x). At least 4 
microscopic fields of both the occipital cortex and the gyrus temporalis medius were 
analyzed and categorized as follows: 0 (-, no CAA), 0-10 (+, sparse CAA), 10-20 (++, 
moderate CAA) and >20 (+++, severe CAA).   
Both human brain pericytes (HBPs) and SMCs were maintained in Eagle's modification of 
essential medium (EMEM), supplemented with 10% human serum (Sanquin Blood Bank, 
Nijmegen, The Netherlands), 20% newborn calf serum (Gibco, Paisley, Scotland), 
recombinant basic fibroblast growth factor (1 ng/ml), heparin (5 U/ml, Organon, Boxtel, 
The Netherlands) and antibiotics. Immuno-electron microscopical detection of Aβ 
accumulating at the surface of cultured cells was performed as described (392, 393). With 
respect to the various types of experiments, we did not observe differences between 
cerebrovascular cell cultures with the same ApoE genotype, but derived from different 
types of patients (i.e. AD or control patients). 
 
Degeneration experiments 
Triplicate wells with cultured cells were preincubated with serum-free medium (EMEM 
with 0.1 % BSA and antibiotics) for 4 hours. Subsequently, cells were incubated with 
fresh serum-free medium, supplemented with synthetic Aβ peptides at 25 μM, for 6 days. 
Cells were routinely inspected and photographed using an Olympus phase-contrast 
microscope. Cell viability was quantitated using a fluorescence live/dead cell assay 
according to the manufacturer's description (Molecular Probes, Leiden, The Netherlands). 
The cultures were examined using an Olympus fluorescence microscope and the 
percentage of dead cells was determined from countings in at least five microscopic fields 
per well. Based on previous studies (382, 383) D-Aβ1-40 was used, since this peptide 
induced a robust degeneration of both pericytes and SMCs. 
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Western blotting analysis  
Cells were grown in serum-free medium and both culture supernatant and cell lysates 
were collected to examine secreted and cell-associated expression of proteins, respectively. 
Culture supernatant was diluted 1:1 with reducing sample buffer. Cells were washed twice 
with phosphate-buffered saline (PBS) and then solubilized in the wells with lysis buffer 
(50 mM Tris-HCl, 150 mM NaCl, pH 7.5, 1% sodium dodecyl sulfate (SDS), 5 mM EDTA, 
500 μM 4-(2-aminoethyl)benzenesulfonyl fluoride, 10 μg/ml leupeptine and 10 μg/ml 
chymostatin) for 15 minutes. The protein content of diluted samples of the cell lysates was 
determined using the bichinchonic acid method (Pierce, Rockford, IL). Equal protein 
amounts were loaded, fractionated on SDS-polyacrylamide gels and subsequently 
electrophoretically transferred to nitrocellulose membranes (Schleicher & Schuell, 's-
Hertogenbosch, The Netherlands) in blotting buffer (25 mM Tris-HCl (pH 8.6), 192 mM 
glycine, 20% methanol). Blots were washed for 15 minutes in PBS containing 0.05% 
Tween-20 (PBST), preincubated with blocking solution (5% low fat milk powder in 
PBST), washed three times with PBST and subsequently incubated with primary 
antibodies and peroxidase-labeled secondary rabbit anti-mouse antibodies (Dako, 
Table 1. Overview of the source of HBP and SMC cell cultures. 
Nr Diagnosis Grade 
(Braak) 
Grade 
(CERAD) 
CAA 
grade 
Cell 
type 
PMI 
(hrs.) 
ApoE Age Gender Cause of 
death 
Vascular risk 
factors 
1 Control II ++ - HBP/
SMC 
5 2 / 3 84 F Cardiac 
failure 
Atherosclerosis 
2 AD VI +++ - HBP 4 3 / 3 94 F Respiratory 
insufficiency 
Atherosclerosis 
3 AD VI +++ +++ HBP 4 3 / 3 81 F Cardiac 
failure 
None 
4 AD VI +++ +++ HBP/
SMC 
3 3 / 3 75 M Pneumonia Atherosclerosis 
5 Control 0 0 - HBP/
SMC 
4 3 / 3 84 F Pneumonia Atherosclerosis 
6 Control 0 0 - SMC 6 3 / 3 71 F Ruptured 
aortic 
aneurysm 
Atherosclerosis 
7 AD V +++ + SMC 6 3 / 3 87 F Bronchopne
umonia 
Atherosclerosis 
8 AD / PD V +++ +++ SMC 4 3 / 4 91 F Pneumonia Atherosclerosis 
9 AD V +++ - HBP 5 3 / 4 84 M Cardiac 
failure 
Atherosclerosis 
10 Control III ++ - HBP/
SMC 
4 3 / 4 83 F Ruptured 
aortic 
aneurysm 
Atherosclerosis 
11 AD VI +++ ++ HBP/
SMC 
3 3 / 4 89 F Pneumonia Atherosclerosis 
12 AD VI ++ +++ HBP 5 4 / 4 83 F Sepsis Atherosclerosis 
13 AD VI +++ +++ HBP/
SMC 
3 4 / 4 69 M Unknown Atherosclerosis 
Abbreviations: AD: Alzheimer's disease; PD: Parkinson's Disease; HBP: human brain pericytes; SMC: smooth muscle cells; 
PMI: post mortem interval in hours; CAA: cerebral amyloid angiopathy. Grading of AD (Braak and CERAD scores) and of 
CAA was performed as described in the materials and methods. 
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Glostrup, Denmark). Detection was performed by chemoluminescence according to the 
manufacturer's description (Boehringer Mannheim, Almere, The Netherlands) and 
exposure to Kodak X-OMAT-R films. 
 
ApoE genotyping  
DNA was isolated from small pieces of brain tissue from which also cell cultures were 
derived, using a DNA isolation kit (Biozym, Landgraaf, The Netherlands). ApoE genotype 
was determined using PCR and HhaI restriction analysis according to previously described 
methods (394, 395). 
 
ApoE quantification 
ApoE secretion by cultured HBPs and SMCs was quantitated both by scanning of Western 
blots and by ELISA. The chemoluminescent signal of both ApoE standards (PanVera), cell 
lysates and culture supernatants obtained after Western blotting were scanned with a 
LabScan (Amersham Pharmacia, Aylesbury, UK). For ELISA, 5 μg/ml of affinity-purified 
goat anti-ApoE (Biodesign International) were coated overnight at 4 C on a 96-well plate. 
Subsequently, wells were incubated with 1 % non-fat milk in PBST to block aspecific 
binding, with ApoE standards (PanVera or from transfected 293 cells) or (diluted) culture 
supernatants, with affinity-purified biotinylated goat anti-ApoE (Biodesign International) 
and finally with peroxidase-labeled avidin (Dako). Tetramethylbenzidin was used as 
substrate and H2SO4 to terminate the peroxidase reaction. No significant differences were 
observed with either type of standards, the use of ApoE3 as a standard only resulted in 
slightly higher signals than with ApoE4. 
 
Partial purification of ApoE from culture supernatant  
Purification of extracellular ApoE protein from medium of cultured HBP was performed 
as described by DeMattos et al (396) with minor modifications. Cells were incubated with 
serum-free EMEM medium for 6 days. Cells remained viable during this period. 
Supernatant was collected and passed through a D100 weakly basic anion exchange filter 
(Sartorius, Goettingen, Germany), and eluted with 1 M ammonium bicarbonate. The 
eluted ApoE was recirculated over a HiTrap heparin column (Amersham Pharmacia). 
Fractions containing ApoE were pooled and dialyzed against PBS. Using the above-
described ApoE sandwich ELISA and comparing the ApoE concentration with the total 
protein amount, it was demonstrated that in the purified fractions 25% of the total protein 
amount consisted of ApoE. 
 
RNA isolation and Northern blotting 
 Total RNA (8 μg) was isolated from cultured cells by using the RNeasy kit (Qiagen, 
Hilden, Germany) according to the manufacturer's protocol. Total RNA was treated with 
formaldehyde (397), separated on a 1.5 % agarose gel and blotted onto a Hybond N+ 
membrane (Amersham Pharmacia). An 1100 base pair fragment containing human ApoE3 
cDNA (a kind gift of Dr. G.W. Rebeck) was released from a pCMV4 expression vector by 
XbaI and KpnI restriction cleavage. ApoE cDNA probe was radiolabeled by [32dCTP] 
incorporation using a random-primed DNA labeling kit (Roche Diagnostics, Penzberg, 
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Germany). After pre-incubation in a hybridization mix (0.25 M sodium phosphate buffer 
pH 7.2, 7% SDS, 1% BSA, 1 mM EDTA, 0.1 mg/ml single strand salmon sperm DNA) at 65 
°C, membranes were hybridized overnight with the radiolabeled probes under the same 
conditions. Afterwards, blots were washed at 58 °C with 0.25 M sodium phosphate buffer 
pH 7.2, 1% SDS and 1 mM EDTA and autoradiographed using Kodak Xomat-S films. 
 
Results 
 
HBPs and SMCs were isolated from ten and nine donor brains, respectively. The 
characterization of HBPs and SMCs has been extensively described in previous reports 
(386, 388). The cultured cells were divided into four different groups according to their 
ApoE genotype: ε2/ε3, ε3/ε3, ε3/ε4 and ε4/ε4 (Table 1). 
After 4-6 days of treatment with 25 μM D-Aβ1-40 cultured cells (HBPs or SMCs) lost 
their characteristic polygonal shape, individual cell contours became less evident and 
signs of cellular atrophy were observed (not shown). Since ApoE is co-deposited with 
amyloid in the vessel walls in CAA, we determined if ApoE production by perivascular 
cells was affected by D-Aβ1-40 treatment as well. In the absence of Aβ treatment, both 
cultured SMCs and HBPs secreted considerable amounts of ApoE into the culture medium 
as shown by Western blot analysis (Figure 1).  In contrast, smaller amounts of ApoE were 
associated with the cells. On the other hand, incubation with D-Aβ1-40 resulted in an 
inversion of ApoE distribution with most of the ApoE remaining associated with the cells. 
This was confirmed by double-immunofluorescence staining of D-Aβ1-40-treated cells, 
showing that both Aβ and ApoE were co-associated on the cell surface (not shown).  
 
These experiments suggested that an interaction occurred between the endogenously 
produced ApoE and the exogenously administered Aβ that accumulated on the cell surface 
(Figure 2).  
 
 
Figure 1. Western blotting analysis of cell-associated (“Cells”) and secreted ApoE (“Medium”) in cultured
human brain pericytes treated for 6 days with 25 μM D-Aβ1-40. In untreated cultures (indicated with “C”),
most ApoE (molecular weight approximately 37 kd) was present in the supernatant, whereas in D-Aβ1-40
treated cells (indicated with “D”) ApoE was predominantly associated with the cellular fraction. 
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Therefore, we investigated if the ApoE genotype of the cultured cells affected the 
toxicity of D-Aβ1-40. The results showed that there were striking differences in the 
response to D-Aβ1-40 between cell cultures with a different ApoE genotype. After 
treatment of HBP cultures with the ε4/ε4 genotype with D-Aβ1-40 for 6 days, the number 
of viable cells was strongly reduced (Figure 3).  
In contrast, cells with either the ε3/ε3 or ε3/ε4 genotype were consistently less susceptible 
to D-Aβ1-40 treatment. In addition, although only a single ε2/ε3 HBP culture was available, 
we consistently observed (n=9 experiments) that cell death was much lower (mean 12 ± 
10% dead cells). In addition, similar results were obtained with SMC cultures of various 
ApoE genotypes (not shown). Both HBPs and SMCs expressed the ApoE-receptor LRP. 
The effects described above, however, could not be explained by differences in LRP 
expression of the cells, which was similar in the cell cultures with different ApoE 
genotype (not shown). Furthermore, the effects could also not be explained by differences 
in the clinico-pathological state of the donors (Braak or CERAD grade of AD, CAA grade; 
see Table 1). 
 
Figure 2. Immuno electron microscopy analysis of HBP for localization of Aβ after 3 days of incubation
with D-Aβ1-40 (25μM), showing decoration of Aβ fibrils extending from the cell surface. Magnification: x
6000. 
 
Figure 3. Comparison of the effect of treatment with 25 μM D-Aβ1-40 for 6 days of human brain pericyte
cultures with different ApoE genotype. Cultured HBPs with the ApoE ε4/ε4 genotype demonstrated
more cell death than HBP cultures with the ApoE ε3/ε4 or ε3/ε3 genotype. Significance of the observed
differences (ANOVA with Tukey’s post-hoc test for multiple comparisons): ε4/ε4 vs ε3/ε4 or ε3/ε3:
p<0.001; ε3/ε3 vs. ε3/ε4: p<0.05. 
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 These data suggested that ApoE protein modulated the association of Aβ with the cell 
surface and subsequent cellular degeneration. We therefore investigated if simultaneous 
incubation of cells with D-Aβ1-40 and ApoE would lead to an ApoE isoform-dependent 
effect on HBP death. Addition of either ApoE3 or ApoE4 (up to 1.6 μg/ml), obtained from 
supernatants of transfected HEK293 cells, resulted in a slight, but non-significant, 
decrease of D-Aβ1-40-induced cell death (Figure 4A).  
Addition of any of the three ApoE isoforms (between 1.5 and 12 μg), produced by 
baculovirus in Sf insect cells, yielded a small, but significant, decrease in cell death of 
cultured HBPs (Figure 4B). Remarkably, when HBP cultures were co-incubated with D-
Aβ1-40 and conditioned supernatant of either ε2/ε3 or ε4/ε4 HBP cultures, a dramatic 
decrease in cell death was observed (Figure 4C).  
Figure 4. Effect of the presence of ApoE obtained from transfected HEK293 cells (A, 1.65 μg ApoE3/4)
or produced by baculovirus in Sf insect cells (B, 1.5 μg ApoE2/3/4) on the number of dead cells in
cultures of human brain pericytes treated with 25 μM D-Aβ1-40. Addition of HEK293 ApoE3/4 did not
affect the number of dead cells induced by exposure to D-Aβ1-40 (A). Addition of any of the ApoE
isoforms, produced by Sf insect cells moderately, but significantly, decreased D-Aβ1-40 – induced cell
death (B). C: Incubation with conditioned medium, obtained from either ε2/ε3 or ε4/ε4 cells (indicated
in the figure inset), significantly decreased the number of dead cells, both in HBP cultures with an ε2/ε3
or ε4/ε4 genotype (indicated on x-axis). Level of significance: *: p<0.05; **: p<0.01; ***: p<0.001; n.s.: not
significant
 
Fig. 5. Addition of ApoE, semi-purified from supernatants of cultured HBPs, reduced D-Aβ1-40 (12.5 μM)-
mediated HBP cell death in a concentration-dependent way. 
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This effect was stronger when culture supernatant was used from ε2/ε3 cells compared to 
that from ε4/ε4 cells. Addition of ApoE, semi-purified from conditioned HBP culture 
supernatants (up to 20 μl, containing 0.25 μg ApoE), resulted in a dose-dependent decrease 
of cellular toxicity (Figure 5).  
We then studied if the differential response of HBPs with different ApoE genotype 
could be explained by differences in the ApoE production capacity of the cells. ApoE 
production by cells with the ε4/ε4, ε3/ε4 or ε3/ε3 genotype was not significantly different 
(p=0.55, ANOVA), although we observed a trend towards lowest production by HBP ε4/ε4 
cultures (Figure 6). In two out of three experiments HBP ε4/ε4 cultures produced the 
smallest amounts of ApoE of all cultures. Interestingly, although based on only one HBP 
culture, cells with the ApoE ε2/ε3 genotype produced a mean 5.0 ± 3.1 ng ApoE/g 
protein/day (n=3 experiments) which is a factor 3- to 12-fold higher than the other cell 
cultures (p=0.02 vs. ApoE ε3/ε3; p=0.21 vs. ApoE ε3/ε4; p=0.01 vs. ApoE ε4/ε4). Similar 
results were obtained with SMC cultures of varying genotype, with the exception of one 
SMC ε3/ε3 culture that consistently secreted high ApoE levels comparable to that of the 
ε2/ε3 cell cultures. In the SMC cultures cells with the ApoE ε2/ε3 genotype produced a 
mean 13.9 ± 5.4 ng ApoE/μg protein/day (n=3 experiments) which is a factor 4-12 higher 
than the other cell cultures (p=0.01 vs. ApoE ε3/ε3; p<0.0001 vs. ApoE ε3/ε4; p=0.02 vs. 
ApoE ε4/ε4; data not shown). Effects on ApoE production by the cultured cells were not 
correlated to differences in the clinico-pathological state of the donors (Braak or CERAD 
grade of AD, CAA grade; see Table 1). 
 
Finally, ApoE mRNA levels in both HBP and SMC cultures were analysed using 
Northern blotting. Although we did not observe a perfect match between protein 
secretion and mRNA levels, this analysis showed that the cells with the ε2/ε3 genotype 
contained the highest whereas the cells with the ε4/ε4 genotype the lowest levels of ApoE 
mRNA, respectively (Figure 7). There was some heterogeneity in the mRNA levels in the 
ε3/ε3 and ε3/ε4 cells. The same SMC culture with the ε3/ε3 genotype that secreted large 
amounts of ApoE protein, also contained a high level of ApoE mRNA, comparable to that 
in the ε2/ε3 cell culture. 
 
Fig. 6. Quantification of ApoE secretion by cultured HBPs with the ApoE ε3/ε3, ε3/ε4 and ε4/ε4
genotype by ELISA. ApoE production by cells with the ε4/ε4, ε3/ε4 or ε3/ε3 genotype was not
significantly different (p=0.55, ANOVA), although we observed a trend towards lowest production by
HBP ε4/ε4 cultures. 
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Discussion 
Since the initial reports of the association of the ApoE ε4 genotype with the development 
of AD, many research groups have tried to identify a biological explanation for this 
epidemiological observation. ApoE binds to Aβ and affects its fibrillogenesis, possibly in 
an isoform-specific manner (53, 55, 398). In other studies, isoform-specific neurotrophic 
or neurotoxic effects have been described for ApoE (399-401). In the present study we 
provide a novel explanation that may, in part, account for the association of ApoE with 
AD development. The major findings of this investigation are: 1) The degree of Aβ-
mediated toxicity of human cerebrovascular cells is dependent on the ApoE genotype of 
the cells. Cultured HBPs with an ApoE ε4/ε4 genotype were more vulnerable to Aβ-
mediated cytotoxicity than cells with other ApoE genotypes; 2) ApoE protein causes a 
direct, concentration-dependent inhibition of Aβ-mediated toxicity of human 
cerebrovascular cells; 3) The production level of ApoE protein may at least, in part, 
depend on the ApoE genotype.  
It has been suggested that in brain a balance exists between Aβ deposition and Aβ 
removal. Aβ removal from the brain may occur by several mechanisms. For example, 
ApoE may play a role in internalization and subsequent degradation of Aβ and in Aβ 
clearance via transport to the circulation.  Aβ may be internalized and degraded by 
smooth muscle cells (402) and by astrocytes (403), a process that is facilitated by ApoE, 
since astrocytes derived from ApoE-/- mice do not degrade Aβ deposits in the brain. 
Alternatively, Aβ may be cleared from the brain via transport across the blood-brain-
barrier. The LDL receptor-related protein-1 (LRP-1) binds free Aβ and possibly is the 
major receptor mediating Aβ internalization (404, 405) and its efflux from the brain to the 
circulation (406). LRP-1 most efficiently removes wild-type Aβ1-40 whereas Aβ peptides 
containing a higher percentage of β-sheet structures (such as wild-type Aβ42 and D-Aβ1-40) 
 
 
Fig. 7. Northern blot analysis of ApoE mRNA expression (upper panels) in cultured HBPs (A) and
SMCs (B). In the lower panels the levels of 28S and 18S RNA are shown as a control for RNA loading.
ApoE mRNA expression was variable, but cells with the ApoE ε4/ε4 genotype consistently contained
the smallest amounts of ApoE mRNA, whereas the (single) cultures with the ε2/ε3 genotype produced
the highest amounts of ApoE mRNA. 
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bind less efficiently leading to accumulation of Aβ in brain microvessels (407). ApoE, 
which is also a ligand for LRP-1, may facilitate the clearance of Aβ from the brain, since 
clearance was significantly reduced in ApoE-/- mice (408). Therefore, it is possible that at 
least part of the cerebral Aβ forms complexes with ApoE and that such complexes via 
ApoE-LRP-1 interactions may be either degraded by astrocytes or cleared from the brain 
by transport over the BBB. However, although the existence of such complexes in the 
brain has been demonstrated (409) their possible interaction with LRP-1 has not yet been 
studied.   
Thus, high cerebral concentrations of ApoE may inhibit deposition of Aβ in the 
form of SPs and CAA. Our in vitro data suggest that, at least at the vascular level, ApoE 
abrogates the pathological interaction of Aβ with vascular cells and retains Aβ in a 
conformation that does not result in its assembly at the cell surface possibly by a 
diminished interaction with LRP-1. These findings are in line with the observation that 
human ApoE, in an isoform-specific way, suppresses Aβ deposition both in young and 
aged APP-V717F transgenic mice (410, 411). Furthermore, human ApoE delays the shift 
in Aβ from soluble pools to insoluble pools in these animals, which is in agreement with 
our observations of decreased accumulation of Aβ at the cell surface in the presence of 
elevated ApoE concentrations (412). 
Thus, relatively high concentrations of cerebral ApoE are beneficial. It can be 
anticipated that the levels of free cerebral ApoE are reflected by its concentration in 
cerebrospinal fluid (CSF). It has been reported, however, that the CSF concentration of 
ApoE is similar in both control and AD groups with different ApoE genotypes (413, 414) 
although a trend towards elevated ApoE levels in patients carrying the ε2 allele was 
observed (415). However, since the applied assays have all been designed to detect 
unbound ApoE, it remains possible that the levels of CSF Aβ-ApoE complexes will be 
different amongst individuals with different ApoE genotypes. 
It has been suggested by Greenberg and by Nicoll (48, 416) that both the ε2 and the 
ε4 allele are risk factors for CAA-related hemorrhages, the latter by increasing the 
vascular amyloid load, and the former by increasing the vessel's susceptibility for rupture. 
Incorporating these suggestions in our in vitro model, one would predict increased cell 
death in cells carrying the ε2 allele, because this would lead to vessel weakening by (Aβ-
mediated) degeneration of SMCs or HBPs. However, our in vitro data show less 
cytotoxicity associated with cells possessing an 2 allele.  Perhaps the e2 allele promotes 
other changes leading to vessel rupture such as increased extracellular proteolysis.    
ApoE produced by cerebrovascular cells may play a prominent role in the 
pathogenesis of CAA. Second only to the liver, the brain is the organ that produces the 
largest amounts of ApoE. Astrocytes are regarded as the major source of cerebral ApoE 
(417), although neurons may be able to produce ApoE as well (418). Here we 
demonstrated that both pericytes and SMCs secrete ApoE and, since both are located at 
the abluminal side of the blood-brain barrier, they may contribute to the pool of cerebral 
ApoE. This may be particularly important with regard to the etiology of CAA. An 
attractive model explaining the pathogenesis of vascular Aβ deposition has been proposed 
by Weller (419), who suggested that Aβ of neuronal origin might be transported from the 
brain parenchyma to the vasculature by drainage of interstitial fluid. Experimental 
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support for this model was provided by the transgenic mice studies of Calhoun (420) who 
demonstrated extensive CAA formation in APP transgenic mice under the control of the 
neuronal Thy-1 promotor. This model of CAA formation requires the availability of local 
factors that enhance or otherwise stimulate Aβ deposition in the vasculature. The 
availability of vessel-derived ApoE, but possibly also factors such as heparan sulphate 
proteoglycans (421), may regulate Aβ clearance and/or deposition in the vasculature. Our 
data suggest that when ApoE is available in high enough concentrations, Aβ may remain 
solubilized and be processed for clearance, whereas if ApoE is available in restricted 
amounts only, Aβ will be prone to deposition and cell surface aggregation in the vessel 
wall. 
The degree of lipidation of the ApoE molecule is crucial to its biological activities. 
Circulating ApoE is tightly bound to several classes of lipoproteins, such as HDL and 
VLDL. It was demonstrated previously that lipidated and unlipidated ApoE differentially 
interact with Aβ, suggesting that the degree and type of lipidation of ApoE is of critical 
importance (53). In accordance with this study, we observed differences in the reduction 
of Aβ-induced cellular toxicity of HBPs by ApoE, dependent on its source: especially 
ApoE secreted by HBPs seemed very efficient. Previous studies by others (422, 423) 
showed that ApoE is secreted by cultured cells as specific lipid-containing particles, 
different from those in CSF (424). Our data suggest that between different cell types 
(HEK293 cells vs. HBPs/SMCs) the degree of ApoE lipidation may vary. The recombinant 
ApoE from PanVera is post-translationally modified, but probably lipidation of the 
molecule is also different in Sf insect cells than in HBPs. 
 Our comparative analysis of ApoE protein secretion and mRNA levels by the 
respective HBP and SMC cell cultures suggests that not only the ApoE genotype but also 
other, unstudied, factors may affect ApoE secretion, e.g. ApoE promotor polymorphisms 
(425), or factors involved in lipid metabolism. Furthermore, although we did not collect 
any evidence in this direction, it cannot be entirely excluded that the original cerebral 
environment of the cells (i.e. AD, control or other diagnosis) contributes to the cellular 
phenotype in vitro. Finally, future studies on other cerebral cell types will have to reveal 
to what extent ApoE will affect other cellular responses to Aβ, including neuronal cell 
death and glial cytokine production. 
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Abstract 
 
Inefficient clearance of Aβ, caused by impaired blood-brain barrier crossing into the 
circulation seems to be a major cause of the accumulation of Aβ in the brain of patients 
with late-onset Alzheimer’s disease (AD) and hereditary cerebral hemorrhage with 
amyloidosis Dutch type (HCHWA-D). We analyzed the presence of potential Aβ-
receptors in uninvolved cerebral vessels, as well as in vessels that had accumulated 
amyloid (cerebral amyloid angiopathy; CAA), of AD, HCHWA-D patients and in a control 
group. Increased presence of RAGE, LRP-1, CD36 and LDLR was observed in CAA in 
both AD and HCHWA-D brain. Since CAA is accompanied by degeneration of pericytes 
and smooth muscle cells (SMCs), we investigated if these receptors are involved in Aβ 
internalization and in the process of Aβ-mediated cell death of human cerebrovascular 
cells and astrocytes. Pericytes, SMCs and astrocytes were incubated with either Aβ1-42, Aβ1-
40 or Aβ1-40 with the Dutch mutation (22Glu´Gln) that induces slowly progressive cellular 
degeneration in vitro. Expression of both the LRP-1 and LDL receptor by human brain 
pericytes and leptomeningeal SMCs, but not by astrocytes, increased upon incubation 
with Aβ. Furthermore, both Aβ internalization and Aβ-mediated cell death could be 
antagonized by adding purified receptor-associated protein or cycloheximide. We 
conclude that: 1) Aβ-receptors LRP-1 and LDLR are involved in Aβ internalization by 
cerebral perivascular cells and, 2) perivascular cells adapt their Aβ clearance capacity to 
the levels of Aβ present, 3) saturated LRP-1/LDLR-mediated clearance of Aβ results in 
degeneration of perivascular cells.  
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Introduction 
 
Alzheimer’s disease (AD) is characterized by accumulation of the 4 kDa amyloid-β 
protein (Aβ) in senile plaques (SPs) and cerebral amyloid angiopathy (CAA). In patients 
with late-onset AD or hereditary cerebral hemorrhage with amyloidosis of the Dutch type 
(HCHWA-D) inefficient clearance of Aβ seems to be the key event leading to 
accumulation of Aβ in the brain, rather than increased Aβ production (128, 129). In CAA, 
both in AD and HCHWA-D, accumulation of Aβ in the vessel walls results in 
degeneration of cerebrovascular cells and disruption of the blood-brain barrier (BBB) 
(339, 341, 347).  
It has been suggested that vascular Aβ-receptors, expressed by endothelial cells, 
transfer Aβ across the BBB into the circulation and thus mediate clearance of Aβ from the 
brain (132). Alternatively, Aβ-receptors may also mediate Aβ clearance via phagocytosis 
of Aβ by microglia and astrocytes (163, 164). Both the low-density lipoprotein receptor 
(LDLR) and the LDLR related protein-1 (LRP-1) may act as Aβ-receptors and are 
expressed by both endothelium and astrocytes (133, 191, 426, 427). LDLR regulates 
apolipoprotein E (ApoE) levels in the central nervous system, binds ApoE/Aβ complexes 
originating from the brain (191). LRP-1 binds both ApoE/Aβ complexes and Aβ, and 
regulates both their clearance from brain to blood (131, 132). Indeed, decreased LRP-1 
expression in experimental animals resulted in increased cerebral amyloid plaque 
formation (140). Besides the LDLR family, six other potential Aβ-binding receptors have 
been identified. First, megalin might be involved in the efflux of Aβ from the brain, since 
this Apolipoprotein J (ApoJ) receptor transports ApoJ/Aβ complexes from brain to blood 
(143). Second, p-glycoprotein (multi-drug resistance 1, MDR1) also transports Aβ from 
blood to brain across the BBB (144). Third, the receptor for advanced glycation end 
products (RAGE) is expressed by various cell types, such as astrocytes, pericytes and 
smooth muscle cells and, in contrast to LRP-1, binds and transports Aβ from blood to 
brain (146, 428). Fourth and fifth, the scavenger receptor CD36 acts as a receptor for 
fibrillar Aβ (147), whereas the formylpeptide receptor-like-1 (FPRL1) plays a role in the 
endocytosis and aggregation of Aβ in mononuclear phagocytes (148). Finally, the 
transmembrane amyloid precursor protein (APP) itself also functions as an Aβ-receptor, 
and binds fibrillar forms of Aβ (150, 151).  
Aβ is produced by neurons and via interstitial fluid drainage (429) first encounters 
pericytes in capillaries and smooth muscle cells in large parenchymal and leptomeningeal 
vessels, before receptor-mediated trans-endothelial transport results in clearance of Aβ 
from the brain (132). In AD brains, Aβ accumulates in the cerebral vessel wall as CAA. 
The initial deposition of Aβ takes place in the adventitia (430) and Aβ induces 
degeneration of perivascular cells. This suggests that perivascular cells may, next to 
endothelial cells, contribute to Aβ clearance and that Aβ accumulation in CAA might 
result from a saturated or inadequate clearance mechanism of cerebrovascular cells. 
In this study, we investigated the distribution of Aβ-receptors in brain vessels of 
various sizes (i.e. capillaries, arterioles, arteries) and in astrocytes, and their colocalization 
with CAA and SPs in AD and HCHWA-D brains to gain insight into the spatial 
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distribution of these receptors and estimate their relative contribution to Aβ clearance. 
Furthermore, we investigated the effect of Aβ on the expression levels of Aβ-receptors on 
cultured pericytes, leptomeningeal smooth muscle cells and astrocytes. Finally, the role of 
Aβ-receptors in Aβ internalization and Aβ-mediated cell death of cerebrovascular cells 
and astrocytes was studied.  
 
Materials and methods 
 
Autopsy material 
Tissue samples from the occipital cortex and hippocampus were obtained after rapid 
autopsy and immediately frozen in liquid nitrogen. Material was obtained from 11 AD 
patients (age 82 ± 7.0 years; post mortem delay 4.2 ± 1.0 hours), 7 of them with moderate 
to severe CAA, and 4 control cases, without neurological disease (age 76 ± 7.7 years; post 
mortem delay 4.3 ± 1.3 hours). Furthermore, tissue samples from the frontal cortex of 5 
patients with HCHWA-D (age 55.2 ± 3.3 years; post mortem delay 3.4 ± 1.8 hours) were 
collected. Diagnosis and grading of AD patients were performed according to the Braak & 
Braak and CERAD criteria (326, 327). CAA grading was performed as described in a 
previous report (243). Table I provides an overview of the diagnosis, Braak & Braak score, 
CERAD score, CAA grade, age, post-mortem interval, gender and apolipoprotein E 
genotype of the patients included in this study. 
Table I. Patient characteristics. 
Number Diagnosis Grade 
(Braak) 
Grade 
(CERAD) 
CAA PMI 
(hrs.) 
ApoE Age Gender 
1 Control 0 0 - 4 3 / 3 84 F 
2 Control 0 0 - 6 3 / 3 71 F 
3 Control I 0 - 3 2 / 3 68 M 
4 Control I 0 - 4 3 / 3 81 M 
5 HCHWA-D I/II 0 +++ 1 3 / 4 55 F 
6 HCHWA-D I/II 0 +++ 4 3 / 3 59 M 
7 HCHWA-D - 0 +++ 3 ND 51 M 
8 HCHWA-D - 0 +++ 3 ND 53 F 
9 HCHWA-D - 0 +++ 6 ND 58 M 
10 AD VI +++ +++ 3 3 / 4 77 M 
11 AD VI +++ + 4 3 / 3 94 F 
12 AD V +++ + 5 3 / 4 84 M 
13 AD VI +++ +++ 4 3 / 3 81 F 
14 AD VI +++ ++ 3 3 / 4 89 F 
15 AD VI ++ +++ 5 4 / 4 83 F 
16 AD VI +++ +++ 3 4 / 4 69 M 
17 AD VI +++ +++ 3 3 / 3 75 M 
18 AD V +++ + 6 3 / 3 87 F 
19 AD V-VI +++ +++ 5 3 / 4 78 F 
20 AD V +++ + 5 3 / 3 82 F 
Overview of the patients used in this study. AD = Alzheimer’s disease, HCHWA-D = hereditary cerebral 
hemorrhage with amyloidosis Dutch type, PMI = post mortem interval (hrs. = hours), ApoE = 
apolipoprotein E genotype, ND = not determined. Grading of AD (Braak and CERAD scores) and of 
CAA was performed as described in the methods. 
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Materials 
Both Aβ1-40 peptide (96% pure, HPLC analysis) containing the Glu22Gln mutation (D-Aβ1-
40), wild-type Aβ1-42 (95% pure, HPLC analysis) and wild-type Aβ1-40 (98% pure, HPLC 
analysis) were obtained from Biosource (Etten-leur, The Netherlands). Aβ40-1 peptide (99% 
pure, HPLC analysis) was obtained from American Peptide Company (Sunnyvale, CA, 
USA). Lyophilized peptides were dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (Sigma-
Aldrich, Zwijndrecht, The Netherlands), dried overnight and subsequently dissolved in 
DMSO, at a concentration of 5 mM and stored at  
–80oC. Fibrillar Aβ1-42 or D-Aβ1-40 was obtained by incubating 10 μM of Aβ in Eagle’s 
minimal essential medium (EMEM) (BioWhittaker Europe, Verviers, Belgium) for 3 days 
at 37oC, and analyzed by electron microscopy (EM); an extensive network of mature Aβ 
fibrils was observed in these preparations (245). 
 
Immunohistochemistry 
To examine the presence of Aβ receptors in control, AD and HCHWA-D brains, serial 
cryo-sections (4 μm) were used. Sections were fixed and treated as described in previous 
reports (243, 244). An overview of the antibodies used in this study is given in Table II. 
Cell culture 
Human brain pericytes (HBP), human leptomeningeal smooth muscle cells (HLSMC) and 
human brain astrocytes were isolated and characterized as described previously (125, 339, 
345, 346). Cerebrovascular cells were maintained in EMEM (BioWhittaker Europe) 
supplemented with 10% human serum (Gemini BioProducts, Calabasas, CA, USA), 20% 
newborn calf serum (Life Technologies, Rockville, USA), 0.1% basic fibroblast growth 
factor and 2% penicillin/streptomycin at 37oC and 5% CO2. Astrocytes were maintained in 
DMEM/HAM-F10 (1:1) containing 10% (v/v) fetal calf serum, 2 mM glutamine, penicillin 
(100 IU/ml), and streptomycin (50 μg/ml). For degeneration studies, cells were incubated 
in an eight-well chamber slide (Nunc, Roskilde, Denmark) with EMEM and 0.1% bovine 
serum albumin (BSA) (serum-free medium) supplemented with 10 μM D-Aβ1-40, 10 μM 
wild-type Aβ1-42 or 10 μM Aβ40-1 (174, 244), with or without 1 μM RAP or cycloheximide 
(0.5 μg/ml) for 6 days. Control cells incubated with EMEM or DMEM/HAM-F10 and 0.1% 
BSA (serum-free medium) demonstrated normal morphology. Cell viability was quantified 
using a fluorescent Live/Dead®Viability/Cytotoxicity Kit according to the manufacturer’s 
Table II. Primary antibodies used in this study. 
Primary 
antibody 
Antigen Species  
raised in 
Dilution Source 
(reference) 
6C6 Aβ Mouse 1:2000 Elan Pharma. San Francisco, CA, USA 
100011 CD36 Rabbit 1:1000 Cayman Chemical, USA 
Ab13177 FPRL1 Rabbit  1:1000 Abcam, Cambridge, UK 
ST1025 RAGE Goat 1:6000 Calbiochem, Darmstadt, Germany 
Ab10333 MDR1 Mouse 1:100 Abcam, Cambridge, UK 
H-245 Megalin Rabbit 1:100 Santa Cruz Biotechnology, CA, USA 
8G1 LRP-1 (α-chain) Mouse 1:100 Progen, Heidelberg, Germany 
3501 LRP-1 (β-chain) Mouse 1:100 American Diagnostica inc., Stanford, USA 
Pab HLDL-R LDLR Chicken 1:200 Progen, Heidelberg, Germany 
P2-1 APP Rabbit 1:1000 Dr. W.E. Van Nostrand (439)  
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description (Molecular Probes, Eugene, OR, USA) and analyzed using a Leica fluorescence 
microscope. The percentage of dead cells was determined from at least four counts per 
well (approximately 800 cells per count), and experiments were performed in duplicate. 
Each experiment was repeated at least three times. HLSMC incubated with scrambled-
sequence Aβ1-42 demonstrated neither signs of degeneration nor loss of cell viability, in line 
with previous data (347). 
 
Immunofluorescence staining of Aβ-receptors on the cell surface 
Cells cultured on eight-well chamber slides, were incubated 10 μM D-Aβ1-40 or 10 μM 
wild-type Aβ1-42 for 3 days at 37oC, with or without 1 μM RAP or cycloheximide (0.5 
μg/ml). Cultures were washed once with phosphate-buffered saline (PBS) and then fixed 
with periodate-lysine-paraformaldehyde (PLP) for 10 minutes. The cell preparations were 
incubated with monoclonal antibody anti-LRP-1 (α-chain, 8G1), monoclonal anti-LRP-1 
(β-chain, 3501) or chicken polyclonal anti-LDLR (Table II). Subsequently, cells were 
incubated with Alexa Fluor 488-labelled goat anti-mouse (1:200, Molecular Probes) or 
biotin-labelled anti-chicken (Vector Laboratories, Burlingame, CA, USA) followed by 
Alexa Fluor 488-labelled streptavidin (1:400, Molecular Probes). Finally, slides were 
incubated with Topro-3 for nuclear staining (Vector) for 45 minutes. Antibodies were 
diluted in PBS/0.1% BSA, which also served as a negative control. After each incubation, 
slides were extensively washed with PBS. Immunofluorescence staining was analyzed 
using a confocal laser-scanning microscope (Leica, Wetzlar, Germany).  
 
Western blotting 
Immunoblot analysis was performed with cell lysates from HBP, HLSMC or astrocytes 
cultured in 6 wells plates in the presence of either 10 μM D-Aβ1-40, 10 μM wild-type Aβ1-42 
or 10 μM wild-type Aβ1-40 for 3 days at 37oC, with or without 1 μM RAP or cycloheximide 
(0.5 μg/ml). Cells were homogenized in RIPA buffer with protease inhibitors (CompleteTM 
Mini, Roche, Mannheim, Germany) and equal amounts of protein were loaded and 
electrophoresed on 15% polyacrylamide gels. Non-specific protein binding was blocked 
by preincubation with Odyssey-blocking buffer (according to manufacture’s guidelines, 
LI-COR, Bad Homburg, Germany). Bound anti-LRP (8G1) or anti-LDLR (chicken) was 
detected using Alexa Fluor 680 or 800-labelled goat anti-mouse, or biotin-labelled anti-
chicken followed by Alexa Fluor 680-labelled streptavidin (Molecular probes). Analysis 
was performed using the Odyssey infrared imaging system (LI-COR, Bad Homburg, 
Germany). 
 
Quantitative Immunofluorescence Staining 
A quantitative immunofluorescence-staining assay with infrared detection using the 
Odyssey infrared imaging system was performed as described (431, 432). In short, 
cerebrovascular cells and astrocytes (20,000 cells/well) were cultured in fibronectin-
coated 96 well plates (NUNC, Roskilde, Danmark), for 1-2 days until confluence, 
additionally the cells were incubated with serum-free medium for at least 4 hours. Next, 
fresh medium containing 0.1% BSA with or without 1-10 μM D-Aβ1-40, 1-10 μM wild-type 
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Aβ1-42, 1 μM RAP or cycloheximide (0.5 μg/ml) was added to the cells. Upon incubation for 
3 days at 37ºC, cells were rinsed twice with PBS and fixed with 4% paraformaldehyde for 
20 minutes at room temperature (RT). Cells were then washed with either PBS (to 
quantify cell surface immunoreactivity only) or PBS containing 0.1% Triton X-100 (to 
quantify overall cellular immunoreactivity) and rinsed again before blocking with 150 μl 
of LI-COR Odyssey blocking Buffer (1:1 in PBS) for 90 minutes at RT. Primary antibodies 
(anti-Aβ (40-4)) and anti-LRP-1 (8G1)) were diluted in Odyssey Blocking Buffer and cells 
were incubated with the diluted antibodies (50 μl/well) overnight at 4ºC. Cells were 
repeatedly washed with PBS and PBS-0.05% Tween-20 (PBS-T) and incubated with 
secondary antibodies diluted in Odyssey Blocking Buffer at RT for 1 hour; i.e. Alexa Fluor 
680-labelled Goat anti-mouse, IRDey 800CW-labelled Goat anti-rabbit (1:400, Rockland 
Immunochemicals) or biotin labeled secondary antibody anti-chicken (1:200, Vector). 
Cells were again rinsed with PBS and PBS-T and, in case of the secondary anti-chicken 
antibody, incubated with Alexa Fluor 680-labelled streptavidin for another 60 minutes at 
RT. Analysis was performed using the Odyssey infrared imaging system (LI-COR). 
 
 
Results 
 
Presence of Aβ-receptors in control, AD and HCHWA-D brains 
Presence of Aβ-receptors in vessels in which no Aβ had accumulated were similar in AD, 
HCHWA-D and control brains. No Aβ was detected (mAb 6C6) in brain vessels of control 
brains (Fig. 1A, E, G). Immunoreactivity for RAGE was observed in astrocytes of white 
and grey matter and in medium-sized parenchymal vessels (Fig. 1B), whereas no staining 
in leptomeningeal vessels and capillaries was seen (Table III). LRP-1 immunostaining was 
observed in astrocytes of the white matter, in neurons, and in both leptomeningeal vessels 
and medium-sized parenchymal (Fig. 1C) vessels in control brains. Presence of MDR1 was 
observed in capillaries (Fig. 1D). APP, as well as CD36 (Fig. 1F) immunostaining was 
observed in astrocytes, and both leptomeningeal and medium-sized parenchymal vessels 
(Table III). Anti-APP staining was also present in neurons (data not shown). LDLR 
immunostaining was observed in astrocytes, neurons and capillaries, and was also present 
in leptomeningeal and medium-sized parenchymal vessels in control brains (Fig. 1H). 
Both anti-FPRL1 and anti-megalin staining was demonstrated in astrocytes but was absent 
in leptomeningeal and medium-sized parenchymal vessels (Table III), and anti-FPRL1 
immunoreactivity was observed in neurons.  
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Figure 1. Immunohistochemical staining of Aβ-receptor antibodies in neocortex of control brains. Anti-Aβ 
(mAb 6c6) antibody staining was absent in control vessels unaffected by CAA (A, E, G). Both anti-RAGE (B, 
arrow) and anti-LRP-1 (C, arrow) antibodies demonstrated immunreactivity in normal medium-sized 
parenchymal vessels in control brains. In contrast, the anti-MDR1 antibody stained capillaries (D). Both 
anti-CD36 (F, arrow) and anti-LDLR (H, arrow) antibodies were immunoreactive in medium-sized 
parenchymal vessels in control brain. Serial sections: A, B, C; E, F; G, H. Original magnification A-C, E-H ¯ 
250, D ¯ 150.  
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Figure 2. Immunohistochemical staining of Aβ-receptor antibodies in CAA in the neocortex of AD brains. 
The anti-Aβ (mAb 6C6) antibody stained CAA in AD brains (A-D). RAGE (E), CD36 (F), LDLR (G) 
immunostaining was observed in CAA, whereas LRP-1 presence was increased in perivascular cells, but not 
in CAA itself (H). Serial sections: A, E; B, F; C, G; D, H. Original magnification A-H ¯ 250.  
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Figure 3. Immunohistochemical staining of Aβ-receptor antibodies in classic SPs in the neocortex of AD 
brain. The anti-Aβ (mAb 6C6) antibody stained both classic and diffuse SPs in AD brains (A-E). CD36 (F, 
arrow), LRP-1 (G, arrow), megalin (H, arrow), FPRL1 (I, arrow) and APP (J, arrow) immunostaining was 
observed in classic SPs. Serial sections: A, F; B, G; C, H; D, I; E, J. Original magnification A-H ¯ 250.  
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Presence of Aβ-receptors in CAA and SPs in AD and HCHWA-D brains 
In both AD and HCHWA-D brains, CAA affected vessels were identified by their intense 
staining by the anti-Aβ antibody (mAb 6C6) (Fig. 2A-D). Anti-RAGE (Fig. 2E), anti-CD36 
(Fig. 2F) and anti-LDLR (Fig. 2G) antibodies stained CAA of leptomeningeal and medium-
sized parenchymal vessels of both AD and HCHWA-D brains. Anti-LRP-1 
immunoreactivity was observed at the abluminal side of CAA-affected vessels (Fig. 2H), in 
both leptomeningeal and medium-sized parenchymal vessels, suggestive of increased 
expression by perivascular cells. No immunostaining for APP, MDR1, megalin and FPRL1 
was observed in CAA.  
The anti-Aβ antibody (mAb 6C6) stained both classic and diffuse SPs (Fig. 3A-E) in 
AD brains and diffuse SPs in HCHWA-D brains. A comparison with the staining of the 
Aβ-receptor antibodies in serial sections demonstrated colocalisation of CD36 (Fig. 3F), 
LRP (Fig. 3G), megalin (Fig. 3H), FPRL1 (Fig. 3I) and APP (Fig. 3J) immunostaining with 
classic SPs in AD brains, but not with diffuse SPs in AD and HCHWA-D brains. No 
immunostaining for RAGE, MDR1 and LDLR was observed in both classic and diffuse SPs 
in AD, and diffuse SPs in HCHWA-D brains. 
The results of the immunohistochemical stainings for the Aβ-receptors in normal, 
AD and HCHWA-D brains are summarized in Table III. 
 
 
 
 
Table III. Overview of the expression of Aβ-receptors in vessels of control, AD and HCHWA-D brains, 
and their association with CAA and SPs in these brains. 
 
 Vessels in control, AD and HCHWA-D brains CAA SPs 
 Lepto- 
meningeal 
vessels 
Medium-sized 
Parenchymal  
vessels 
Capil-
laries 
 
Astro-
cytes 
Leptomeningeal and 
parenchymal 
 vessels 
Classic Diffuse 
APP + + - + - + - 
MDR1 - + + - - - - 
RAGE - + - + + - - 
LRP-1 + + - + + + - 
Megalin - - - + - + - 
CD36 + + - + + + - 
FPRL1 - - - + - + - 
LDLR + + + + + - - 
Expression of Aβ-receptors various brain vessels and in cerebral amyloid angiopathy (CAA) and diffuse 
senile plaques (SPs) in Alzheimer’s disease (AD) and hereditary cerebral hemorrhage with amyloidosis 
of the Dutch type (HCHWA-D). The presence of Aβ-receptors staining in a specific vessel or lesion is 
indicated as follows: absent (-), present (+).  
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Aβ-mediated upregulation of Aβ-receptors by cerebrovascular cells 
We analyzed expression of the Aβ-receptors in cultured HBP, HLSMC and astrocytes. 
LRP-1, LDLR, RAGE and CD36 were observed in both HBPs and HLSMC using Western 
blot analysis (Fig. 4A). In astrocytes, however, LRP-1, LDLR and RAGE were observed, 
whereas expression of CD36 was absent (Fig. 4A). LRP-1 and LDLR expression, but not 
that of CD36 or RAGE, was increased in HBPs and HLSMCs incubated with 10 μM D-Aβ1-
40 for 3 days (Fig. 4A), whereas similar incubations in astrocytes did not result in 
upregulation of any of the Aβ-receptors studied (Fig. 4A). 
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Figure 4. Western blot analysis of LRP-1 and LDLR expression in cultured cerebrovascular cells and
astrocytes. HBP and astrocytes were incubated with or without 10 μM D-Aβ1-40 for 3 days at 37oC (A). In
HBP, expression of LRP-1, LDLR, RAGE and CD36 was observed, and both LRP-1 and LDLR were
upregulated by incubation with 10 μM D-Aβ1-40 (A). In astrocytes expression of LRP-1, LDLR and RAGE
was observed, but Aβ did not affect receptor expression (A). In HBPs co-incubated with RAP (1 μM) or
cycloheximide (0.5 μg/ml) for 3 days at 37oC, reduction of LRP-1 upregulation was observed, whereas
LDLR expression remained unaffected (B). Similar effects on both LRP-1 and LDLR expression on HBPs
were observed after incubations with Aβ1-42 (C). Incubation of HBP with Aβ1-40 had no effect on both
LRP-1 and LDLR expression (D). Astrocytes incubated with 10 μM of Aβ1-40, Aβ1-42, or D-Aβ1-40,
demonstrated no effects on both LRP-1 and LDLR expression (E). Incubation of either 10 μM fibrillar D-
Aβ1-40 (F) or Aβ1-42 (G) resulted in increased LRP-1 expression by HBPs, whereas no differences were
observed for LDLR levels. In addition, co-incubation of fibrillar Aβ with RAP or cycloheximide inhibited
this effect (F, G). 
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To antagonize both LRP-1 and LDLR upregulation in HBPs, cells were co-
incubated with the receptor-associated protein, RAP (1 μM), or cycloheximide (0.5 μg/ml) 
(433, 434). Treatment of HBPs for 3 days at with RAP or cycloheximide alone had no 
effect on both LRP-1 and LDLR expression, whereas co-incubation of 10 μM D-Aβ1-40 
with RAP or cycloheximide reduced LRP-1 expression to control levels, but did not affect 
LDLR expression (Fig. 4B). Incubation of HBPs with 10 μM Aβ1-42 resulted in upregulation 
of LRP-1 expression but not of LDLR (Fig. 4C). Co-incubation with 10 μM Aβ1-42 and RAP 
or cycloheximide again reduced LRP-1 expression to control levels, whereas expression of 
LDLR remained unaffected (Fig. 4C). Aβ1-40 had no effect on LRP-1 or LDLR expression 
and, consequently, co-incubation with RAP or cycloheximide remained ineffective (Fig. 
4D). In astrocytes incubated with either Aβ1-40, Aβ1-42 or D-Aβ1-40, no effects on both LRP-1 
and LDLR expression were observed (Fig. 4E). Treatment of HBPs with either 10 μM 
fibrillar D-Aβ1-40 (Fig. 4F) or fibrillar Aβ1-42 (Fig. 4G) also resulted in an increase in LRP-1 
expression by HBPs, whereas no differences were found for LDLR levels (Fig. 4F). Co-
incubation of fibrillar D-Aβ1-40 (Fig. 4F) or fibrillar Aβ1-42 (Fig. 4G) with either RAP or 
cycloheximide reduced the LRP-1 upregulation by fibrillar Aβ.  
 
The effects of D-Aβ1-40 on LRP-1 expression in HBPs were confirmed by confocal 
laser scanning microscopy (Fig. 5). Upregulation of LRP-1 staining in HBP was observed 
after incubation with 10 μM D-Aβ1-40 for 3 days at 37oC, whereas co-incubations with RAP 
or cycloheximide decreased anti-LRP-1 immunoreactivity compared to D-Aβ1-40 alone 
(Fig. 5).  
The relation between Aβ and LRP-1 expression was studied in more detail by 
quantitative immunofluorescence. Treatment of HBP with 1-10 μM D-Aβ1-40 resulted in a 
dose-dependent increase in LRP-1 expression that was antagonized by RAP, as well as by 
cycloheximide (Fig. 6A). Neither RAP nor cycloheximide affected the association of D-
Aβ1-40 with the cell surface (Fig. 6B). Similar to D-Aβ1-40, also 1-10 μM Aβ1-42 induced a 
dose-dependent increase in LRP-1 expression by HBP (Fig. 6C), and co-incubation with 
RAP or cycloheximide inhibited this increase (Fig. 6C). As observed for D-Aβ1-40, both 
RAP and cycloheximide did not affect Aβ immunoreactivity on the cell surface (Fig. 6D). 
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Figure 5. Confocal laser scanning miscroscopy analysis of Aβ-mediated upregulation of LRP-1 in HBPs.
HBP incubated with 10 μM D-Aβ1-40, or in combination with RAP (1 μM) or cycloheximide (0.5 μg/ml)
for 3 days at 37oC. Increased immunoreactivity of anti-LRP antibody (red) was observed after treatment
with 10 μM D-Aβ1-40, compared to control levels of LRP-1 in HBPs. Co-incubation of D-Aβ1-40 with RAP
or cycloheximide demonstrated a reduced immunoreactivity of the anti-LRP-1 antibody. Magnification:
¯630. Nuclei are counterstained blue.  
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We observed similar effects on LRP-1 expression and anti-Aβ immunoreactivity when 
cultured HLSMC were used (not shown). Incubation of fibrillar D-Aβ1-40 or Aβ1-42 (not 
shown) resulted in increased expression of LRP-1 by HBPs, which could be inhibited both 
by RAP and cycloheximide (Fig. 6E). Co-incubation of fibrillar D-Aβ1-40 or Aβ1-42 (not 
shown) with RAP resulted in a decreased anti-Aβ immunoreactivity on the cells, whereas 
incubation of cycloheximide had no effect (Fig. 6F).  
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Figure 6. Quantitative immunofluorescence analysis of LRP-1 expression in cerebrovascular cells. HBP 
were incubated with peptide concentrations as indicated for 3 days at 37oC, and anti-LRP-1 and anti-Aβ 
immunoreactivity was analyzed as described in Materials and Methods. Treatment with 1-10 μM D-
Aβ1-40 resulted in a dose-dependent increase in LRP-1 expression (A). This increased expression was 
antagonized by co-incubations with RAP (1 μM) or cycloheximide (0.5 μg/ml) (A). Co-incubations of 
D-Aβ1-40 with both RAP and cycloheximide had no effect on cell surface Aβ compared to D-Aβ1-40 alone 
(B). Similar effects were also observed in treatment with 1-10 μM Aβ1-42 and in co-incubations of Aβ1-42
with RAP or cycloheximide (C, D). Treatment of HBPs with 10 μM of fibrillar D-Aβ1-40 (F-D-Aβ1-40)
resulted in increased LRP-1 expression, whereas co-incubation of fibrillar D-Aβ1-40 with either RAP or 
cycloheximide reduced this effect (E). In addition, co-incubation of 10 μM of fibrillar D-Aβ1-40 with 
RAP resulted in moderately decreased D-Aβ1-40 accumulation at the cell surface, compared to D-Aβ1-40
alone (F), whereas co-incubations with cycloheximide had no effect on accumulation of D-Aβ1-40 at the 
cell surface (F). Statistical analysis was performed using Student’s t-test. The level of significance of the 
difference with 10 μM (F-) D-Aβ1-40 or Aβ1-42 and the combination with RAP or cycloheximide is 
indicated as follows: *p< 0.05; **p< 0.01; ***p< 0.001; p> 0.05 is not indicated. Mean ± S.E.M. of 
quadruplicates are shown. 
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LRP is involved in Aβ internalization and Aβ-mediated cell death of cerebrovascular cells 
To analyze the role of LRP-1 in Aβ internalization by HBPs, quantitative 
immunofluorescence of Aβ internalized by the cells was performed. HBPs were incubated 
with 5 μM Aβ1-40 for 0, 1, 4, 21 and 24 hours at 37oC. Increasing levels of intracellular Aβ 
were observed over time (Fig. 7). Co-incubation of 5 μM Aβ1-40 with either RAP or 
cycloheximide inhibited internalization of Aβ (Fig. 7). Astrocytes incubated with 5 μM 
Aβ1-40 for 0, 1, 4 and 24 hours at 37oC, also demonstrated internalization of Aβ, but co-
incubations with either RAP or cycloheximide were ineffective in preventing Aβ 
internalization (not shown). 
Incubation of cultured HBPs with 10 μM D-Aβ1-40 for 6 days reduced the 
percentage of viable cells to 51%, whereas in control incubations 4% of the cells were 
dead (Fig. 8A). Aβ treatment resulted in visible signs of cellular degeneration, with cell 
contours becoming blurred, although all cell bodies remained attached to the culture dish. 
Incubation with 25 μM of the inverted sequence Aβ40-1 had no effect on cell death, 
compared to the control incubations (not shown) (245). RAP and cycloheximide had no 
effect on cell viability (Fig. 8A).  
Co-incubation of 10 μM D-Aβ1-40 with RAP reduced the percentage of dead cells to 
21%, whereas co-incubation of cycloheximide reduced cell death to 18% (Fig. 8A). After 6 
days, the percentage of dead cells in cultured HBPs treated with 10 μM Aβ1-42 was 42%, 
whereas after co-incubation with RAP (17%) or cycloheximide (18%) cell death was 
similar to incubations of D-Aβ1-40 with RAP or cycloheximide (Fig. 8A). Treatment with 
10 μM Aβ1-40 did not affect cell viability. 
co
ntr
ol
0 h
ou
rs 
1 h
ou
r
4 h
ou
rs 
21
 ho
urs
24
 ho
urs
 
24
 ho
urs
 / R
AP
24
 ho
urs
 / c
yc
loh
ex
.
0
1000
2000
3000
4000
5 μM Aβ1-40
Aβ
 in
te
rn
al
iz
at
io
n
 
Figure 7. Internalization of Aβ by cerebrovascular cells. 
HBP were incubated with 5 μM Aβ1-40, with or without RAP (1 μM) or cycloheximide (0.5 μg/ml) for 0,
1, 4, 21, and 24 hours at 37oC. Aβ immunoreactivity was analyzed, as described in Materials and
Methods. Cell surface immunoreactivity was subtracted from overall immunoreactivity resulting in the
percentage of Aβ that is internalized. Increasing levels of Aβ1-40 were observed in time, whereas co-
incubation of 5 μM Aβ1-40 with RAP or cycloheximide inhibited Aβ internalization after 24 hours,
compared to Aβ1-40 alone. 
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Incubation of cultured astrocytes with 10 μM D-Aβ1-40 for 6 days resulted in 18% 
cell death, whereas in controls 4% cell death was observed (Fig. 8B). Co-incubation of 10 
μM D-Aβ1-40 with RAP or cycloheximide resulted in approximately similar percentages of 
dead cells compared to D-Aβ1-40 alone (Fig. 8B). 
Incubation of cultured HBPs with 10 μM fibrillar D-Aβ1-40 or Aβ1-42 for 6 days 
resulted in 26% and 37% dead cells, respectively (Fig. 8C). Co-incubation with RAP 
reduced cell death to 18% in case of D-Aβ1-40, and 15% in case of Aβ1-42, whereas 
cycloheximide showed no effects on cell death compared to D-Aβ1-40 or Aβ1-42 alone (Fig. 
8C). 
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Figure 8. LRP antagonists reduce Aβ-mediated cell death of cerebrovascular cells.  
Effects of RAP or cycloheximide on cerebrovascular and astrocyte cell death after incubation with 10 μM 
D-Aβ1-40, 10 μM Aβ1-42, with or without RAP (1 μM) or cycloheximide (0.5 μg/ml) for 6 days at 37oC. 
Incubation of both 10 μM D-Aβ1-40 or 10 μM Aβ1-42 resulted in cell death of HBPs, approximately 51% and 
43%, respectively (A). Co-incubations with either RAP or cycloheximide significantly reduced both D-
Aβ1-40 and Aβ1-42-mediated cell death of HBPs (A). Astrocytes incubated with 10 μM D-Aβ1-40 showed a 
cell death of approximately 18%, whereas co-incubation with RAP or cycloheximide had no effect on cell 
viability compared to D-Aβ1-40 alone (B). HBPs incubated with 10 μM of fibrillar forms of D-Aβ1-40 or Aβ1-
42 resulted in a cell death of approximately 25% and 35%, respectively (C). Co-incubation with RAP 
inhibited cell death compared to both fibrillar D-Aβ1-40 or fibrillar Aβ1-42 alone, whereas co-incubation 
with cycloheximide had no effect (C). Statistical analysis was performed using Student’s t-test. The level 
of significance of the difference with 10 μM D-Aβ1-40 or Aβ1-42 and combinations with RAP or 
cycloheximide is indicated as follows: *p< 0.05; **p< 0.01; ***p< 0.001; p> 0.05 is not indicated. Mean ± 
S.E.M. are shown. 
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Discussion 
 
The main findings of our study are that: 1) presence of LRP-1, LDLR, RAGE and CD36 are 
associated with CAA in both AD and HCHWA-D brains, 2) Aβ increases LRP-1 and LDLR 
expression by cerebrovascular cells in vitro, 3) internalization of Aβ by these cells occurs 
via both LRP-1 and LDLR, 4) both LRP-1 and LDLR play a role in the mechanism of Aβ-
mediated death of cerebrovascular cells.  
We observed vascular presence of a number of potential Aβ-receptors (LRP-1, 
RAGE, CD36, LDLR, APP) in control and AD and HCHWA-D brains. LRP-1 and CD36 
were only observed in the larger brain vessels, whereas MDR1 was predominantly found 
in capillaries. These findings suggest that transvascular transport of Aβ might be mediated 
by different Aβ receptors in different types of brain vessels. Well-known Aβ-receptors 
such as LRP-1 and RAGE were predominantly observed in middle-sized parenchymal 
vessels, which suggests that, apart from the capillaries, the contribution of these larger 
vessels to Aβ transport across the BBB is substantial. However, how the distribution 
pattern of the various Aβ-receptors reflects Aβ transport in vivo remains to be elucidated.  
From several in vitro studies and observations in transgenic mouse models it was 
suggested that in AD, expression of Aβ-receptors such as LRP-1 might be decreased, and 
that this change in Aβ-receptor expression might be directly related to the accumulation 
of Aβ in AD brains (131, 146, 435, 436). In contrast to these findings, we neither observed 
spatial and quantitative differences in presence of LRP-1 nor of other potential Aβ-
receptors in brain vessels between control, AD and HCHWA-D brains. Nevertheless, 
since accumulation of Aβ in AD is a long-term chronic process, subtle differences in 
presence of LRP-1 or other Aβ-receptors that remain undetected by 
immunohistochemical analysis, may be significant for the process of Aβ clearance.  
In brain, Aβ is predominantly produced by neurons and transported towards the 
cerebral vasculature by interstitial fluid drainage (429). One of the possible mechanisms 
by which Aβ is cleared from the brain is transport across the blood-brain barrier (BBB). In 
several studies it has been demonstrated that transport from brain-to-blood is mediated by 
LRP-1 and vice versa by RAGE (131, 132, 146, 168). In normail brain, clearance of Aβ 
from brain is the net result of these counteractive mechanisms. Trans-endothelial, LRP-1-
mediated transport of Aβ seems to be an essential part of this process. In AD, endothelial 
LRP-1 expression seems to be reduced leading to impaired export of Aβ from the brain 
(168). However, since Aβ is a constituent of the interstitial fluid flowing along 
perivascular cells towards the cerebrospinal fluid, and since Aβ in CAA is initially 
deposited in the adventitia (430), it is possible that perivascular cells (i.e. pericytes and 
smooth muscle cells) contribute to the process of vascular clearance of Aβ as well. 
 Although immunohistochemical studies do not allow for a distinction between 
presence of these receptors in endothelial cells, pericytes or smooth muscle cells (in 
arterioles), particularly because of the small size of pericytes (345), our in vitro data 
demonstrated that both pericytes and SMCs express LRP-1, LDLR, RAGE and CD36. 
Furthermore, we describe that both cultured HBPs and SMCs internalize Aβ, which can 
be inhibited by RAP, showing that LRP-1 and LDLR mediate this uptake (437). 
Additionally, expression of LRP-1 and LDLR on cerebrovascular cells was also increased 
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in response to Aβ, suggesting that the capacity to internalize Aβ is positively influenced by 
the Aβ levels present. This, however, is in contrast to published observations, describing 
down-regulated endothelial LRP-1 expression in response to Aβ treatment (168). In 
conclusion, both pericytes and SMCs may contribute to Aβ clearance from the brain, a 
function which, given their anatomical position and contact with the interstitial fluid, 
seems to be relevant in vivo. 
Thus, although pericytes and SMCs may contribute to vascular clearance of Aβ, it 
is conceivable that at relatively high concentrations of Aβ the cells clearance machinery 
has insufficient capacity to remove Aβ, and that Aβ bound to LRP-1 (or LDLR) may serve 
as an anchor for Aβ accumulation at the cell surface. This “frustrated” clearance of Aβ may 
result in degeneration of cerebrovascular cells and might induce accumulation of Aβ 
eventually leading to CAA. Evidence that this “frustrated” clearance is also mediated by 
LRP-1 (or LDLR) comes from the observation that 1 μM RAP antagonizes both LRP-1 and 
LDLR (433, 434), and inhibits Aβ-mediated cell death (this study).  
Accumulation of Aβ at the cell surface of cerebrovascular cells is tightly linked to 
degeneration of these cells (339, 341, 438). However, in this study both RAP and 
cycloheximide inhibited the monomeric as well as the fibrillar Aβ-mediated increase in 
expression of LRP-1 and reduced monomeric and fibrillar Aβ-mediated cell death, 
without affecting Aβ accumulation at the cell surface. Cycloheximide, but not RAP, 
reduced the increase in LRP-1 expression upon treatment with non-fibrillar Aβ. These 
data are in line with a single report describing a similar uncoupling of Aβ cell surface 
association and cell death after incubation with humanin (351). Thus, our study suggests 
that not the association of Aβ with the cell surface, resulting in disturbance of the cell 
membrane integrity, but downstream cellular signaling events, mediated by LRP-1 or 
LDLR, are crucial for initiating cellular degeneration, although this process is independent 
of LRP-1 (or LDLR) protein synthesis since cycloheximide did not attenuate Aβ-induced 
cell death.   
In contrast to the results with pericytes, LRP-1 and LDLR expression by astrocytes 
that, to some degree, may also contribute to cerebral Aβ clearance (163), is not increased 
in response to Aβ treatment. Thus, although astrocytes may internalize Aβ, their capacity 
to do so is not increased in a way as observed for HBPs and HLMSCs. Furthermore, both 
internalization of Aβ and degeneration of these cells were not inhibited by RAP, which 
suggests that other Aβ-receptors or even entirely other, receptor-independent 
mechanisms are involved in the internalization of Aβ by astrocytes. 
Pericyte LRP-1 expression was upregulated by Aβ1-42, D-Aβ1-40 and fibrillar forms of 
these Aβs, but not by the less amyloidogenic Aβ1-40. In addition, Aβ1-42 did not result in 
upregulation of LDLR, as observed for D-Aβ1-40. Deane and colleagues demonstrated a 
higher binding affinity of LRP-1 for Aβ1-40, compared to Aβ1-42 and D-Aβ1-40, which 
suggests that receptor-mediated clearance of Aβ1-40 is more efficient than for other Aβ 
isoforms, and which may be an explanation for the lack of LRP-1 upregulation by Aβ1-40 
(168). In HCHWA-D patients, a mutation in the Aβ1-40 sequence results in the more 
amyloidogenic D-Aβ1-40. This Aβ isoform is cleared less efficiently (168) and possibly as a 
compensation for this reduced efficiency, LRP-1 and LDLR expression is upregulated by 
perivascular cells. Both the amyloidogenic properties and the endothelial clearance of Aβ1-
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42 is intermediate compared to Aβ1-40 and D-Aβ1-40, which may, accordingly, be 
compensated for by increased LRP-1 expression only. Higher concentrations of D-Aβ1-40 
induce degeneration of cerebrovascular cells, and eventually lead to the extensive 
development of CAA in these patients (26, 341), possibly as a result of ”frustrated” 
clearance by perivascular cells.  
Our data suggest that cerebrovascular cell death induced by Aβ might be a 
receptor-mediated process instead of an aspecific loss of membrane integrity, and that 
accumulation of Aβ at the cell surface is the result of a saturated Aβ transport system. In 
contrast, internalization and cell death induced by Aβ in astrocytes might be regulated by 
yet other receptors or by other mechanisms. We suggest that expression of Aβ-receptors 
by pericytes and SMCs may contribute to the clearance of Aβ from the brain and that 
these cells may adapt their clearance capacity to the levels of Aβ present. If this cellular 
clearance machinery becomes saturated because of either high concentrations of Aβ or the 
presence of relatively amyloidogenic forms of Aβ (e.g. D-Aβ1-40, Aβ1-42), these 
cerebrovascular cells may start to degenerate, Aβ will accumulate in vessel walls and CAA 
will develop. However, the relative contributions of endothelial cells on the one hand, 
and pericytes and SMCs on the other, in the process of Aβ clearance and the development 
and progression of CAA remain to be elucidated.  
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Small heat shock proteins and apolipoprotein E in Alzheimer’s disease  
 
Summary 
Aβ-associated proteins in Alzheimer’s disease 
Small heat shock proteins (sHsps) function as molecular chaperones that prevent proteins 
from adopting an incorrect conformation (238). Apolipoprotein E (ApoE) is a lipid 
transporter and a well-known risk factor for AD (179). Both ApoE and members of the 
sHsp family have been implicated in several ways in the pathogenesis of Alzheimer’s 
disease (AD), including the genesis of senile plaques (SPs), neurofibrillary tangles (NFTs) 
and cerebral amyloid angiopathy (CAA). Nowadays, evidence is accumulating that 
“amateur” and “professional” chaperones, such as ApoE and the sHsps, respectively, might 
contribute to the pathogenesis of AD. Several studies already stressed the importance of 
sHsps, such as αB-crystallin and Hsp27 in the development of SPs (240, 253, 254). In 
addition, increased levels of sHsps were observed in neurodegenerative diseases such as 
AD and Creutzfeld-Jacob’s disease (240, 241, 253). Furthermore, interaction between αB-
crystallin or Hsp27 with amyloid-β (Aβ) has been described and αB-crystallin/Aβ-
complexes demonstrated neurotoxicity (249). However, the involvement of more recently 
discovered sHsps, such as Hsp20, HspB2/B3 and HspB8, in the pathogenesis of AD and in 
the interaction with Aβ, is unexplored.  
ApoE binds Aβ and promotes aggregation of Aβ in vitro in an isoform-dependent 
manner (ε2>ε3>ε4) (95, 96). In vivo, ApoE contributes to the formation of fibrillar Aβ 
deposits (98). This contribution is also isoform-dependent, since in APPV717F Tg mice 
human ApoE4 induces a 10-fold higher deposition of fibrillar Aβ than ApoE3 (188). These 
data suggest that isoform-dependent binding plays an important role in the in vivo effects 
of ApoE.  
 
In the first part of this thesis (Chapters 3-6) the distribution of sHsps, αB-crystallin, 
Hsp27, Hsp20, HspB2 and HspB8 in AD brains and hereditary cerebral hemorrhage with 
amyloidosis of the ‘Dutch’ type (HCHWA-D) were described. Furthermore, the 
interaction of sHsps with Aβ, the effect of sHsps on Aβ aggregation, and the protective 
effect of sHsps on Aβ-mediated cell death towards cerebrovascular cells, were studied.   
 
Association of small heat shock proteins with the pathological lesions of AD and 
HCHWA-D 
It has been demonstrated in AD brain tissue that αB-crystallin and Hsp27 expression is 
upregulated in astrocytes surrounding SPs and NFTs (239-242). Here, we confirm these 
findings and additionally demonstrated that Hsp20 colocalized with Aβ in diffuse and 
classic SPs in AD brains. Furthermore, both HspB2 and HspB8 were associated with 
classic SPs. Strikingly, HspB2 was also strongly expressed in CAA in AD brains, whereas 
other sHsps, including αB-crystallin, Hsp20, Hsp27 and HspB8, were not observed in CAA 
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lesions (Chapters 3 and 5). Although Hsp27 had been demonstrated in NFTs, we could not 
confirm these findings. In addition, we also did not observe colocalization of αB-
crystallin, Hsp20, HspB2 and HspB8 with NFTs. Thus, in AD, both Hsp20 and HspB2 
appear extracellularly, whereas the presence of αB-crystallin and Hsp27 was observed 
intracelularly in astrocytes associated with AD lesions. Furthermore, these data suggest 
that Hsp20 was predominantly associated with soluble Aβ, whereas HspB2 was associated 
with fibrillar forms of Aβ. In HCHWA-D brains, however, HspB2, Hsp20 and HspB8 were 
associated with Aβ in the vessel walls, whereas none of the above-described sHsps 
colocalized with the SPs observed in HCHWA-D brains (Chapters 5 and 6). These data 
suggest a differential role for sHsps in SPs and CAA in AD and HCHWA-D brains. Table I 
provides a summary of the distribution of sHsps in the pathological lesions of both AD 
and HCHWA-D. 
 
Small heat shock proteins interact with amyloid-β, affect amyloid-β aggregation, inhibit 
amyloid-β toxicity towards cerebrovascular cells and induce cytokine secretion 
Direct interaction of αB-crystallin and Hsp27 with Aβ has been demonstrated in vitro 
(246-248). Here, we demonstrate that the sHsps Hsp20, Hsp27, HspB8 and αB-crystallin, 
but not HspB2/B3, strongly bind to Aβ (both D-Aβ1-40 and Aβ1-42). Although Hsp20, Hsp27, 
and αB-crystallin demonstrated a higher affinity for Aβ1-42 (αB-crystallin>Hsp20>Hsp27), 
HspB8 showed a higher affinity for D-Aβ1-40 (Chapters 4 and 5). Furthermore, we observed 
a reduction in Aβ aggregation upon coincubation of αB-crystallin, Hsp20, Hsp27 and 
HspB8 with D-Aβ1-40, whereas co-incubation of these sHsps with Aβ1-42 did not result in a 
significant reduction in β-sheet formation and, thus, mature Aβ1-42 fibril formation. 
Moreover, HspB2/B3 did not affect fibril formation of both D-Aβ1-40 and Aβ1-42 (Chapters 4 
and 5).  
In vessels affected by CAA, both smooth muscle cells and pericytes degenerate as a 
result of Aβ deposition (21). Incubation of human brain pericytes (HBPs) with D-Aβ1-40 or 
Aβ1-42 results in accumulation of Aβ at the cell surface, as demonstrated previously by us 
(340). Co-incubations of Hsp20, Hsp27 and αB-crystallin with both D-Aβ1-40 and Aβ1-42 
resulted in an inhibition of Aβ-mediated cell death (αB-crystallin>Hsp20>Hsp27), 
although these sHsps seemed to inhibit Aβ1-42 more efficiently than D-Aβ1-40. In contrast, 
HspB8 inhibited D-Aβ1-40-mediated cell death, whereas effects on toxicity induced by Aβ1-
42 were absent (Chapters 4 and 5). Surprisingly, the capacity of sHsps to inhibit Aβ-
mediated cell death correlates with their binding affinity for the type of Aβ (D-Aβ1-40 or 
Aβ1-42), but not with their ability to induce Aβ aggregation. This suggests that sHsps might 
not inhibit mature fibril formation, but prevent the formation of toxic intermediates. In 
addition, sHsps might also interfere with the binding of Aβ or Aβ aggregates to the cell 
surface.  
Given the direct link between Aβ accumulation in the brain of AD patients and 
inflammation, it is suggested that this Aβ accumulation triggers inflammation in AD (374). 
Cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor α 
(TNF-α), are all upregulated in AD (305). This upregulation is associated with microglial 
activation, astrogliosis and enhanced secretion of other proinflammatory molecules and 
Aβ (371). In AD, an inflammatory reaction is associated with SPs, whereas in CAA, only 
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activation of the complement system occurs (149). In contrast, activated microglia and 
astrocytes are associated with CAA in HCHWA-D brains, but not with SPs (26, 375). We 
observed that only those sHsps that occur extracellularly and are associated with Aβ in 
SPs and CAA in AD and HCHWA-D, such as Hsp20, HspB2/B3 and HspB8, induce a 
much more pronounced IL-6 production in cultured HBPs and astrocytes (Chapter 6), 
than αB-crystallin and Hsp27, that do not appear extracellularly, and even more than Aβ 
itself (243, 244). Our data suggest that chaperones, such as the sHsps, that colocalise with 
Aβ in SPs and CAA might contribute to the local inflammation more than Aβ itself. 
Table I provides a summary of the interaction of αB-crystallin, Hsp20, Hsp27, 
HspB2/B3 and HspB8 with both D-Aβ1-40 and Aβ1-42, the effect of these sHsps on Aβ 
aggregation, their capacity to inhibit Aβ-mediated cell death, and their ability to induce 
IL-6 secretion by HBPs and astrocytes. In conclusion, direct binding of sHsps to Aβ 
regulates both the interaction of Aβ with the cell surface and Aβ toxicity. However, this 
effect dependents on both the type Aβ and type of sHsps. Furthermore, extracellular sHsps 
contribute to the inflammatory response resulting in both vascular and neuronal damage. 
  
The role of Apolipoprotein E in amyloid-β toxicity towards cerebrovascular cells  
Ever since the ApoE ε4 genotype was identified as a risk factor for AD, many research 
groups have tried to identify a biological explanation for this epidemiological observation. 
ApoE binds to Aβ and affects its fibrillogenesis, possibly in an isoform-specific manner 
(ε2<ε3<<ε4) (53, 55, 398). In other studies, isoform-specific neurotrophic or neurotoxic 
effects have been described for ApoE (440-442). In Chapter 7 we provide a novel 
explanation that may, in part, account for the association of ApoE with AD development. 
We demonstrated an ApoE genotype-dependent effect on Aβ-mediated toxicity towards 
HBPs and human leptomeningeal smooth muscle cells (HLSMCs), since cultured HBPs 
with an ApoE ε4/ε4 genotype were more vulnerable to Aβ-mediated cytotoxicity than 
cells with other ApoE genotypes. In addition, we observed an ApoE concentration-
dependent inhibition of Aβ-mediated toxicity of human cerebrovascular cells. Therefore, 
we suggested that the production level of ApoE protein may at least, in part, depend on 
the ApoE genotype and directly correlate to the cell’s vulnerability to Aβ-mediated cell 
death.  
 
The LRP-1 and LDL receptor in amyloid-β internalization and cytotoxicity 
Clearance of Aβ from AD brains is, in part, mediated by vascular Aβ-receptors that 
transfer Aβ across the blood-brain barrier (BBB) into the circulation (132). Alternatively, 
Aβ-receptors may also play a role in the Aβ clearance via phagocytosis by microglia and 
astrocytes (163, 164). Both the low-density lipoprotein receptor (LDLR) and the low-
density lipoprotein receptor related protein-1 (LRP-1) expressed by both endothelium and 
astrocytes might contribute to the clearance of Aβ from the brain (133, 191, 426, 427). In 
our immunohistochemical study, we found association of LRP-1, LDLR, receptor for 
advanced glycosylated end products (RAGE) and scavenger receptor CD36 with CAA in 
both AD and HCHWA-D brains (Chapter 8). In addition, we observed an Aβ-mediated 
upregulation of LRP-1 and LDLR by cerebrovascular cells such as pericytes and smooth 
muscle cells in culture. Furthermore, we observed internalization of Aβ by these cells, 
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probably mediated by both the LRP-1 and LDLR receptor. Finally, we demonstrated that 
both receptors play a role in the regulation of Aβ-mediated death of cerebrovascular cells, 
since the LRP-1 and LDLR receptors antagonist receptor-associated protein (RAP) and 
cycloheximide reduced Aβ-mediated death (Chapter 8). These data suggest that 
perivascular cells internalize Aβ via both LRP-1 and LDLR, and that increasing amounts 
of Aβ result in an increase of Aβ uptake by these cells, probably as an attempt to clear Aβ 
more efficiently. Yet, this “frustrated” clearance of Aβ might result in Aβ-induced cell 
death of perivascular cells, as observed in CAA. 
 
In summary, the major conclusions of our immunohistochemical, biochemical and cell 
culture studies are that: 
1. Several members of the sHsp family, including αB-crystallin, Hsp20, Hsp27, 
HspB2/B3 and HspB8, are associated with the pathological lesions of both AD and 
HCHWA-D brains (Table I). 
2. αB-crystallin, Hsp20, Hsp27 and HspB8 bind to Aβ directly, affect β-sheet 
formation, and are effective inhibitors of Aβ-mediated toxicity towards 
cerebrovascular cells (Table I). 
3. Hsp20, HspB2/B3 and HspB8 colocalize with extracellular Aβ deposits and induce 
IL-6 production in cultured HBPs and astrocytes (Table I). 
4. ApoE genotype affects Aβ-mediated toxicity towards cerebrovascular cells in an 
isoform-dependent manner (ε2>ε3>ε4). 
5. Aβ-mediated toxicity towards HBPs and HLSMCs is inhibited by ApoE in a 
concentration-dependent manner. 
6. Aβ-receptors LRP-1, LDLR, RAGE and CD36 are associated with CAA in both AD 
and HCHWA-D brains. 
7. Aβ is internalized via both the LRP-1 and LDL receptor in HBPs and HLSMCs and 
induces upregulation of both receptors in these cells. 
8. Aβ-mediated cell death of cerebrovascular cells is regulated by both LRP-1 and 
LDLR. 
9. Both HBPs and HLSMCs play a role in clearance of Aβ from the brain.   
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   Table I. Summary of the distribution of sHsps in AD and HCHWA-D brains and of the interactions of sHsps with Aβ. 
 Analysis  αB-
crystallin 
Hsp20 Hsp27  HspB2/B3 HspB8 
Colocalization 
with Aβ in 
classic SPs 
IHC AD no yes yes** yes* yes 
AD no yes no no no Colocalization 
with Aβ in 
diffuse SPs 
IHC 
HCHWA-D no no no no no 
AD no no no yes* no Colocalization 
with Aβ in 
CAA 
IHC 
HCHWA-D no yes no yes* yes 
Aβ1-42 ±1.1 × 10-9     ±7.8 × 10-7      ±1.1 × 10-6      ND ±9.7 × 10-7 Binding affinity 
for Aβ (relative 
KD in M, mean 
± SE) 
SPR 
D-Aβ1-40 ±1.7 × 10-7      ±1.1 × 10-6      ±1.4 × 10-6      ND ±1.6 × 10-9 
Aβ1-42 Not 
Significant 
Not 
Significant 
Not 
Significant 
Not 
Significant 
Not Significant Reduction of β-
sheet formation  
CD 
 
D-Aβ1-40 Significant Significant Significant Not 
Significant 
Significant 
Aβ1-42 - - - - Not determined Reduction of 
mature Aβ 
fibril 
formation1 
EM 
D-Aβ1-40 +++ ++ ++ + Not determined 
Aβ1-42 1:50 1:5 1:1 >>1:1 - Molar ratio 
(sHsps:Aβ) at 
which complete 
inhibition of 
Aβ-mediated 
cell death is 
achieved 
Viability
assay 
D-Aβ1-40 1:5 1:1 >>1:1 >>1:1 2:1 
Induction of 
Interleukin-6 
secretion by 
HBPs 
ELISA HBP and 
Astrocytes 
no yes no yes yes 
  1Effects on β-sheet formation or fibril formation is categorized in the following order: +++ (strong effect),  ++ (moderate 
effect), +  (minor effect), - (no effect). SPR (surface plasmon resonance), CD (circular dichroism spectroscopy), EM 
(electron microscopy), ND (no detectable binding), SE (standard error), AD (Alzheimer’s disease), HCHWA-D 
(hereditary cerebral hemorrhage with amyloidosis of the Dutch type), SPs (senile plaques), CAA (cerebral amyloid 
angiopathy), IHC (immunohistochemistry), HBP (human brain pericytes).  * Only immunoreactivity of HspB2 was 
analyzed. ** Only a small percentage of the classic SPs demonstrated Hsp27 immunostaining. 
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Discussion 
 
Chaperones in amyloid-β aggregation, accumulation and clearance 
In AD, Aβ interacts with itself, resulting in the formation of Aβ aggregates. As a result of 
this self-interacting property of Aβ, various molecular forms, ranging from relatively 
soluble monomers, to an increasing state of aggregation in the form of oligomers, 
protofibrils and mature fibrils, exist in human brain (443). Nowadays, Aβ intermediates, 
such as oligomers and protofibrils, are assumed to be the toxic variants of Aβ that cause 
degeneration of neurons in AD (444). 
Amateur and professional chaperones, such as ApoE and the sHsps, bind Aβ and 
interfere with the aggregation process of Aβ. ApoE promotes aggregation of Aβ in vitro 
(97, 98, 183), whereas sHsps inhibit the aggregation process (Chapters 4 and 5). Promotion 
of Aβ aggregation, as described for ApoE and heparan sulfate proteoglycans (HSPGs) (103, 
108-110), might prevent neurotoxicity by avoiding the existence of neurotoxic 
intermediates, such as Aβ oligomers and protofibrils. In line with these data, we observed 
that the level of ApoE, contributes to protection from Aβ-mediated cell death of 
cerebrovascular cells (Chapter 7). Cultured cerebrovascular cells expressing the ApoE3 
isoform produced more ApoE, and were less vulnerable to Aβ-mediated cell death, 
compared to ApoE4 cells. Thus, the presence of higher levels of ApoE might induce a 
higher turnover of Aβ towards the more harmless fibrillar Aβ forms. However, if similar 
concentrations of ApoE3 and ApoE4 result in an equal turnover of Aβ remains to be 
demonstrated. After purification of ApoE4 from an ApoE4 genotype cell type, as 
demonstrated for ApoE3 (Chapter 7), co-incubation of HBPs with equal amounts of either 
ApoE4 or ApoE3 might elucidate this question. In addition to the ApoE levels, the 
isoform-specific binding of ApoE to Aβ  (ε2<ε3<<ε4) (53, 55, 398) might also contribute to 
this conversion into aggregated Aβ. Furthermore, the physiological state of ApoE might 
also play an important role in the interaction with Aβ. Only physiologically secreted 
ApoE affected Aβ-mediated toxicity, whereas recombinant, naive, ApoE was ineffective. 
Indeed, binding of ApoE to Aβ may be modulated by the degree of lipidation of ApoE 
(95). In conclusion, the ApoE isoform, ApoE levels, and degree of lipidation of ApoE may 
contribute to the biological function of ApoE in vivo, and thus, its role in the pathogenesis 
of AD.  
 In contrast to ApoE, sHsps inhibit aggregation of Aβ as described in Chapters 4 and 
5. This inhibition protects cultured cerebrovascular cells from Aβ-mediated cell death, 
probably by preventing the accumulation or binding of Aβ to the cell surface. SHsps, such 
as Hsp20, HspB8, Hsp27 and HspB2/B3 interfere with Aβ aggregation and reduce the 
amount of β-sheets formed. However, these sHsps do not prevent the formation of mature 
fibrils. In contrast, αB-crystallin inhibits the formation of mature fibrils and arrests Aβ 
aggregation at the level of protofibril-like structures, which are non-toxic for 
cerebrovascular cells. Thus, although there are differences in the effects on Aβ aggregation 
of members of the sHsp family, in general, sHsps interact with Aβ aggregation and are 
able to form Aβ/chaperone complexes that are non-toxic to cerebrovascular cells. In 
contrast, these specific complexes might be even be more toxic towards other cell types, 
since αB-cystallin/Aβ-complexes have been reported to be more toxic to neurons than Aβ 
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alone (249). This suggests that Aβ intermediates initiated by these chaperones might be 
toxic towards neurons, yet protective towards cerebrovascular cells. However, the effects 
of sHsps on Aβ aggregation in vivo are probably even more complex. Although sHsps 
function as chaperones intracellularly, we observed sHsps in extracellular deposits. There, 
sHsps might interact with Aβ and Aβ intermediates as a complex composed of multiple 
members of the sHsp family, since sHsps bind with each other and from functional 
hetero-complexes in vivo. Analysis of the cerebral spinal fluid (CSF) might confirm if 
sHsps are able to form such a functional complex extracellularly. In addition, although 
sHsps have been found extracellularly, both the cellular source and the extracellular 
amounts of sHsps in the human brain are unknown. We observed a concentration-
dependent effect of extracellular sHsps on Aβ aggregation and inhibition of Aβ-mediated 
toxicity. Yet, it remains to be investigated if extracellular levels of sHsps in human brain 
are sufficient to contribute to an inhibition of Aβ aggregation in vivo. Analysis of the CSF 
may provide an indication of the extracellular sHsps levels present in the brain, although 
local sHsps levels might vary. Furthermore, immunoprecipitation of the CSF might reveal 
if sHsp/Aβ-complexes are formed in the brain, as observed in our in vitro data. In 
addition, analysis of sHsp level in the CSF might also reveal if sHsp levels changes during 
normal aging, or during AD disease progression. If this is true, sHsps levels in the CSF 
might serve as a diagnostic marker for AD. A decrease of Hsp has already been 
demonstrated in aged rats (255), indicating that levels of Hsps might alter during aging. 
Furthermore, the chaperone activity of isolated extracellular sHsps from the brain, via the 
CSF, could be analyzed. Apart from the sHsp levels, bioactivity of chaperones might also 
alter in aging, which might result in a less efficient defence mechanism against Aβ 
aggregation.  
 SHsps bind Aβ and prevent its aggregation in vitro. These properties of sHsps 
suggest the use of this protein family in therapeutic approaches. As demonstrated for 
gelsolin (161), sHsps might function as a peripheral sink for Aβ by binding Aβ in the 
circulation and initiate clearance of Aβ from the brain, as described in Chapter 2. This 
hypothesis could be tested by periodic intravenous injections of αB-crystallin, since this 
sHsps demonstrated a high affinity for Aβ in vitro, in transgenic mouse models for AD. 
Apart from the use of αB-crystallin as a peripheral sink, αB-crystallin might also cross the 
BBB and prevent aggregation of Aβ in the brain. However, to do so αB-crystallin needs to 
cross the BBB. The use of smaller proteins, which cross the BBB more easily, with similar 
properties towards Aβ might therefore be promising. Recently, the functional element of 
αB-crystallin was found, which also demonstrates chaperone activity (447). These types of 
small functional chaperones might therefore not only serve as a peripheral sink for Aβ, 
but might also cross the BBB and prevent Aβ aggregation in the brain. 
 The natural function of sHsps is to prevent proteins from misfolding 
intracellularly. This might suggest that sHsps already interact with Aβ intracellularly, and 
prevent the aggregation of Aβ within the cell. In addition, sHsps might also play a role in 
the degradation of internalized Aβ by recognizing aggregated Aβ and traffic it to the 
proteasome. Colocalization of sHsps with Aβ intracellularly could be analyzed using 
confocal laser scanning microscopy. In addition, by incubating cells with biotin-labelled 
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Aβ, the routing of Aβ through the cell could be analyzed and possible interactions with 
sHsps could be demonstrated.    
In addition to the role of chaperones in Aβ aggregation, they might also contribute 
to clearance of Aβ from the brain, either by directly regulating Aβ transport across the 
BBB, or by keeping Aβ in a conformation that is cleared more efficiently. Transport of Aβ 
cross the BBB is mediated by Aβ-receptors, such as LRP-1 and LDLR (Chapter 8) that 
transport Aβ or a chaperone/Aβ-complex, such as the ApoE/Aβ-complex. Clearance of 
Aβ/ApoE-complexes from brain might be dependent on both ApoE isoform and ApoE 
levels. ApoE4 forms less stable complexes with Aβ than ApoE3 or ApoE2, and thus, ApoE4 
might reduce Aβ transport efficacy across the BBB. In addition, higher ApoE levels, as in 
ApoE3 carriers compared to ApoE4 carriers, might contribute to Aβ transport across the 
BBB. However, it is unknown if Aβ or Aβ/ApoE-complexes are transported equally 
efficient, or if ApoE levels in the brain are sufficient to bind all Aβ present. In addition to 
the Aβ-internalization experiments described in Chapter 8, the role of ApoE levels in 
internalization of Aβ by cerebrovascular cells could be investigated by coincubating Aβ 
with purified ApoE (as described in Chapter 7). These co-incubation experiments of Aβ 
with ApoE might elucidate the role of ApoE in Aβ internalization by cerebrovascular 
cells. Similar experiments with coincubation of sHsps with Aβ might reveal if sHsps 
contribute to the internalization and clearance of Aβ by cerebrovascular cells by keeping 
Aβ in an intermediate form.   
In addition, properties of Aβ-receptors might also play a role in Aβ clearance, since 
the LDL receptor shows a marked preference for the ApoE3 and ApoE4 isoforms and 
binds the ApoE2 isoform poorly (302). Given the similarity between the LDL receptor 
family, other LDL receptors, such as the LRP-1 receptor, might display similar specificities 
towards the ApoE isoforms. Moreover, lipidation of ApoE might also affect the clearance 
of ApoE and ApoE/Aβ-complexes from the brain, since LRP prefers lipid-bound forms of 
ApoE (302). These data suggest that Aβ-binding proteins, such as ApoE, directly 
contribute to transport of Aβ across the BBB, and that the ApoE isoform, levels and 
lipidation state might affect Aβ clearance. 
Binding of sHsps with Aβ might result in the formation of Aβ-intermediates. 
Transport of aggregated Aβ out of the brain is less efficient than soluble Aβ (168). 
Therefore, sHsps might contribute to clearance of Aβ from brain by keeping Aβ in a more 
soluble form. However, which Aβ-intermediates are formed by binding of sHsps to Aβ in 
vivo, and how this binding will affect the clearance of Aβ, remains to be determined.  
 
Development of cerebral amyloid angiopathy in Alzheimer’s disease 
Accumulation of Aβ in the vessel walls in human brain results in development of CAA. 
The cellular source of this Aβ is probably neuronal, although several other cell types, such 
as cerebrovascular cells, astrocytes and microglia, may also contribute to extracellular Aβ 
levels in brain. Via interstitial fluid drainage, Aβ is transported towards the brain 
capillaries. Normally, Aβ-receptors located on the endothelial cells of the brain capillaries, 
such as the LRP-1 and LDL receptors, internalize Aβ and transport it across the BBB to the 
blood. However, as a reaction to Aβ, LRP-1 expression on endothelial cells is decreased 
(168), probably resulting in less Aβ internalization and transport by endothelial cells. Via 
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interstitial fluid drainage, increasing levels of Aβ are transported towards the larger brain 
vessels where it accumulates in the adventitia (445, 446). As described in Chapter 8, the 
increasing levels of Aβ induce both LRP-1 and LDLR upregulation in HBPs and SMCs. 
This upregulation is probably an attempt of the perivascular cells to clear the locally 
increasing levels of Aβ. Eventually, this “frustrated clearance” of Aβ by perivascular cells, 
via internalization and transport of Aβ to the endothelial cells, results in the degeneration 
of these cell types (339, 341, 350), generating an Aβ “seed” that induces further 
accumulation of Aβ in the vascular wall leading to CAA. If this upregulation of both LRP-
1 and LDLR as a reaction to increasing Aβ levels also occurs in vivo might be 
demonstrated in transgenic AD mouse models, by analyzing the expression levels of LRP-
1 and LDLR during the different stages of AD development.       
 
The role of chaperones in inflammation in Alzheimer’s disease  
Neuroinflammation in AD comprises both activation of microglial cells and astrocytes, 
and activation of the complement system. Aβ deposits in brain are associated with 
activated microglia and astrocytes, but also with elevated levels of complement (163, 164, 
215). The Aβ protein itself activates both astrocytes and microglia, and triggers the 
complement system (114-116). Furthermore, Aβ induces increased expression of the major 
histocompatibility complex II (MHC II), pro-inflammatory cytokines, such as IL-1β, IL-6 
and TNFα, and chemokines in microglia (122, 169). We observed that chaperones that 
accumulate in extracellular Aβ deposits, such as the Hsp20, HspB2/B3 and HspB8, induce 
IL-6 secretion in cerebrovascular cells and astrocytes, more than Aβ itself (Chapter 6). 
This might indicate that chaperones that colocalize with Aβ in SPs and CAA contribute to 
the inflammation observed in AD. However, we only observed an induction of IL-6 and 
not of IL-1β or TNFα. Furthermore, it remains to be elucidated if IL-6 upregulation alone 
is sufficient enough to induce an inflammatory reaction in vivo, and if other cell types, 
such as microglial cells, are also triggered by these chaperones to induce pro-
inflammatory agents. Thus, further research needs to clarify the possible role of 
chaperones in the inflammation process in AD.   
 
Chaperones and the Aβ protein: clues for therapy 
Studies in which chaperones are used to interfere with protein aggregation as a possible 
therapeutic target are accumulating. Interesting candidates for therapeutic intervention 
are the heparan sulfates, that bind to Aβ and interfere with its fibrillogenesis (213). 
Glycosaminoglycan mimetics are able to inhibit this binding and may block the formation 
of β-pleated sheets and adherence of Aβ to the cell surface (214). The use of 
glycosaminoglycan mimetics is already being tested in mouse models, where they reduce 
the progression of inflammation-associated amyloid (111). However, the bioavailability of 
these compounds in human patients remains to be improved. Aggregation and 
accumulation of Aβ in AD is representative for all amyloidoses, therefore the inhibitory 
effects on aggregation and accumulation of Aβ by chaperones in AD might not only 
provide new therapeutic approaches for AD, but also for other neurodegenerative 
diseases. Evidence for a possible common mechanism of chaperones towards several 
neurodegenerative diseases, such as Parkinson’s disease, are accumulating. For instance, 
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αB-crystallin directly interacts with α-synuclein and seems to inhibit α-synuclein 
fibrillization (448), and HSPGs are capable of inducing the formation of α-synuclein 
fibrils (449).  
A pitfall in the use of professional chaperones as therapeutic agents, however, is 
their ability to bind misfolded proteins and keep them in an intermediate conformation. 
This type of conformation might even be more toxic than the aggregated state, since Stege 
and co-workers demonstrated that co-incubations of αB-cystallin with Aβ are more toxic 
to neurons than Aβ alone (249). Detailed preclinical analysis of the toxic effects of 
chaperone/Aβ aggregates is, therefore, required.                
 
Conclusion 
Chaperones such as the heat shock protein family, apolipoproteins, HSPGs and 
complement factors all affect aggregation, persistence and clearance of misfolded protein 
aggregates, characteristic of neurodegenerative diseases. This suggests that these 
chaperones might form interesting therapeutic targets in the prevention and treatment of 
neurodegenerative diseases. Administration of several of these chaperones already showed 
an inhibiting effect on the development of toxic aggregates and a positive effect on the 
clearance of these aggregates in vivo.  However, the normal functions of these chaperones 
are numerous and in some cases largely unknown, just as their expression and properties 
in normal and pathological conditions. Furthermore, heat shock proteins are most likely 
to be involved in the early development of neurodegenerative diseases, given their natural 
function. Yet, the role of this protein family in the development of the lesions in 
neurodegenerative diseases remains to be clarified. Therefore, studying the role of 
chaperones in the development of neurodegenerative diseases might provide us with a 
better understanding of the mechanisms underlying the formation of toxic aggregates in 
neurodegenerative diseases.   
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 In 1907 werd voor het eerst de ziekte van Alzheimer beschreven door de Duitse 
psychiater Alois Alzheimer. Deze ziekte blijkt de belangrijkste vorm van dementie te zijn 
en wordt gekenmerkt door achteruitgang van het korte-termijn geheugen. Naarmate de 
ziekte vordert, gaat ook het verstandelijke geheugen achteruit en vinden er 
persoonlijkheidsveranderingen plaats.  
Ondanks de stijging van het aantal testen die de ziekte van Alzheimer mogelijk 
kunnen detecteren, zoals bloedonderzoek, neuropsychologische testen, neuroimaging 
(MRI) en biochemische analyses van de hersenvloeistof, is de uiteindelijk diagnose alleen 
mogelijk met behulp van histologisch onderzoek van de hersenen van de patiënt. Het 
belangrijkste kenmerk van de hersenen van patiënten met de ziekte van Alzheimer is 
atrofie van een aantal hersengebieden, ontstaan door de degeneratie van neuronen 
(zenuwcellen). Op microscopisch niveau zijn er drie typische afwijkingen te vinden die 
kenmerkend zijn voor de ziekte van Alzheimer. Ten eerste zijn er de seniele plaques (SPs), 
eiwitophopingen in de hersenen, die voornamelijk bestaan uit aggregaten van het 
amyloid-beta (Aβ) eiwit. Daarnaast zijn er eiwitneerslagen terug te vinden in neuronen. 
Dit zijn de zogenaamde neurofibrillaire tangles (NFTs), die zich kenmerken door 
ophoping van het tau eiwit. Zowel SPs als NFTs hebben sterfte van neuronen tot gevolg. 
Het derde en laatste kenmerk zijn aggregaten van het Aβ eiwit in de wand van 
hersenvaten, cerebrale amyloid angiopathy (CAA) genaamd. Dit proces is er de oorzaak 
van dat cellen die onderdeel uit maken van de hersenbloedvaten, zoals pericyten en 
gladde spiercellen, sterven en dat er daardoor hersenbloedingen kunnen ontstaan. Naast 
het ontstaan van SPs, NFTs en CAA in AD hersenen, vindt er ook een ontstekingsreactie 
plaats die geassocieerd is met deze afwijkingen. Een kenmerk van deze ontstekingsreactie 
is het verschijnen van specifieke cellen, zoals astrocyten en microglia, rondom de AD 
afwijkingen. 
Het Aβ eiwit dat zich ophoopt in SPs en CAA is een sptitsingsproduct van het 
amyloid precursor eiwit APP. Door middel van enzymen worden voornamelijk twee 
vormen van Aβ geknipt, Aβ1-40 en Aβ1-42. Mutaties in het APP, zowel binnen als buiten de 
Aβ regio, kunnen ertoe leiden dat er sneller en meer Aβ ophoping plaatsvindt in de vorm 
van SPs en CAA. Een voorbeeld hier van is de “Dutch” mutatie in Aβ, die ervoor zorgt dat 
dragers fatale hersenbloedingen krijgen op een relatief jonge leeftijd. Deze mutatie, 
waarbij een extra toxische vorm van Aβ ontstaat (D-Aβ) die vooral CAA veroorzaakt, is 
ontdekt in een Nederlandse familie en is genaamd: “hereditary cerebral hemorrhage with 
amyloidosis of the Dutch type (HCHWA-D)”.  
Het Aβ eiwit kan een binding aangaan met andere Aβ moleculen en zo aggregaten 
vormen die zich ophopen en SPs en CAA vormen. Tijdens het aggregatieproces van Aβ 
ontstaan een aantal specifieke vormen, zoals Aβ oligomeren, protofibrillen en uiteindelijk 
volwassen Aβ fibrillen. In de hersenen komt echter niet alleen Aβ voor, maar er zijn ook 
allerlei andere eiwitten die aan het Aβ eiwit kunnen binden en die zo hun invloed 
kunnen uitoefenen op het aggregatieproces van Aβ.  
In dit proefschrift is gekeken naar eiwitten die colokaliseren met SPs, NFTs en 
CAA, binden aan Aβ en zo het aggregatieproces beïnvloeden, en die eventueel betrokken 
zijn bij het ontstekingsproces in AD. Ten eerste is gekeken naar een familie van eiwitten, 
de zogenaamde “small heat shock” eiwitten. Ten tweede naar een eiwit dat een rol speelt 
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bij het cholesteroltransport, het apolipoproteïne E. Verder werd er in dit proefschrift 
onderzocht of Aβ-receptoren betrokken zijn bij de klaring van Aβ uit de hersenen over de 
bloed-hersen barrière en of deze receptoren verantwoordelijk zijn voor de door Aβ-
geïnduceerde celdood van cellen van hersenvaten. 
 
Hoofdstuk 2 betreft een literatuur studie over de rol van diverse Aβ-bindende 
eiwitten in het aggregatieproces van Aβ, de ophoping van Aβ in de hersenen, de rol van 
deze Aβ-bindende eiwitten in de ontstekingsreactie in het AD hersenen, en de klaring van 
Aβ uit de hersenen. Diverse eiwitten colokaliseren met Aβ in SPs en CAA en met tau in 
NFTs: “amateur” chaperonnes zoals apolipoproteïne E, heparan sulfaat proteoglycanen 
(HSPGs), complement factoren, maar ook “professionele” chaperonnes zoals diverse leden 
van de heat shock proteïne familie. Deze amateur chaperonnes en professionele 
chaperonnes kunnen invloed hebben op de aggregatie van Aβ. Zo versnellen 
apolipoproteine E (ApoE) en HSPGs de aggregatie van Aβ, terwijl leden van de kleine heat 
shock proteïne familie de aggregatie remmen. Verder kunnen deze chaperonnes ook effect 
hebben op de ontstekingsreactie die in de hersenen in van een Alzheimer patiënt. Tevens 
hebben zij effect op de klaring van Aβ uit de hersenen via Aβ-receptoren op hersenvaten, 
die Aβ van de hersenen naar het bloed transporteren, of via opname en afbraak van Aβ 
door astrocyten en microglia cellen in de hersenen. 
 
In hoofdstuk 3 tot en met hoofdstuk 6 werd de colokalisatie van small heat shock 
proteïnes (sHsps) met de afwijkingen van de ziekte van Alzheimer en HCHWA-D 
beschreven. Verder werd gekeken naar de binding van sHsps, zoals αB-crystalline, Hsp20, 
Hsp27, HspB2/B3 en HspB8 met verschillende vormen van Aβ, en het effect van deze 
sHsps op de aggregatie van Aβ. Met behulp van gekweekte hersenpericyten en gladde 
spiercellen werd nagegaan of de sHsps deze cellen kunnen beschermen tegen celdood, 
veroorzaakt door Aβ. 
Er werd aangetoond dat Hsp20 colokaliseert met Aβ in zowel klassieke als diffuse 
SPs in AD hersenen. Hsp27, HspB2 en HspB8 komen echter alleen voor in klassieke SPs in 
AD hersenen. Verder colokaliseren alleen Hsp20 en HspB2 met CAA in AD hersenen. In 
HCHWA-D hersenen colokaliseert geen van de sHsps met Aβ in SPs, terwijl Hsp20, 
HspB2 en HspB8 colokaliseren met CAA in deze hersenen. Deze data geven aan dat, 
ondanks dat sHsps  onderling erg homoloog zijn, zij kennelijk verschillen voor wat betreft 
hun invloed op de ontwikkeling van SPs en CAA in zowel AD als HCHWA-D hersenen. 
Met behulp van bindingsstudies werd vervolgens vastgesteld dat sHsps inderdaad 
verschillen in affiniteit voor verschillende Aβ’s, zoals Aβ1-42 en D-Aβ1-40. De sHsps, αB-
crystalline, Hsp20 en Hsp27 toonden een hogere affiniteit voor Aβ1-42, terwijl HspB8 juist 
beter aan D-Aβ1-40 bond. Naast het binden van deze sHsps aan Aβ, waren ze ook in staat de 
aggregatie van Aβ te remmen. HspB2/B3 toonde geen binding met beide vormen van Aβ, 
en had ook geen effect op de aggregatie. Met behulp van gekweekte pericyten en gladde 
spiercellen is vervolgens gevonden dat de sHsps die aan Aβ bonden ook Aβ-geïnduceerde 
celdood van beide celtypen konden remmen, waarschijnlijk omdat ze voorkomen dat Aβ 
kan binden aan het celoppervlak. Deze data suggereren dat sHsps Aβ-geïnduceerde 
celdood kunnen remmen door te binden aan Aβ. Deze interactie belemmert vervolgens de 
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verdere aggregatie van Aβ en voorkomt binding van Aβ aan het celoppervlak van 
pericyten en gladde spiercellen, hetgeen uiteindelijk voorkomt dat Aβ celdood kan 
induceren. Aangezien sHsps colokaliseren met Aβ in SPs en CAA, binden aan Aβ, effect 
hebben op Aβ aggregatie, en cerebrovasculaire cellen beschermen tegen Aβ-gemedieerde 
celdood, duidt dit sterk op een rol van sHsps in de pathogenese van zowel SPs als CAA. Of 
de interactie van sHsps met Aβ in de hersenen daadwerkelijk soortgelijke effecten laat 
zien zal nog moeten worden onderzocht.    
Omdat in AD een toename van de aanwezigheid van sHsps werd gevonden is er 
gekeken of pericyten of astrocyten mogelijk de bron van deze verhoging in AD hersenen 
zijn. Er werd echter geen effect op sHsp expressie gevonden in gekweekte pericyten en 
astrocyten na blootstelling aan Aβ. Incubatie van deze cellen met sHsps die colokaliseren 
met Aβ ophoping in SPs en CAA, zoals Hsp20, HspB2/B3 en HspB8 resulteerde 
daarentegen in een verhoging van de productie van een cytokine, interleukine-6 (IL-6), 
tewijl αB-crystalline, Hsp27 en Aβ dit effect niet lieten zien. Deze data wijzen erop dat 
eiwitten die colokaliseren met Aβ in SPs en CAA, zoals Hsp20, HspB2/B3 en HspB8, een 
belangrijkere rol bij het oproepen van ontstekingsreacties in AD hersenen hebben, dan Aβ 
zelf. Of de IL-6 inductie, zoals aangetoond in celkweek, ook voldoende is om bij te dragen 
aan de ontstekingsreactie in de hersenen in vivo, zal nog moeten worden geanalyseerd. 
 
In hoofdstuk 7  werd gekeken naar het effect van het ApoE genotype van pericyten 
en gladde spiercellen op de productie van ApoE door deze cellen, en het effect op de 
gevoeligheid voor Aβ van deze cellen. De mens kan verschillende genotype hebben van 
het ApoE gen (ε2, ε3 en ε4). Dragerschap van een ApoE4 genotype, en dus het hebben van 
de ApoE4 isovorm van het eiwit, is een belangrijke risicofactor voor het krijgen van de 
ziekte van Alzheimer. De binding van ApoE aan Aβ is isovorm-afhankelijk (ε2<ε3<<ε4). 
Gekweekte cellen met verschillend ApoE genotype toonden een verschil in vatbaarheid 
voor Aβ. Zo waren cellen met een ApoE4 isotype vatbaarder voor Aβ-gemedieerde 
celdood, dan cellen met een ApoE3 isotype. Dit verschil bleek verklaard te kunnen 
worden door de mate van ApoE productie van de cellen met verschillend ApoE 
genotypen. Zo maakten cellen met een ApoE4 genotype minder ApoE dan cellen met een 
ApoE3 genotype. Deze data suggereren dat naast het verschil in binding tussen de ApoE 
isovormen met Aβ ook een verschil in productie een oorzaak ervan is waarom mensen 
met een ApoE4 genotype een verhoogd risico hebben op het krijgen van de ziekte van 
Alzheimer. 
 
In hoofdstuk 8 werd gekeken naar de rol van Aβ-receptoren bij het ontstaan van 
CAA en Aβ-gemedieerde celdood van cerebrovasculaire cellen en astrocyten. In AD vindt 
een verstoring van de balans tussen Aβ productie en verwijdering plaats, waardoor er Aβ 
kan ophopen in de hersenen. Aβ kan op twee manieren de hersenen verlaten. Ten eerste 
kan het via Aβ-receptoren, die op endotheelcellen tot expressie komen, actief van de 
hersenen naar de bloedsomloop getransporteerd worden. Ten tweede kunnen microglia 
cellen en astrocyten Aβ opnemen via fagocytose en vervolgens afbreken. In CAA slaat Aβ 
in de vaatwand voornamelijk neer in de grotere hersenvaten. Dit resulteert in degeneratie 
van zowel gladde spiercellen als pericyten. Gezien de rol van Aβ-receptoren in het 
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verwijderen van Aβ uit de hersenen, hebben wij gekeken naar expressie van de 
verschillende Aβ-receptoren op: a) de verschillende vaten in de hersenen, en b) 
hersenvaten van normale patiënten, AD patiënten en HCHWA-D patiënten. 
Immunohistochemische analyse van de diverse hersenen toonde aan dat de Aβ-receptoren 
APP, CD36, RAGE, LDLR en LRP-1 voornamelijk voorkomen in de grote hersenvaten, 
terwijl MDR-1 voornamelijk tot expressie kwam op capillairen. De Aβ-receptoren megalin 
en FPRL1 kwamen helemaal niet voor op hersenvaten. Dit suggereerde dat, ondanks dat 
het allemaal Aβ-receptoren zijn, er toch een verschil in lokalisatie van deze receptoren op 
hersenvaten is, en dat zij dus mogelijk verschillend bijdragen aan de klaring van Aβ uit de 
hersenen. Verder colokaliseerde RAGE, LRP-1, LDLR en CD36 met CAA in hersenvaten 
van zowel AD als HCHWA-D patiënten. De expressie van RAGE, LRP-1, LDLR en CD36 
werd ook bevestigd in gekweekte pericyten en gladde spiercellen. In gekweekte 
astrocyten werd tevens expressie van RAGE, LRP-1 en LDLR waargenomen. Na 
bloostelling van zowel cerebrovasculaire cellen als astrocyten aan Aβ, bleek zowel de 
LRP-1 als de LDL receptor verhoogd tot expressie te worden gebracht. Door toevoeging 
van specifieke remmers voor deze receptoren kon worden bewezen dat beide receptoren 
een rol spelen bij de opname van Aβ door cerebrovasculaire cellen, en dat deze opname 
van Aβ via LRP-1 en LDLR direct leidt tot celdood. Deze data geven aan dat 
cerebrovasculaire celdood, zoals we die zien in CAA, veroorzaakt wordt door opname van 
Aβ via de LRP-1 en LDL receptoren. De toename van Aβ in de grote hersenvaten, 
veroorzaakt door de toename van Aβ in AD hersenen, zou kunnen leiden tot een 
verhoogde opname van Aβ door cerebrovasculaire cellen die Aβ proberen te transporteren 
naar het endotheel. Op deze wijze kan het endotheel het Aβ aan het bloed afgeven. 
Echter, deze gefrustreerde poging van de cerebrovasculaire cellen om de toenemende 
hoeveelheden Aβ op te nemen en door te geven aan de endotheelcellen zou wel eens de 
oorzaak kunnen zijn van de degeneratie van deze cellen, en uiteindelijk resulteren in 
CAA.  
  
Dit proefschrift beschrijft de rol van enkele leden van de sHsp familie, van ApoE 
en van de Aβ-receptoren in de pathogenese van AD en HCHWA-D. Chaperonnes, zoals 
leden van de sHsp familie en ApoE, hebben invloed op de aggregatie en toxiciteit van Aβ. 
Dit impliceert dat dit soort chaperonnes een belangrijke rol spelen in het ontstaan van SPs 
en CAA in AD en HCHWA-D. Het gebruik van dit soort chaperonnes blijkt in celkweek 
succesvol te zijn in het voorkomen van Aβ aggregatie en/of Aβ toxiciteit. Ze zijn in staat 
het aggregatie proces te verhinderen of te versnellen, zodat er geen of minder toxische 
tussenvormen kunnen ontstaan. Er wordt gedacht dat er een balans bestaat tussen de Aβ 
concentratie in het bloed en de hersenen. Aβ-chaperonnes kunnen zorgen voor een 
verwijdering van Aβ uit de hersenen, door te binden aan het Aβ in het bloed en het zo 
weg te vangen. Hierdoor wordt de balans van Aβ verstoord en zal er meer Aβ van de 
hersenen naar het bloed worden getransporteerd. 
Het gebruik van chaperonnes als therapie is helaas niet zonder risico. Chaperonnes 
kunnen Aβ binden en gevangen houden in een bepaalde conformatie die juist toxisch is 
voor bepaalde cellen. Verder is het van een aantal chaperonnes, zoals de sHsps, 
onduidelijk hoe zij buiten de cel komen, of ze daar nog een functie hebben, en of de 
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concentratie van deze sHsps toereikend is om Aβ aggregatie te beïnvloeden. Het is daarom 
van groot belang om achter de biologische functie en activiteit van deze chaperonnes in 
het extracellulaire milieu te komen. Het bestuderen van de rol van chaperonnes in de 
ontwikkeling van AD zou ervoor kunnen zorgen dat we een beter inzicht krijgen in de 
onderliggende mechanismen van de toxische aggregaten zoals we die vinden in AD. 
Tevens kunnen deze studies bijdragen aan een beter begrip van andere 
neurodegeneratieve ziekten waar soortgelijke toxische aggregaten een rol spelen, zoals de 
ziekte van Parkinson en de ziekte van Huntington.             
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Figure 4. Staining for sHsps and Aβ at the surface of cultured HBPs. HBP were incubated with 25 μM D-
Aβ1-40 (A and B, cross section) and co-incubated with 1 μM Hsp20, molar ratio (sHsps:Aβ) 1:25 (C, D) and
1:1 (E, F), for 3 days. HBP were co-incubated with 25 μM D-Aβ1-40 and 25 μM of HspB2/B3 (G, H), or
Hsp27 (I, J), or αB-crystallin (K, L), molar ratio 1:1 (sHsps:Aβ), for 3 days. Immunofluorescence staining of
Aβ (40/4, polyclonal, green), Hsp20 (monoclonal, red), HspB2 (polyclonal, red), Hsp27 (monoclonal, red)
and αB-crystallin (monoclonal, red). Magnification x 630. Nuclei are counterstained blue. 
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Figure 4. Staining for HspB8 and Aβ at the surface of cultured HBPs. HBP were co-incubated with D-
Aβ1-40 and HspB8, molar ratio (HspB8:Aβ) 1:25 (A, B) and 1:1 (C, D), for 3 days. Immunofluorescence
staining of Aβ (6C6, monoclonal, green) and HspB8 (polyclonal, red) is shown. Nuclei are counter
stained blue. HspB8 co-localized with Aβ at the cell surface. Cross-section analysis using confocal laser
scanning microscopy demonstrated co-localization of both proteins at the cell surface of HBPs (E).
Magnification × 630.
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Figure 5. Confocal laser scanning miscroscopy analysis of Aβ-mediated upregulation of LRP-1 in HBPs.
HBP incubated with 10 μM D-Aβ1-40, or in combination with RAP (1 μM) or cycloheximide (0.5 μg/ml)
for 3 days at 37oC. Increased immunoreactivity of anti-LRP antibody (red) was observed after treatment
with 10 μM D-Aβ1-40, compared to control levels of LRP-1 in HBPs. Co-incubation of D-Aβ1-40 with RAP
or cycloheximide demonstrated a reduced immunoreactivity of the anti-LRP-1 antibody. Magnification:
¯630. Nuclei are counterstained blue. 
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